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Summary 
 
1 
Summary 
 
The majority of secretory proteins is exported from mammalian cells by the classical 
secretory pathway involving subcellular compartments such as the endoplasmic 
reticulum (ER) and the Golgi apparatus. However, basic fibroblast growth factor 
(FGF2), a potent mediator of tumor-induced angiogenesis, has been shown to be 
secreted by a non-classical pathway that does not depend on the functions of the ER 
and the Golgi apparatus. The molecular characterization of the FGF2 export 
mechanism is not only a fundamental problem in cell biology but also of great interest 
for biomedical research since it may pave the way for the development of a novel 
class of anti-angiogenic drugs. 
In this thesis, a robust model system designed to quantitatively assess FGF2 
secretion under various experimental conditions was developed. A retroviral 
expression system was established in CHO cells that allows for a stable integration 
of reporter constructs whose expression can be induced by doxicycline. In order to 
monitor expression of FGF2 reporter molecules they were constructed as GFP fusion 
proteins. Based on this experimental system, secretion of FGF2-GFP can be 
quantified by flow cytometry, confocal microscopy and biochemical methods since 
exported FGF2-GFP binds to cell surface heparan sulfate proteoglycans and, 
therefore, is accessible by membrane-impermeable tools such as antibodies and 
biotinylation reagents. 
In the second part of this thesis, a systematic mutational analysis of the FGF2 open 
reading frame was conducted in order to identify cis elements that direct FGF2 to its 
export machinery. Initial experiments revealed the identification of FGF2 mutants that 
are defective in binding to heparan sulfate proteoglycans. Such mutants were neither 
detectable on the cell surface nor in the medium of cells suggesting that the 
interaction of FGF2 with heparan sulfate proteoglycans does not only play a role in 
FGF2 signaling but also in the overall process of FGF2 externalization from 
mammalian cells. A collection of more than a hundred FGF2 mutants and 
corresponding stable cell lines described in this thesis now provide a basis for future 
studies in order to conduct a detailed analysis of determinants required for FGF2 
secretion. 
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2 
1 Introduction 
 
Eukaryotic cells possess an elaborate endomembrane system, compartmenting the 
cell into different organelles. Each compartment provides a specialized environment 
for certain biological processes. The transport of proteins into the lumen of these 
organelles involves polypeptide translocation across membranes. Well characterized 
translocation processes are transport in and out of the nucleus (Gorlich and Kutay, 
1999; Weis, 2003), import into mitochondria (Gordon et al., 2000; Endo et al., 2003) 
and peroxisomes (McNew and Goodman, 1994; Walton et al., 1995; Holroyd and 
Erdmann, 2001). Secretory proteins pass the membrane of the endoplasmatic 
reticulum, are modified in different organelles and finally reach the extracellular 
space by fusion of secretory vesicles with the plasma membrane.  
 
 
1.1 Classical Protein Secretion  
 
The transport of soluble secretory proteins to the extracellular space is understood in 
great detail. The first step of this process called classical protein secretion is the 
cotranslational transport of the nascent polypeptide chain into the endoplasmatic 
reticulum (ER). Soluble secretory proteins contain N-terminal signal peptides 
directing them to the transport machinery of the ER (Walter et al., 1984). Interaction 
of this signal peptide with its receptor, the signal recognition particle (SRP) leads to 
an arrest in translation elongation (Sakaguchi et al., 1987; Wessels and Spiess, 1988; 
Kuroiwa et al., 1996). The complex of SRP, nascent polypeptide chain and ribosome 
diffuses to the ER membrane where SRP binds to the SRP receptor (Rapoport et al., 
1992). The arrest in protein elongation is released (Gilmore et al., 1982a) and the 
nascent polypeptide is synthesized into the lumen of the ER (Gilmore et al., 1982b; 
Walter et al., 1984; Brodsky, 1998). Subsequently, the signal peptide is cleaved off 
by specific peptidases and luminal chaperones ensure correct folding of the 
polypeptide chain (Hebert et al., 1995). Once present in the lumen of the ER, 
disulfide bonds are formed and the protein gets N-glycosylated by oligosaccharyl 
transferase, transferring N-linked oligosaccharide precursor chains to asparagine 
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residues of the protein (Sharma et al., 1981). Subsequently, glucose and mannose 
moieties are trimmed from these precursor chains by glucosidases or mannosidases 
(Lucocq et al., 1986; Roth et al., 1990; Roth et al., 2003). The modified and correctly 
folded protein leaves the ER via small vesicles and enters the Golgi apparatus, which 
is composed of different cisternae, mediating typical modifications, like sulfatation 
(Hille et al., 1984; Baeuerle and Huttner, 1987), O-glycosylation (Sadeghi and 
Birnbaumer, 1999; Ernst and Prill, 2001; Hanisch, 2001) and further trimming of 
sugar moieties from N-glycans (Zuber et al., 2000). Secretory proteins are 
transported through the distinct cisternae, are specifically modified there, and finally 
packaged into secretory vesicles (Pearse, 1976; Tooze and Tooze, 1986; Seeger 
and Payne, 1992), leaving the donor membrane (trans-Golgi cisternae) and targeted 
to the acceptor membrane (plasma membrane). The vesicles travel along the 
microtubule network (Wacker et al., 1997; Pruyne et al., 1998; Vega and Hsu, 2001; 
Martin-Verdeaux et al., 2003) and finally fuse with the plasma membrane thereby 
releasing the protein into the extracellular space (Guo et al., 1999; Sivaram et al., 
2005; Tsuboi et al., 2005).  
 
Two non-clathrin coats, COPI and COPII, drive the formation of vesicles that mediate 
transport between the ER and the Golgi and between the compartments of the Golgi 
(Salama and Schekman, 1995). COPII vesicles mediate anterograde transport from 
the ER to the Golgi (Barlowe et al., 1994; Schekman and Orci, 1996). The general 
consensus for COPI vesicles is that they are involved in the retrograde transport 
(Lippincott-Schwartz et al., 1998) of cargo proteins. Additionally evidence is 
accumulating that COPI vesicles also transport cargo proteins in an anterograde 
manner (Rothman and Wieland, 1996; Nickel et al., 1998). The formation of a vesicle 
is mediated by coat components, which are recruited to the appropriate sites, interact 
with cargo proteins and drive vesicle budding. GTP-binding proteins drive the initial 
recruitment of the coat and act as molecular switches to facilitate coat assembly (Lee 
et al., 2004). 
 
Once budded off the donor membrane, the vesicle is targeted specifically to an 
acceptor membrane involving a complex molecular machinery that mediates 
specificity and vesicle fusion with the acceptor membrane. Small receptor molecules, 
the SNARES (soluble NSF attachment protein receptors), located in the membrane 
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of the vesicle (v-SNARE) and in the target membrane (t-SNARE; (Sollner et al., 
1993)) are involved in membrane fusion (Rothman, 1996; Weber et al., 1998; Nickel 
et al., 1999). Leading a vesicle to its correct acceptor membrane is likely mediated by 
rab proteins and other tethering factors. Once the vesicle is localized at the correct 
target membrane, the fusion process is facilitated by the assembly of v- and t-
SNAREs, interacting in specific combinations. The assembly converts trans-SNARE 
complexes from an instable high-energetic state into a stable low-energetic cis-
SNARE conformation. The energy provided is used to overcome the natural energy 
barrier of two negatively charged and hydrated surfaces allowing fusion of opposing 
membranes. Following fusion, N-ethylmaleimide-sensitive factor (NSF) provides 
energy by ATP hydrolysis, which is required for the disassembly of the cis-SNARE 
complex. The t-SNAREs remain in the acceptor membrane and are available again 
for further rounds of fusion processes (Hanson et al., 1997), whereas the v-SNAREs 
are recycled back to their donor membrane by retrograde transport (Ballensiefen et 
al., 1998), although recent studies on yeast vacuoles suggest that recycling of v-
SNAREs might also be mediated by a mechanism independent of retrograde 
transport (Dietrich et al., 2005).  
 
The ER/Golgi dependent secretory pathway can be selectively blocked by inhibitors 
like monensin, which irreversibly inhibit trans-Golgi transport (Maxfield et al., 1979; 
Tartakoff, 1983) and brefeldin A, which induces the redistribution of Golgi 
components into the ER, thereby reversibly destructing the Golgi apparatus (Misumi 
et al., 1986; Lippincott-Schwartz et al., 1990; Ivessa et al., 1995). 
 
 
1.2 Unconventional Protein Secretion 
 
In contrast to the well characterized conventional protein secretion, unconventional 
protein secretion (also known as “nonclassical protein export”) was discovered about 
15 years ago, but the molecular mechanisms and the identity of machinery 
components remain elusive (Rubartelli et al., 1992; Florkiewicz et al., 1995; Cleves et 
al., 1996; Nickel, 2003). However, unconventionally secreted proteins share the 
following common features: 
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-    they can not be detected in the lumen of ER or the Golgi apparatus 
-    they lack a conventional signal peptide. 
-    they do not contain ER/Golgi dependent post-translational modifications. 
-  their secretion is not blocked by brefeldin A, a typical inhibitor of the 
classical secretory pathway.  
 
Although unconventionally secreted proteins demonstrate the same characteristics, it 
has been shown that they do not take the same export route, but use different 
secretion pathways (Hughes, 1999; Nickel, 2003; Nickel, 2005). The potential 
mechanisms for unconventional secretory processes are summarized in the following 
figure 1.1: 
  
 
Figure 1.1: Current models of pathways potentially involved in unconventional secretory processes (Nickel, 2005) 
 
1) Export by secretory lysosomes. 
Lysosomal contents gain access to the exterior of cells when specialized 
endocytic structures such as secretory lysosomes of cytotoxic T lymphocytes 
or melanosomes of melanocytes fuse with the plasma membrane 
(Stinchcombe et al., 2004). A classical example of an unconventional 
secretory protein whose export mechanism involves endo-lysosomal vesicles 
is IL-1β (Rubartelli et al., 1990). 
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2) Export mediated by plasma membrane-resident transporters. 
Direct translocation of cytosolic factors across the plasma membrane using 
protein conducting channels such as adenosine triphosphate-binding cassette 
(ABC) transporters (Cleves and Kelly, 1996). Examples are the leishmania 
protein HASPB which translocation is likely to be mediated by a plasma 
membrane-resident transporter (Stegmayer et al., 2005) and FGF1 that is also 
suggested to rely on a direct transport mechanism at the level of the plasma 
membrane (Prudovsky et al., 2002). 
 
3) Export through the release of exosomes derived from multivesicular bodies. 
Luminal contents of endocytic structures can be released into the extracellular 
space when multivesicular bodies fuse with the plasma membrane, a process 
that results in the release of exosomal vesicles along with their cargo 
molecules (Stoorvogel et al., 2002). 
 
4) Export mediated by plasma membrane shedding of microvesicles. 
Direct translocation of cytosolic factors across the plasma membrane using a 
process called membrane blebbing being characterized by shedding of plasma 
membrane-derived microvesicles that are released into the extracellular space 
(Hugel et al., 2005; Martinez et al., 2005).  Evidence existing in a number of 
studies indicates that the secretory process for members of the galectin family 
involves the formation of exovesicles generated by membrane blebbing 
(Hughes, 1999). 
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1.3 Unconventionally secreted proteins 
 
Nowadays it is not known how many proteins are secreted using mechanisms distinct 
from the classical secretory pathway. Since the discovery of the existence of non-
classical secretion (Cooper and Barondes, 1990; Muesch et al., 1990; Florkiewicz et 
al., 1995), the list of proteins demonstrated to be externalized by unconventional 
means is steadily growing. The following proteins are known to be secreted in an 
ER/Golgi-independent manner and are introduced in the following sections. 
 
- Cytokines: Thioredoxin, interleukin-1 and migration inhibitory factor (MIF) 
- Leishmania HASPB 
- Viral proteins: HIV-Tat, FV Bet and HSV VP22 
- Homeodomain-containing transcription factors and HMG chromatin-binding 
proteins 
- Lectins of the extracellular matrix: Galectin-1 and -3 
- Pro-angiogenic growth factors: Fibroblast growth factor 1 and 2 
 
 
 
Figure 1.2: Proteins exported by unconventional means and their potential export routes (Nickel 2003). 
 
The various proteins secreted in an unconventional manner and their proposed 
export routes are summarized in figure 1.2. 
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1.3.1 Interleukin-1 
 
Interleukin-1 (IL-1) is the prototypic pro-inflammatory cytokine. Two forms of IL-1, IL-
1α and IL-1β have been identified, mediating a wide range of indistinguishable 
biological activities. IL-1 affects nearly every cell type, is a highly inflammatory 
cytokine and plays an important role in immune response and host defences 
(Dinarello, 1985). Regulation of IL-1 activity is mediated by low numbers of surface 
receptors, circulating soluble receptors and a cell surface "decoy" receptor, which 
down-regulates responses to IL-1 (Dinarello, 1997). 
Both forms of Interleukin-1 lack a classical secretion signal and are exported from 
activated monocytes (Auron et al., 1987).   
 
 
1.3.1.1 Interleukin-1α 
 
IL-1α is synthesized as an 31 kDa precursor form (pro IL-1α) from cytoskeleton-
associated polyribosomes (Stevenson et al., 1992). Intracellular IL-1α is distributed 
asymmetrically between cytosol, microtubules and nuclear compartments and is 
modified by myristoylation (Stevenson et al., 1993), therefore inserted into the 
plasma membrane and finally a target for specific cysteine proteases, the calpains 
(Kobayashi et al., 1990; Miller et al., 1994). However, IL-1α is also found on the 
surface of monocytes and lymphocytes (Kurt-Jones et al., 1985). The molecular 
mechanism of IL-1α secretion has not been classified at a molecular level, but it has 
been shown that shear stress increases the release of interleukin 1α (Sterpetti et al., 
1993) and that IL1-α is secreted upon heat shock treatment (Tarantini et al., 2001).  
 
 
1.3.1.2 Interleukin-1β 
 
Interleukin-1β is also synthesized as a 31 kDa proIL-1β form that is mainly distributed 
in the cytosol. The precursor form is processed by the IL-1β converting enzyme (ICE) 
to the mature form of 17 kDa size. The protein is not glycosylated despite bearing 
multiple consensus sites for N-glycosylation. 
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It was shown that only the processed form is secreted from IL-1β expressing cells, 
whereas the precursor remains in the cell. IL-1β was found to be partially present 
within intracellular vesicles only in cells also secreting IL-1β, indicating that packaging 
of IL-1β into these vesicles may be a part of the secretion pathway. Recently it was 
shown that these intracellular vesicles fuse with the plasma membrane, releasing 
their content to the extracellular space (Andrei et al., 1999). The secretion of IL-1β is 
blocked by methylamine, low temperature or serum free medium. In contrast, the 
secretion is increased by heat shock treatment or by the presence of calcium 
ionophores, brefeldin A, monensin, dinitrophenol or carbonyl cyanide 
chlorophenylhydrazone (Rubartelli et al., 1990). Moreover, the ABC transporter 
ABCA1 has been implicated to be involved in the overall process of IL-1β secretion 
since secretion of IL-1β is sensitive to glyburide, a drug targeted to the ABC1 family 
of membrane transporters (Hamon et al., 1997). However ABCA1 has been 
implicated in the membrane translocation of cholesterol (Raggers et al., 2000) and 
therefore, it seems unlikely that a defined type of ABC transporter is capable of 
translocating two classes of molecules structurally as different as a small protein and 
a membrane lipid. It was shown that IL-1β secretion is dependent on this ABC 
transporter in macrophages, but not in monocytes (Zhou et al., 2002). However, for 
this cell type it was proposed that microvesicle shedding plays a central role in the 
mechanism of IL-1β secretion (MacKenzie et al., 2001).  
 
1.3.2 Thioredoxin 
 
Thioredoxin (TRX) is an ubiquitous intracellular protein (12 kDa) that contains an 
active site with a redox-active disulfide, which is involved in the redox-system of 
mammals (Holmgren, 1989) and plants (Balmer et al., 2004). Besides intracellular 
thioredoxin, two isoforms (10 and 12 kDa) have been detected extracellularly, 
although they do not contain a signal peptide. The secretory pathway postulated for 
thioredoxin occurs independently of its redox state (Tanudji et al., 2003) by an 
unknown mechanism. However, secretion of TRX shows several features which are 
also described for the unconventional secretion pathway of interleukin-1β (IL-1β). 
Both pathways are shown to be sensitive to methylamine and are stimulated by 
brefeldin A (Rubartelli et al., 1992). In contrast to IL-1β, TRX is not inhibited by 
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reagents that interfere with ABC transporters and is not found to be incorporated into 
intracellular vesicles (Rubartelli et al., 1995).  
 
1.3.3 Macrophage migration inhibitory factor (MIF) 
 
Macrophage inhibitory factor (MIF) is a pleiotropic cytokine mediating a number of 
immune and inflammatory conditions. Monocytes, macrophages and lymphocytes 
constitutively express MIF, which is rapidly released after stimulation with bacterial 
endotoxins, exotoxins, and cytokines (Calandra, 2003). Its immunological functions 
include the modulation of host macrophage T and B cell response (Bernhagen et al., 
1998). 
MIF lacks a classical signal sequence for the translocation into the ER and is found 
to be mainly localized to the cytosol. Additionally, MIF is not glycosylated and 
secretion from monocytes is not blocked by inhibitors of the classical pathway, such 
as BFA or monensin but is stimulated by heat and redox stress (Flieger et al., 2003). 
The secretion mechanism of MIF remains elusive, however in 2001 it was suggested 
that MIF is exported by membrane blebbing as it was observed that MIF containing 
vesicles pinch off the plasma membrane (Eickhoff et al., 2001). In addition, it was 
reported that MIF export is fully blocked by the ABC transporter inhibitors glyburide 
and probenecide (Flieger et al., 2003), suggesting a pathway depending on the 
function of ABC transporters. It has been proposed that the export pathway taken by 
MIF could be similar to the secretion mechanism that has been suggested for IL-1β, 
since both cytokines share similar pro-inflammatory activities and involve ABC 
transporters during their secretion. 
 
1.3.4 Leishmania hydrophilic acylated surface protein B (HASPB) 
 
HASPB is a lipoprotein synthesized on free ribosomes in the cytoplasm of 
Leishmania parasites. It gets modified with both myristoyl and palmitoyl residues 
covalently attached to an SH4 domain present at the N-terminus by which it is 
anchored within membranes. The palmitoylation occurs at the Golgi membrane, 
where the palmitoylacyltransferase is localized which is required for the thioester-
based acylation of a distinct cysteine residue present in the SH4 domain (Denny et 
al., 2000).  
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Only the infectious forms of Leishmania parasites express HASPB which is then 
found to be associated with the outer leaflet of the plasma membrane (Flinn et al., 
1994). It is currently unclear how this transport step is mediated; however, there are 
in principle three options: (1) HASPB might be transported to the plasma membrane 
associated with the cytoplasmic leaflet of secretory vesicles, (2) HASPB might be 
targeted first to endosomal structures followed by translocation to the plasma 
membrane or (3) HASPB transport from the Golgi to the plasma membrane might not 
rely on transport vesicles (Nickel, 2005). The translocation mechanism of HASPB to 
the outer leaflet remains elusive, however it was demonstrated that the plasma 
membrane is the subcellular site of membrane translocation of HASPB (Stegmayer 
et al., 2005). It also has been reported that HASPB when expressed in mammalian 
cells can be detected on the cell surface of CHO cells, suggesting a conserved 
machinery among eukaryotes (Denny et al., 2000).  
 
1.3.5 Viral proteins: HIV Tat, FV Bet and HSV VP22 
 
Viral proteins have been reported to be secreted by nonclassical means. Among 
them are many factors whose localization-dependent functions are of high biomedical 
relevance. Such proteins include virus-encoded factors that are critical for the viral 
replication cycle. 
 
1.3.5.1 HIV Tat 
 
The Human immunodeficiency virus type 1 (HIV-1) encodes an early trans-activator 
protein (HIV Tat), which is necessary for the replication of the viral genome (Wong-
Staal and Haseltine, 1992; Goldstein, 1996). HIV-infected T cells, as well as HIV-
transfected cultured cells release Tat into the extracellular space in the absence of 
cell death, followed by its binding to heparan sulfate proteoglycans (Chang et al., 
1997) mediated by a basic region present at position 49-57 of its amino acid structure. 
This region, also called basic transduction domain, is also thought to mediate the 
transport over the plasma membrane (Becker-Hapak et al., 2001). The translocation 
across the plasma membrane is most probably mediated by a non-proteinaceous 
machinery, because it has been shown for basic transduction domains containing 
proteins that they are able to cross the lipid bilayer in protein free membranes 
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(Derossi et al., 1998). Furthermore it has been shown that translocation of these 
proteins across membranes occurs at 4°C (Thoren et al., 2000). However, the 
translocation properties of the basic transduction domain have been discussed in a 
controversial way recently. It was suggested that basic transduction domains do not 
act to enhance translocation, but instead merely to increase binding to the cell 
surface, because it was demonstrated that the most dramatic demonstrations of 
basic transduction domain efficiency have been obtained using fixed cells and/or 
denatured proteins (Leifert et al., 2002).  
 
1.3.5.2 HSV VP22 
 
Herpes simplex virus type 1 (HSV-1) protein VP22 is a structural protein of 38 kDa 
size present in the viral tegument. Upon expression in the cytosol it travels along an 
unknown pathway to the cell periphery (Elliott and O'Hare, 1999). Features of VP22 
include intercellular transport, binding to and bundling of microfilaments, thereby 
inducing cytoskeleton collapse, nuclear translocation during mitosis, and binding to 
chromatin and the nuclear membrane (Aints et al., 2001). 
The secretion of VP22 is an ER/Golgi independent process shown by its insensitivity 
to brefeldin A. A classical signal sequence was not identified, but mutations in the C-
terminal half of the protein prevent its secretion (Elliott and O'Hare, 1997). 
Interestingly, cytochalasin D, which inhibits actin polymerization, blocks export of 
VP22 suggesting an unconventional export route depending on the cytoskeleton. 
VP22 re-enters surrounding cells upon release from expressing cells (Wybranietz et 
al., 1999). Once imported into target cells, VP22 is transported into the nucleus 
during mitosis, binds to the condensing cellular chromatin and remains bound 
through all stages of mitosis and chromatin decondensation until the G(1) stage of 
the next cycle (Elliott and O'Hare, 2000). This effect mediated by imported VP22 is 
discussed in a controversary way, because recently experimental evidence was 
reported demonstrating nuclear targeting after import to be an artefact (Lundberg and 
Johansson, 2001).  
 
Introduction 
 
13 
1.3.5.3 FV Bet 
 
Foamy viruses (FV) are retroviruses inducing persistent infections in their host 
without causing any apparent disease. Foamy viruses infect most cell lines in culture, 
but circulating lymphocytes seem to be their major reservoir in vivo (Tobaly-Tapiero 
et al., 2005). The major host of FV are non-human primates, but it has been reported 
that the virus is transmitted to humans, although with low transmission rate and 
resulting in non-pathogenic diseases (Heneine et al., 2003).  
Foamy viruses express a cytosolic protein of 160 kDa size, termed Bet (Giron et al., 
1998), which is capable to spread between cultured cells (Lecellier et al., 2002). The 
function of foamy FV Bet during the viral replication cycle has yet to be reported, but 
it seems to play a key role in the establishment and persistence of viral infection.  
Since Bet is found outside of expressing cells and a classical secretory signal was 
not identified, it has been proposed that FV Bet makes use of an ER/Golgi 
independent export route. This hypothesis is affirmed by the observation that Bet 
export is insensitive to brefeldin A (Lecellier et al., 2002). However, the mechanism of 
FV Bet secretion has not yet been elucidated. 
 
1.3.6 Homeodomain-containing transcription factors and HMG chromatin-
binding proteins 
 
The transcription factor Engrailed homeoprotein isoform 2 (En2) is mainly localized to 
the nucleus of neurons. The protein induces the transcription of genes with a 
homeodomain motif thus playing a decisive role in the establishment of cerebral 
structures and cell differentiation (Retaux et al., 1999).  
However, significant amounts of the protein are also found in the cytoplasm or 
associated with membrane microdomains enriched in cholesterol and 
glycosphingoglycolipids. In addition, En2 is associated with caveolae-like vesicles 
that localize to the cell surface (Joliot et al., 1997). It has access to these vesicles 
targeted to the cell surface but lacks a signal sequence for secretion (Maizel et al., 
2002). It has been suggested, that a short sequence, overlapping with the nuclear 
import signal of Engrailed 2 is responsible for its non-classical secretion. These 
results have been taken to mean that retrotranslocation of En2 from the nucleus to 
the cytoplasm is a prerequisite for nonclassical export of En2 (Maizel et al., 1999). 
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However, recently it was shown that phosphorylation of a serine-rich domain within 
Engrailed 2 is required for its unconventional export (Maizel et al., 2002) . 
 
The high mobility group protein B 1 (HMGB1), also localized to the nucleus, does not 
contain a signal peptide, but nevertheless it has been reported to be secreted from 
monocytes after stimulation with bacterial lipopolysaccharides (Gardella et al., 2002). 
Its unconventional secretion is enhanced by raising the intracellular Ca2+-level 
(Passalacqua et al., 1997). 
After stimulation of monocytes, HMBG1 is redistributed from the nucleus to the 
cytoplasm. Following relocalization, HMBG1 is targeted by an unknown mechanism 
to an endo-lysosomal compartment, from which it is secreted (Gardella et al., 2002). 
Since the secretion pathway shows similarities to the mechanism of IL-1β secretion, it 
is possible that, although the physiological triggers of secretion are different, both 
proteins are externalized in a similar way.  
 
1.3.7 Galectins 
 
The members of the galectin family are β-galactoside-binding lectins of the 
extracellular matrix. A common feature of all galectins is the highly conserved 
carbohydrate recognition domain (CRD (Leffler, 2001). Most galectins possess two 
CRDs, enabling multivalent binding properties.  
Galectins act intra- and extracellularly (Harrison, 1991; Liu et al., 2002) mediating 
many biological activities, such as cell proliferation, apoptosis, inflammation and cell 
differentiation (Perillo et al., 1995; Perillo et al., 1998; Pace et al., 1999; Liu, 2000). 
Inside the cell, galectins are mainly found in the cytoplasm, but were also shown to 
be localized inside the nucleus (Wang et al., 1991).  Upon secretion, galectins are 
found to be present as components of the extracellular matrix (Cooper and Barondes, 
1990), or they interact with the cell surface by β-galactose-terminated 
oligosaccharide side chains of glycoproteins and galactose-containing glycolipids, 
such as the ganglioside GM1 (Mehul et al., 1995; Kopitz et al., 1998). 
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1.3.7.1 Galectin-1 
 
Galectin-1 (Gal-1) is a homodimeric low molecular weight protein of 14 kDa size. It is 
synthesized on free ribosomes (Wilson et al., 1989) and mainly found in the 
cytoplasm of most galectin-expressing cells (Briles et al., 1979). It lacks 
intramolecular disulfide bonds but contains free sulfhydryls and is unstable and 
inactive in the absence of reducing agents (Hirabayashi and Kasai, 1991; Tracey et 
al., 1992). 
Additionally, galectin-1 lacks a signal peptide, which would target the protein to the 
classical secretory pathway (Couraud et al., 1989). Nevertheless it is found to be 
secreted  from mammalian cells in a brefeldin A-resistant manner (Sato et al., 1993). 
Galectin-1 binds to counter receptors, such as laminin (Zhou and Cummings, 1990), 
fibronectin (Ozeki et al., 1995) and cell type specific receptors as T cell CD43 and 
CD45 (Pace et al., 1999) as well as to the tumour specific cell surface antigen CA125 
(Seelenmeyer et al., 2003). Unlike interleukin 1β, galectin-1 is not packaged into 
intracellular vesicles prior to export. In contrast, galectin-1 was shown to accumulate 
directly below the plasma membrane, followed by an export mechanism that involves 
the formation of membrane-bound vesicles that pinch off the plasma membrane in 
order to be released into the extracellular space. This process has been termed 
“membrane blebbing” (Hughes, 1999). However, based on various experimental 
systems, evidence is accumulating that galectin-1 export is mediated by direct 
translocation from the cytoplasm across the plasma membrane into the extracellular 
space (Schäfer et al., 2004). So far, it has been assumed that galectins do not 
interact with their counter receptors until they have been released into the 
extracellular space. However, it has been shown that these interactions are an 
integral part of the export mechanism itself, becausealectin counter receptors (i.e. 
-galactoside-containing cell surface glycolipids and/or glycoproteins) were identified 
to be essential components of the overall process of gal-1 secretion. It was shown 
that both Gal-1 mutants, deficient in -galactoside binding and mutant cell lines 
deficient in the biogenesis of galectin counter receptors, are defective with regard to 
gal-1 secretion (Seelenmeyer et al., 2005). 
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1.3.7.2 Galectin-3 
 
Galectin-3 is a high molecular weight β-galactoside-binding protein (30 kDa) and is 
synthesized on free ribosomes. The protein contains a large flexible N-terminal 
domain that appears to be involved in oligomerization. 
As an unconventionally secreted protein, galectin-3 does not contain a signal 
sequence and its secretion is not blocked by brefeldin A. Fetuin, a serum protein, 
which is abundant in fetal serum is able to induce the rapid release of galectin-3 from 
breast carcinoma cells (Zhu and Ochieng, 2001). Galectin-3 was also found to be 
secreted in vesicles, which pinch off the plasma membrane. This process of 
“membrane blebbing” was also observed for the secretion of galectin-1. 
Once secreted, galectin-3 is found bound to receptors present on the cell surface, 
such as laminin (Hughes, 1997), AGE (advanced end product) receptors that 
mediate multiple biological activities (Thornalley, 1998) and various cell surface 
glycoproteins.   
 
1.3.8 Fibroblast growth factors 
 
The fibroblast growth factors (FGFs) belong to a family of proteins currently thought 
to consist of at least 23 different members. In vertebrates, the members of the 
mammalian FGF family range in molecular mass from 17 to 34 kDa (Drosophila FGF 
is 84 kDa) and share 13-71% amino acid identity (Ornitz and Itoh, 2001). Most of the 
FGF family members contain 6 identical and 28 highly conserved amino acids from 
which ten are thought to mediate the interaction with FGF receptors (Plotnikov et al., 
2000).  The FGFR tyrosine kinase receptors contain two or three immunoglobulin-like 
domains and one heparin-binding domain (McKeehan et al., 1998). Alternative 
mRNA splicing, regulated in a tissue-specific manner, of the FGFR gene specifies 
the sequence of the carboxy terminal half of immunoglobulin-domain II, resulting in 
two different isoforms (Miki et al., 1992) and affecting ligand-receptor specificity 
(Ortega et al., 1998). 
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Figure 1.3: Structural features of the FGF polypeptide. The amino terminus of some FGFs contains a signal sequence (shaded). 
All FGFs have a core region that contains conserved amino-acid residues and conserved structural motifs. The location of β-
strands within the core region are numbered and shown as black boxes. The heparin-binding region (pink) includes residues in 
the loop between β-strands 1 and 2 and the β-strands 10 and 11. Residues that contact the FGFR are shown in green, blue and 
red. Picture taken from (Ornitz and Itoh, 2001). 
 
 
As depicted in figure 1.3, structural studies on FGF1 and FGF2 identified 12 
antiparallel β-strands in the conserved core region of these proteins (Eriksson et al., 
1991). They have a β−trefoil structure that contains four-stranded β sheets arranged 
in a triangular array (Faham et al., 1996). Two β-strands (strands 10 and 11) contain 
several basic amino acid residues that form the primary heparin-binding site of FGF2. 
Regions thought to be involved in receptor binding are distinct from those regions 
that bind to heparin.   
Most FGFs (FGFs 3-8, 10, 15, 17-19 and 21-23) have amino-terminal signal peptides 
and are secreted from cells via the ER/Golgi-dependent route. FGFs 9, 16 and 20 
lack an obvious amino-terminal signal peptide but are also nevertheless secreted via 
the classical secretory pathway (Miyake et al., 1998; Miyakawa et al., 1999). 
Therefore, it can be concluded that the lack of a signal peptide does not conclusively 
lead to a secretion in an unconventional manner.  A subset of FGFs (FGF 11-14) lack 
signal sequences and are thought to remain intracellular. It is not known whether 
these FGFs interact with known FGF receptors or function in a receptor-independent 
manner within the cell (Ornitz and Itoh, 2001). 
An important characteristic of FGFs is their interaction with heparin, heparin sulfate 
(HS) or heparan sulfate proteoglycans (HSPG) (Gleizes et al., 1995). These 
interactions stabilize FGFs with regard to thermal denaturation and proteolysis and 
may limit their diffusion and release into the interstitial space (Moscatelli, 1987; 
Flaumenhaft et al., 1990). It was suggested that FGFs must saturate nearby HS-
binding sites before exerting an effect on other tissues or must be mobilized by 
heparin/HS-degrading enzymes. The interaction between FGFs and HS results in the 
formation of dimers and higher ordered oligomers (Mach et al., 1993; Herr et al., 
1997). It has been shown that a ternary complex of HSPG, FGF and FGFR is 
required for the biological activity of FGF2  (Pellegrini et al., 2000).  
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FGF1 and FGF2 are exported in an unconventional manner independently from the 
ER-Golgi pathway (Mignatti et al., 1992; Engling et al., 2002; Prudovsky et al., 2003). 
 
 
1.3.8.1 Fibroblast growth factor 1 
 
The primary structure of FGF1, also known as acidic FGF, contains a nuclear 
localization signal (NLS) which plays an important role for its mitogenic activity 
(Imamura et al., 1990; Imamura et al., 1992). When extracellular FGF1 binds to cell-
surface receptors (FGFR 1-4) or to heparan sulfates, it is internalized in association 
with its receptor via an uncharacterized pathway. It has been reported that externally 
added FGF1 was localized to sorting/early endosomes after 15 min at 37°C 
(Haugsten et al., 2005). The endosomal compartment acts as a sorting station for 
FGF1 bound to its receptor. Depending on the association with its different receptors, 
FGF1 is sorted to the recycling compartment (FGFR 4) or sorted for degradation into 
lysosomes (FGFR 1-3) (Haugsten et al., 2005). Internalized FGF1 which is not 
destined for degradation is able to cross cellular membranes (Wiedlocha and 
Sorensen, 2004), is found in the cytosol and is then shown to translocate to the 
nucleus in a cell-cycle dependent manner (Zhan et al., 1992). Both the activation of 
FGF receptors and the internalization of FGF1 are necessary to induce proliferation 
(Wiedlocha et al., 1994). In addition to internalized FGF1, endogenously expressed 
FGF1 is also found predominantly in the cytosol, which is consistent with the 
absence of a signal sequence in its primary structure (Shi et al., 1997). However, 
export of intracellular FGF1 is induced upon heat shock (Jackson et al., 1992; 
Tarantini et al., 1998) or serum starvation (Shin et al., 1996) and occurs in presence 
of brefeldin A (Jackson et al., 1992).  
The formation of a Cys 30-mediated FGF1 homodimer is a prerequisite for its 
secretion (Jackson et al., 1995; Tarantini et al., 1995). Dimerized FGF1 is associated 
with the extravesicular p40 fragment of p65 Syt1 - an integral transmembrane protein 
participating in secretory vesicle docking (LaVallee et al., 1998) - and S100A13, a 
member of the family of intracellular calcium-binding S100 proteins (Mouta Carreira 
et al., 1998; Landriscina et al., 2001b). The formation of this multiprotein release 
complex (FGF1, S100A13, and p40) requires the oxidative function of copper 
(Landriscina et al., 2001a). It was suggested that FGF1 is transported to the inner 
surface of the plasma membrane where the multiprotein complex is assembled and 
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exported (Prudovsky et al., 2002). FGF1 redistribution is inhibited by amlexanox, 
which specifically binds to S100A13 (Shishibori et al., 1999) and attenuates actin 
assembly (Landriscina et al., 2000), suggesting that actin stress fibers may be used 
to transport FGF1 to the inner leaflet of the plasma membrane.  
 
1.3.8.2 Fibroblast growth factor 2 
 
Five isoforms of FGF2, with molecular weights of 18, 22, 22.5, 24 and 34 kDa, have 
been identified, all derived from a single messenger RNA. The translation of the 18 
kDa form is initiated from an AUG codon, whereas the high molecular weight 
isoforms are translated using alternative upstream CUG start codons (Florkiewicz 
and Sommer, 1989; Prats et al., 1989). The 18 kDa FGF2 is primarily a cytosolic 
protein and lacks a classical hydrophobic signal sequence. It is exported out of the 
cells in an unconventional manner and stored within the extracellular matrix, whereas 
the high molecular weight isoforms are predominantly localized to the nucleus 
(Renko et al., 1990). 
Structural characteristics 
 
FGF2 is very well conserved during evolution. For bovine and human FGF2, only two 
amino acids are different, resulting in an overall amino acid homology of 98.7% 
(Abraham et al., 1986). Comparison of the primary structure of FGF2 and FGF1 has 
shown that 55% of their amino acids are identical. A weak homology of 25% exists in 
the primary structure between FGF2 and Interleukin-1β (Gimenez-Gallego et al., 
1985). However, their 3-dimensional structures share significant similarities (Ago et 
al., 1991; Eriksson et al., 1991).  
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Figure 1.4: Three-dimensional structure of FGF2. A ribbon diagram shows β-strands (labelled from 1 to 12) and regions in 
contact with FGFR and heparin are labelled as in figure 1.3. Picture taken from Ornitz and Itoh, 2001. 
 
As depicted in figure 1.4, the 12 β-sheets have a β−trefoil structure that contains four-
stranded β-sheets arranged in a triangular array (Faham et al., 1996). 10 out of the 
12 β-sheets meet the criteria of Kabsch and Sander for β-sheet strands (Kabsch and 
Sander, 1983). Additionaly, two segments exist, comprising residues 117-119 and 
124-129 that do not meet these criteria for β-sheet strands, but, nevertheless, form 
the 10th and 11th of the 12 β-strands that comprise the overall framework of the 
FGF2 structure (Eriksson et al., 1991). Three motifs are present in the structure of 
FGF2 mediating high-affinity binding to immunoglobuline-like domains (Ig-domain) of 
the receptor (Lee et al., 1989). The motifs are present in different β-sheets, and are 
widely spread over the protein. Residues contacting Ig-domain 2 of the receptor 
(figure 1.4, green) are present in β11 and 12, close to the C-terminus, those 
contacting Ig-domain 3 (blue) link β4 and 5 and are also part of β5. Additionally 
amino acids present in β4 and 6 contact the alternatively spliced region of the 
receptors Ig-domain (red). Importantly, two β-strands (strands 10 and 11) contain 
several basic amino-acid residues that form the primary heparin-binding site in FGF2 
(pink). A second heparin binding site is located in the linking region between sheets 
β1 and β2 (Faham et al., 1996; Plotnikov et al., 2000).  
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Binding to heparin and heparan sulfate proteoglycans 
 
An intact three-dimensional structure is required for binding of FGF2 to heparin 
(Seddon et al., 1991). From the crystal structure of FGF2, two pairs of basic residues, 
K128 and K138, and R129 and K134, respectively, were found to form binding sites 
for two sulfate molecules (Li et al., 1994). It was shown that heparin binding is also 
mediated by N-terminal amino acids located at position 20-30 (Baird et al., 1988), 
suggesting that binding of heparin to the growth factor is not mediated by a single 
heparin binding site, but rather by cumulative effects of heparin binding sequences. 
Binding of FGF2 in vivo is mediated by high affinity receptors and heparan sulfate 
proteoglycans present on the cell surface of mammalian cells. The latter consist of 
proteoglycan core protein (e.g. perlecan, syndecan) and heparan sulfates (HS). 
Heparan sulfates exist in a broad structural variety, up to date 23 different 
disaccharides have been identified to be present in heparin (Esko and Selleck, 2002).  
To mediate biological activity, a ternary complex composed of FGF2, heparin and 
FGF receptor must be assembled to activate signalling by the tyrosine kinase of 
FGFR (depicted in figure 1.5). 
 
Figure 1.5: Receptor signalling requires the formation of a trimeric complex as indicated, where the polysaccharide binds both to 
the growth factor, through Site A, and to the receptor, through Site B. Picture taken from (Guimond et al., 1993). 
 
The addition of heparin, which is too short to span both binding regions, may block 
the activity induced by full-size heparin (or heparan sulfate) due to competitive 
binding to the growth factor (Ishihara et al., 1993). 
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Biological functions of FGF2 
 
FGF2 is a pleiotropic growth factor mediating many different biological activities. 
Binding of FGF2 to HSPGs and its receptor present on the plasma membrane 
activates signalling cascades inside the target cells.  
FGF2 induces cell proliferation or differentiation in a variety of cell types of 
mesodermal and neuroectodermal origin (Gospodarowicz, 1991). It was also shown 
to induce chemotaxis and protease production in cultured endothelial cells (Presta et 
al., 1986). 
The most important biological activity of FGF2 is its role as a mediator of 
angiogenesis by the stimulation of VEGF (vascular endothelian growth factor) 
receptors and direct stimulation of endothelial cells. FGF2 was one of the first 
identified angiogenic growth factors (Moscatelli et al., 1986; Shin et al., 1996).  
In vivo, FGF2 is thought to play a role in the growth and neovascularization of solid 
tumours. Various tumour cell lines express FGF2 in vitro (Moscatelli et al., 1986; 
Okumura et al., 1989; Nakamoto et al., 1992), as shown by in situ hybridization and 
immunolocalization experiments, in which FGF2 mRNA and protein was found to be 
present in neoplastic cells, endothelial cells, and infiltrating cells within human 
tumours of different origin (Schulze-Osthoff et al., 1990; Zanetta, 1998; Tanudji et al., 
2002). Additionally, neovascularization and growth of human melanomas were 
inhibited by expression of antisense cDNAs for FGF2 and FGFR-1 (Wang and 
Becker, 1997).  
FGF2 is released from producing cells in an unconventional manner (Mignatti et al., 
1992; Florkiewicz et al., 1995) and accumulates in the ECM, where it is mobilized by 
ECM-degrading enzymes (Ribatti et al., 1999).  
 
Unconventional secretion of FGF2 
 
About 15 years ago, it was believed that FGF2 is primarily released from injured or 
dead cells thereby mediating its biological activities. In 1990 it was reported that the 
structurally related cytokine Interleukin-1β is secreted, although lacking a signal 
peptide, by a pathway independent from the classical, Golgi-dependent secretion 
(Rubartelli et al., 1990). In 1991, Mignatti and Rifkin were the first to report that FGF2, 
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despite lacking a signal sequence, might be exported by a controlled mechanism, 
because FGF2 was shown to be released from a single, uninjured cell, mediating its 
biological functions in an autocrine manner (Mignatti and Rifkin, 1991). In 1995, 
Florkiewicz et al. demonstrated that FGF2 is selectively and quantitatively exported 
from transiently transfected Cos-1 cells. FGF2 export was found not to be blocked by 
brefeldin A, a known inhibitor of the classical secretory pathway. Additionally, export 
of FGF2 was shown to be ATP-dependent since depletion of ATP blocked the 
release of the growth factor. As shown by pulse label experiments, FGF2 required 
two hours to appear in the extracellular space (Florkiewicz et al., 1995). Three years 
later, Florkiewicz et al. could show that export of FGF2 is specifically blocked by 
cardenolides such as ouabain, a known inhibitor of the Na+/K+ ATPase. FGF2 was 
copurified with the α-subunit of the plasma membrane resident Na+/K+ ATPase, 
suggesting a direct interaction of the growth factor with the transmembrane protein 
(Florkiewicz et al., 1998). This observation was underlined by the finding that an 
ouabain resistant mutant of the rodent α-1 subunit of the Na+/K+ ATPase was 
capable of rescuing ouabain-inhibitable FGF2 export (Dahl et al., 2000). In 2000, the 
existence of an unconventional pathway for the secretion of FGF2 was further 
substantiated. By performing biochemical studies like biotinylation of cell surface 
proteins and purification of those using streptavidin beads, it was demonstrated that 
FGF2 is translocated to the outer surface of the plasma membrane and is retained 
there by binding to HSPGs. It was also suggested that release of FGF2 into the 
medium of expressing cells is uncoupled from the transport process itself. To be able 
to perform biological activities as a growth factor, cell surface FGF2 must then be 
released from sequestration on the cell surface into the extracellular matrix or 
biological fluids (Trudel et al., 2000). In 2002, another model for the secretion of 
FGF2 was proposed, as it was shown that FGF2 is released from endothelial cells 
after stimulation by shear stress and under the tight control of a specific integrin 
(Gloe et al., 2002). The observation that shear stress has been found to promote 
microvesicle shedding (Martinez et al., 2005) is consitent to yet another model for 
FGF2 secretion which was proposed one year later. In 2003, Taverna et al. showed, 
that three isoforms of FGF2 (18, 22 and 24 kDa) were present in vesicles which were 
shed from the plasma membrane after stimulation by serum addition to serum-
starved cells (Taverna et al., 2003). However, this model is discussed in a 
controversial way, since FGF2-containing vesicles found in cell culture supernatants 
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could be affinity-purified using immobilized annexin V, a well known binding protein of 
phosphatidylserine. Thus, annexin V affinity-purified vesicles are likely to be derived 
from apoptotic cells as translocation of phosphatidylserine to the outer leaflet of the 
plasma membrane is a hallmark of programmed cell death. Moreover, readdition of 
medium to cells serum-starved for longer periods of time is a procedure which is 
commonly used to artificially induce apoptosis. Although it appears to be unlikely that 
FGF2 secretion involves shedding of plasma membrane vesicles, it can not be 
excluded (Nickel, 2005). 
In 2004, the translocation process of FGF2 at the plasma membrane was 
characterized by reconstitution of the translocation of FGF2 using inside-out vesicles 
obtained from the plasma membrane. The translocation was observed to be 
temperature- and incubation time-dependent. In contrast, right side-out vesicles were 
not shown to translocate FGF2-GFP into the lumen of the vesicle. Moreover, 
galectin-1 was found to traverse the membrane of inside-out vesicles, whereas the 
unconventional secretory protein MIF and the classical secretory protein FGF4 were 
not found to be translocated. Additionally, removal of vesicle-associated proteins by 
high salt conditions or protease treatment resulted in a loss of FGF2 translocation 
across the membrane, indicating that proteins present on the extracellular site of the 
plasma membrane (e.g. heparan sulfate proteoglycans) are involved in the 
translocation process. These data, obtained by Tobias Schäfer from our working 
group suggest that FGF2 translocation is mediated by a plasma membrane resident 
protein transporter (Schäfer et al., 2004). 
 
1.4 Aim of the present thesis 
 
The molecular machinery involved in unconventional secretion of fibroblast growth 
factor 2 is poorly understood. Therefore, in the first part of this thesis, a novel 
experimental system was implemented that will greatly facilitate studies on the 
molecular machinery of FGF2 secretion. A key aspect was to reconstitute FGF2 
secretion in living cells based on a read-out method that provides a precise and 
quantitative analysis of this process. A considerable advantage of the FGF2-GFP-
based system is that total protein expression (GFP-derived fluorescence) and 
secreted FGF2-GFP (APC-derived cell surface staining) can be measured 
simultaneously. Therefore, a phenotype determined by cell surface staining can be 
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corrected by normalization based on the degree of total FGF2-GFP expression. 
Moreover, by using FGF receptor-deficient CHO cells, secondary effects based on 
FGF2 induced signal transduction can be avoided. This robust and efficient FACS-
based assay was then used in our group to elucidate unconventional secretion of 
FGF2, HASPB and galectin-1. Another obvious application is a systematic high 
throughput screening for inhibitors of FGF2 secretion and the subsequent functional 
identification of their cellular targets. Given the biological function of FGF2 as a direct 
stimulator of tumour angiogenesis, inhibitors of FGF2 secretion might have strong 
biomedical implications as potential lead compounds for the development of anti-
angiogenic drugs. 
The second part of this thesis deals with the question of how FGF2 is recognized by 
its transport machinery. A targeting motif, directing the protein to its interaction 
partners of the membrane translocation apparatus has so far not been reported. 
Therefore, a mutational analysis was conducted in order to screen for amino acids 
which might play a major role in the overall transport process. The FACS-based 
assay, established in the first part of this thesis, and other assays were used as a 
read-out systems to elucidate amino acids mediating heparin binding and influence 
export of FGF2. By performing the mutational analysis, it was not possible to find 
distinct amino acids serving as a targeting motif for the secretion of FGF2. 
Additionally, single amino acid exchanges and truncations of the N-terminus did not 
result in a knock-out of heparin-binding capabilities of FGF2. However, C-terminal 
truncations of FGF2 demonstrated a loss of binding ability to heparan sulfate 
proteoglycans and heparin, resulting in FGF2-GFP secretion deficiency. Therefore, it 
can be suggested that binding of FGF2 to its low affinity receptors present on the 
extracellular site of the plasma membrane is a prerequisite for the translocation of 
FGF2 across the lipid bilayer, thereby providing a mechanism for quality control, 
since only correctly folded and biological active forms of the growth factor are 
secreted from mammalian cells.  
 
Material and Methods 
 
26 
2 Material and Methods 
 
2.1 Material 
2.1.1 Chemicals  
 
Chemicals Manufacturers 
Agar  Beckton Dickinson, Le Pont de Claix, France 
Agarose electrophoresis grade Invitrogen Ltd., Paisley, UK 
MEM Biochrom KG, Berlin 
Ampicillin sodium salt Gerbu Biotechnik GmbH, Gaiberg 
APS (Ammonium peroxo disulfate) Carl Roth GmbH, Karlsruhe 
-Mercaptoethanol  Merck , Darmstadt 
Bromphenol Blue Na-salt Serva Electrophoresis GmbH, Heidelberg 
BSA (Bovine serum albumine, Albumin fraction V) Carl Roth GmbH, Karlsruhe 
Calcium chloride dihydrate Applichem, Darmstadt 
Cell dissociation buffer (CDB) Invitrogen, Paisley, UK 
Chloroquine Sigma-Aldrich Chemie GmbH, Steinheim 
CL-4B Sepharose (Beads) Amersham Biosciences Pharmacia, , Sweden 
Clear Nail Protector Wet’n Wild USA, North Arlington, USA 
Complete Mini (Protease Inhibitor Cocktail Tablets) Roche Diagnostics, Mannheim 
Deoxycholic acid sodium salt Sigma-Aldrich Chemie GmbH, Steinheim 
DMEM Biochrom KG, Berlin 
DMSO (Dimethyl sulfoxide) J.T. Baker, Deventer, USA 
dNTP-Mix Peqlab, Erlangen 
Doxicycline Clontech, Palo Alto, USA 
ECL Western Blotting Detection Reagent Amersham Biosciences Pharmacia, Sweden 
EDTA (Ethylene diamine tetraacetic acid) Merck, Darmstadt 
Ethanol pro analysis Riedel-de Haën, Seelze 
FCS (Fetal Calf Serum) PAA Laboratories GmbH, Linz, Austria 
Fluoromount G Southern Biotechnologies Inc USA 
Glacial acidic acid Carl Roth GmbH, Karlsruhe 
Glycerine Carl Roth GmbH, Karlsruhe 
Glycine  Applichem, Darmstadt 
Isopropanol Merck , Darmstadt 
L-Glutamine Biochrom AG, Berlin 
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Magnesium chloride hexahydrate Applichem, Darmstadt 
Mangan chloride Merck, Darmstadt 
Methanol pro analysis Merck , Darmstadt 
Milk Powder Carl Roth GmbH, Karlsruhe 
Nonidet P40 (NP-40) Roche, Mannheim 
Paraformaldehyde Electron Microscope Sciences, Hatfield, UK 
Penicillin/Streptomycin for cell culture Biochrom AG, Berlin 
Ponceau S Serva Electrophoresis GmbH, Heidelberg 
Potassium dihydrogen carbonate Carl Roth GmbH, Karlsruhe 
Potassium hydroxide J.T.Baker, Deventer, USA 
Protein A CL-4B-Sepharose(Beads) Amersham Biosciences Pharmacia, Sweden 
PVDF Membrane Immobilon P Blotting Millipore Corporation, Bedford 
PVDF Membrane Immobilon XL Millipore Corporation, Bedford 
Rotiphorese Gel 30 (37.5:1) Carl Roth GmbH, Karlsruhe 
Sodium chloride J.T. Baker, Deventer, USA 
Sodium dodecyl sulfate  Serva Electrophoreis GmbH, Heidelberg 
Sodium hydrogen carbonate J.T. Baker, Deventer, USA 
Sodium hydroxide  J.T. Baker, Deventer, USA 
Temed (N,N,N',N'-tetramethylethylenediamine) Bio-Rad Laboratories GmbH, München 
Tris Carl Roth GmbH, Karlsruhe 
Trition X-100 Roche, Mannheim 
Trypsin / EDTA for cell culture Biochrom KG, Berlin 
Trypsine (Protease Protection) Sigma-Aldrich Chemie GmbH, Steinheim 
Tryptone Beckton Dickinson, Le Pont de Claix 
Tween 20 (Polyoxyethylenesorbitan monolaurate) Carl Roth GmbH, Karlsruhe 
UltraLink immobilized streptavidin (Beads) Pierce, Perbio Sciences, Bonn 
Whatman MM  Whatman AG, Würzburg 
Xylencyanol FF Serva Electrophoresis GmbH, Heidelberg 
Yeast Extract Beckton Dickinson, Le Pont de Claix 
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2.1.2 Enzymes 
 
Restriction enzymes were purchased from New Englang Biolabs. The restriction 
enzymes listed below were used for cloning of the different cDNA constructs. 
 
Age I      
Sph I      
BamH I     
Not I      
Apa I      
    
2.1.3 Antibodies 
 
 
For flow cytometry analysis, immunoprecipitation experiments and Western blot 
detection of FGF2-GFP fusion proteins, affinity-purified polyclonal rabbit anti-GFP 
antibodies were used (Engling et al., 2002). Secondary antibodies used for flow 
cytometry (Allophycocyanin (APC)-conjugated or Phycoerythrin (PE)-conjugated goat 
anti-rabbit antibodies) were purchase from Molecular Probes, HRP-coupled mouse 
anti-rabbit secondary antibodies used for Western blot detection of 
immunoprecipitates using ECL were from Sigma (clone RG-16). Alexa 680-coupled 
goat anti-rabbit antibodies used for quantitative analysis of antigens processed by 
Western blotting employing the LI-COR Odyssey system were purchased from 
Molecular Probes. 
 
2.1.4 Equipment 
 
Technical devices manufacturers 
Bacterial Incubator Infors HT ITE Infors AG, Einsbach 
Bacterial Shaker Centromat R Braun, Melsungen 
FACSAria Becton Dickinson, Heidelberg 
FACSVantage Becton Dickinson, Heidelberg 
FASCCalibur Becton Dickinson, Heidelberg 
Gel Doc 2000 Bio-Rad, München 
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Microscope Axiovert 40 C Zeiss, Göttingen 
Microscope LSM 510 Meta Confocal Zeiss, Göttingen 
Mini-PROTEAN 3 Electrophoresis System Bio-Rad, München 
Nanodrop ND-1000 Spectrophotometer Peqlab, Erlangen 
Odyssey Infrared Imaging System LI-COR Biosciences, Bad Homburg 
PCR Primus Advanced 25 and 96 Peqlab, Erlangen 
Sonifier Cell Disruptor B 30 Heinemann, Schwäbisch Gmünd 
Sonorex Super RK 103 h Bandelin, Berlin 
 
 
2.1.5 Plasmids and Primers 
 
pVPack Eco      BD Bioscience, Clontech  
pVPack GP      BD Bioscience, Clontech 
pRevTRE2     BD Bioscience, Clontech, Mountain View 
pBI-rtTA2M2/CD2    kindly provided by Dr. Blanche Schwappach 
pGEM-T     Promega 
 
 
Primers for Random Mutagenesis 
 
In the following table, the primer specific sequence and its melting temperature are 
listed in column “Sequence” and “Tm”, respectively. 
 
 
Primer Sequence Tm (°C) 
FGF2-MUT-FOR CGGGATCCCGCATCGATCGCCACCATGG 78,4° 
FGF2-MUT-REV CCTAGGTTTTGTCCTGGACCG 55,0° 
 
 
Primers for Point Mutations 
 
In the following table, primer specific sequences are listed. The triplet encoding the 
original amino acid is listed in column “Codon” whereas the triplet encoding the 
amino acid for mutation is marked with bold letters in column “Sequence”. 
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Additionally, the melting temperature of the specific primer is indicated in column “Tm” 
as well as the length of the primer in nucleotides in column “N”.  
 
Primer Sequence Tm (°C) N Codon 
A-3-V-For ATCGCCACCATGGTAGCCGGGAGCATC 80,1 27 GCC 
A-3-V-Rev GATGCTCCCGGCTACCATGGTGGCGAT 80,1 27  
G-4-A-For GCCACCATGGCAGTCGGGAGCATCACC 78,4 25 GGG 
G-4-A-Rev GGTGATGCTCCCGACTGCCATGGTGGC 78,4 25  
S-5-A-For CATGGCAGCCGCGAGCATCACCACG 79,5 27 AGC 
S-5-A-Rev CGTGGTGATGCTCGCGGCTGCCATG 79,5 27  
I-6-A-For TGGCAGCCGGGGCCATCACCACGCTGC 79,3 25 ATC 
I-6-A-For GCAGCGTGGTGATGGCCCCGGCTGCCA 79,3 25  
T-7-A-For CAGCCGGGAGCGCCACCACGCTGCC 79,9 23 ACC 
T-7-A-Rev GGCAGCGTGGTGGCGCTCCCGGCTG 79,9 23  
T-7-E-For CGGGAGCATCGCCACGCTGCCCG 79,1 31 ACC 
T-7-E-Rev CGGGCAGCGTGGCGATGCTCCCG 79,1 31  
T-7-D-For CAGCCGGGAGCATCGAGACGCTGCCCGCCTT 80,5 33 ACC 
T-7-D-Rev AAGGCGGGCAGCGTCTCGATGCTCCCGGCTG 80,5 33  
T-8-M-For GGGAGCATCACCATGCTGCCCGCCT 78,4 25 ACG 
T-8-M-Rev AGGCGGGCAGCATGGTGATGCTCCC 78,4 25  
P-13-H-For GCCCGCCTTGCACGAGGATGGCG 78,1 23 CCC 
P-13-H-Rev CGCCATCCTCGTGCAAGGCGGGC 78,1 23  
E-14-D-For CGCCTTGCCCGACGATGGCGGCA 78,1 23 GAG 
E-14-D-Rev TGCCGCCATCGTCGGGCAAGGCG 78,1 23  
F-21-I-For CAGCGGCGCCATCCCGCCCGGCC 83,5 23 TTC 
F-21-I-Rev GGCCGGGCGGGATGGCGCCGCTG 83,5 23  
P-23-S-For CGCCTTCCCGTCCGGCCACTTCAAG 78,4 25 CCC 
P-23-S-Rev CTTGAAGTGGCCGGACGGGAAGGCG 78,4 25  
F-26-A-For CGCCCGGCCACGCCAAGGACCCCAAGC 81,0 27 TTC 
F-26-A-Rev GCTTGGGGTCCTTGGCGTGGCCGGGCG 81,0 27  
K-30-E-For TTCAAGGACCCCGAGCGGCTGTACTGC 78,6 27 AAG 
K-30-E-Rev GCAGTACAGCCGCTCGGGGTCCTTGAA 78,6 27  
Y-33-A-For CCCAAGCGGCTGGCCTGCAAAAACGGGGG 79,6 29 TAC 
Y-33-A-Rev CCCCCGTTTTTGCAGGCCAGCCGCTTGGG 79,6 29  
F-39-L-For CAAAAACGGGGGCCTCTTCCTGCGCATCC 80,2 29 TTC 
F-39-L-Rev GGATGCGCAGGAAGAGGCCCCCGTTTTTG 80,2 29  
F-39-A-For CAAAAACGGGGGCGCCTTCCTGCGCATCC 78,2 29 TTC 
F-39-A-Rev GGATGCGCAGGAAGGCGCCCCCGTTTTTG 78,2 29  
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Primer Sequence Tm (°C) N Codon 
F-40-L-For CGGGGGCTTCCTCCTGCGCATCC 78,1 23 TTC 
F-40-L-Rev GGATGCGCAGGAGGAAGCCCCCG 78,1 23  
R-42-H-For GGCTTCTTCCTGCACATCCACCCCGAC 78,6 27 CGC 
R-42-H-Rev GTCGGGGTGGATGTGCAGGAAGAAGCC 78,6 27  
V-52-A-For GAGTTGACGGGGCCCGGGAGAAGAG 78,4 25 GTC 
V-52-A-Rev CTCTTCTCCCGGGCCCCGTCAACTC 78,4 25  
R-53-A-For AGTTGACGGGGTCGCGGAGAAGAGCGACC 78,2 29   CGG 
R-53-A-Rev GGTCGCTCTTCTCCGCGACCCCGTCAACT 78,2 29  
K-55-T-For GGTCCGGGAGACGAGCGACCCTC 78,1 23 AAG 
K-55-T-Rev GAGGGTCGCTCGTCTCCCGGACC 78,1 23  
K-55-R-For GGTCCGGGAGAGGAGCGACCCTC 78,1 23 AAG 
K-55-R-Rev GAGGGTCGCTCCTCTCCCGGACC 78,1 23  
H-59-P-For AGAAGAGCGACCCTCCCATCAAGCTACAACTTC 79,1 33 CAC 
H-59-P-Rev GAAGTTGTAGCTTGATGGGAGGGTCGCTCTTCT 79,1 33  
K-61-E-For GCGACCCTCACATCGAGCTACAACTTCAAGCAG 80,4 33 AAG 
K-61-E-Rev CTGCTTGAAGTTGTAGCTCGATGTGAGGGTCGC 80,4 33  
L-64-P-For TCACATCAAGCTACAACCTCAAGCAGAAGAGAGAG 78,1 35 CTT 
L-64-P-Rev CTCTCTCTTCTGCTTGAGGTTGTAGCTTGATGTGA 78,1 35  
Q-65-A-For CTCACATCAAGCTACAACTTGCAGCAGAAGAGAGAGGAGTT 79,2 41 CAA 
Q-65-A-Rev AACTCCTCTCTCTTCTGCTGCAAGTTGTAGCTTGATGTGAG 79,2 41  
E-67-V-For GCTACAACTTCAAGCAGTAGAGAGAGGAGTTGTGT 78,1 35 GAG 
E-67-V-Rev ACACAACTCCTCTCTCTACTGCTTGAAGTTGTAGC 78,1 35  
E-68-A-For TACAACTTCAAGCAGAAGCGAGAGGAGTTGTGTCT 78,1 35 GAG 
E-68-A-Rev AGACACAACTCCTCTCGCTTCTGCTTGAAGTTGTA 78,1 35  
E-68-G-For TACAACTTCAAGCAGAAGGGAGAGGAGTTGTGTCT 78,1 35 GAG 
E-68-G-Rev AGACACAACTCCTCTCCCTTCTGCTTGAAGTTGTA 78,1 35  
R-69-A-For ACAACTTCAAGCAGAAGAGGCAGGAGTTGTGTCTATCAAAG 78,2 41 AGA 
R-69-A-Rev CTTTGATAGACACAACTCCTGCCTCTTCTGCTTGAAGTTGT 78,2 41  
V-72-A-For AGAAGAGAGAGGAGTTGCGTCTATCAAAGGAGTGT 78,1 35 GTG 
V-72-A-Rev ACACTCCTTTGATAGACGCAACTCCTCTCTCTTCT 78,1 35  
I-74-T-For GAGAGGAGTTGTGTCTACCAAAGGAGTGTGTGCTA 79,3 37 ATC 
I-74-T-Rev TAGCACACACTCCTTTGGTAGACACAACTCCTCTC 79,3 37  
K-75-I-For AGGAGTTGTGTCTATCATAGGAGTGTGTGCTAACC 78,1 35 AAA 
K-75-I-Rev GGTTAGCACACACTCCTATGATAGACACAACTCCT 78,1 35  
V-77-A-For TGTGTCTATCAAAGGAGCGTGTGCTAACCGTTACC 79,3 35 GTG 
V-77-A-Rev GGTAACGGTTAGCACACGCTCCTTTGATAGACACA 79,3 35  
C-78-A-For GTGTCTATCAAAGGAGTGGCTGCTAACCGTTACCTGG 78,9 37 TGT 
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Primer Sequence Tm (°C) N Codon 
C-78-A-Rev CCAGGTAACGGTTAGCAGCCACTCCTTTGATAGACAC 78,9 37  
N-80-A-For CAAAGGAGTGTGTGCTGCCCGTTACCTGGCTATGA 78,8 35 AAC 
N-80-A-Rev TCATAGCCAGGTAACGGGCAGCACACACTCCTTTG 78,8 35  
Y-82-A-For AGTGTGTGCTAACCGTGCCCTGGCTATGAAGGAAG 78,8 35 TAC 
Y-82-A-Rev CTTCCTTCATAGCCAGGGCACGGTTAGCACACACT 78,8 35  
E-87-K-For GTTACCTGGCTATGAAGAAAGATGGAAGATTACTGGC 78,3 37 GAA 
E-87-K-Rev GCCAGTAATCTTCCATCTTTCTTCATAGCCAGGTAAC 78,3 37  
D-88-A-For CCTGGCTATGAAGGAAGCTGGAAGATTACTGGCTT 79,3 35 GAT 
D-88-A-Rev AAGCCAGTAATCTTCCAGCTTCCTTCATAGCCAGG 79,3 35  
L-92-A-For GAAGGAAGATGGAAGATTAGCGGCTTCTAAATGTGTTACGG 78,2 41 CTG 
L-92-A-Rev CCGTAACACATTTAGAAGCCGCTAATCTTCCATCTTCCTTC 78,2 41  
C-96-A-For GGAAGATTACTGGCTTCTAAAGCTGTTACGGATGAGTGTTTCT 78,3 43 TGT 
C-96-A-Rev AGAAACACTCATCCGTAACAGCTTTAGAAGCCAGTAATCTTCC 78.3 43  
F-102-A-For CTAAATGTGTTACGGATGAGTGTGCCTTTTTTGAACGATTGGAATCTAATA 78,8 49 TTC 
F-102-A-Rev TATTAGATTCCAATCGTTCAAAAAAGGCACACTCATCCGTAACACATTTAG 78,8 49  
F-104-A-For GTGTTACGGATGAGTGTTTCTTTGCTGAACGATTGGAATCTAATAACTA 78,7 47 TTT 
F-104-A-Rev TAGTTATTAGATTCCAATCGTTCAGCAAAGAAACACTCATCCGTAACAC 78,7 47  
Y-112-A-For GAACGATTGGAATCTAATAACGCCAATACTTACCGGTCAAGGA 78,3 41 TAC 
Y-112-A-Rev TCCTTGACCGGTAAGTATTGGCGTTATTAGATTCCAATCGTTC 78,3 41  
S-122-A-For CGGTCAAGGAAATACACCGCTTGGTATGTGGCACTGAAA 79,0 39 AGT 
S-122-A-Rev TTTCAGTGCCACATACCAAGCGGTGTATTTCCTTGACCG 79,0 39  
K-128-E-For GGTATGTGGCACTGGAACGAACTGGGCAG 78,8 29 AAA 
K-128-E-Rev CTGCCCAGTTCGTTCCAGTGCCACATACC 78,8 29  
R-129-Q-For GGTATGTGGCACTGAAACAAACTGGGCAGTATAAACT 78,3 37 CGA 
R-129-Q-Rev AGTTTATACTGCCCAGTTTGTTTCAGTGCCACATACC 78,3 37  
Q-132-R-For CTGAAACGAACTGGGCGGTATAAACTTGGATCCAA 78,1 35 CAG 
Q-132-R-Rev TTGGATCCAAGTTTATACCGCCCAGTTCGTTTCAG 78,1 35  
Y-133-H-For GAAACGAACTGGGCAGCATAAACTTGGATCCAAAACA 78,3 37 TAT 
Y-133-H-Rev TGTTTTGGATCCAAGTTTATGCTGCCCAGTTCGTTTC 78,3 37  
Y-133-A-For CTGAAACGAACTGGGCAGGCTAAACTTGGATCCAAAACAGG 80,2 41 TAT 
Y-133-A-Rev CCTGTTTTGGATCCAAGTTTAGCCTGCCCAGTTCGTTTCAG 80,2 41  
K-138-A-For GCAGTATAAACTTGGATCCGCGACAGGACCTGGGCAGAA 78,6 39 AAA 
K-138-A-Rev TTCTGCCCAGGTCCTGTCGCGGATCCAAGTTTATACTGC 78,6 39  
S-152-A-For TATACTTTTTCTTCCAATGGCTGCTAAGAGCATGGTGAG 78,4 39 TCT 
S-152-A-Rev CTCACCATGCTCTTAGCAGCCATTGGAAGAAAAAGTATA 78,4 39  
C-96-A-For GGAAGATTACTGGCTTCTAAAGCTGTTACGGATGAGTGTTTCT 78,3 43 TGT 
C-96-A-Rev AGAAACACTCATCCGTAACAGCTTTAGAAGCCAGTAATCTTCC 78.3 43  
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Primers for FGF2 truncations 
 
The primers used for the generation are listed in the following tables. 
 
 
N-terminal Truncations 
 
Primer Sequence 
N-10 CGGGATCCCGCCACCATGGGCCCCGAGGATGGCGGCAGCG 
N-20 CGGGATCCCGCCACCATGGGCCCCGGCCACTTCAAGGACCCC 
N-30 CGGGATCCCGCCACCATGGGCTACTGCAAAAACGGGGGCTTCTTCC 
N-40 CGGGATCCCGCCACCATGGGCATCCACCCCGACGGCCG 
N-50 CGGGATCCCGCCACCATGGGCCGGGAGAAGAGCGACCCTCAC 
REV CGGGATCCGTAAGTATTGTAGTTATTAGATTCCAATCG 
 
 
C-terminal Truncations 
 
Primer Sequence 
FOR CCAAGCTTGCGGCCGCACCG 
C1-146 GACGGGGCCCTATAGCTTTCTGCCCAGGTCCTGTTTTGG 
C1-136 GACGGGGCCCTCCAAGTTTATACTGCCCAGTTCG 
C1-126 GACGGGGCCCTGCCACATACCAACTGGTGTATTTCC 
C1-116 GACGGGGCCCCCGGTAAGTATTGTAGTTATTAGATTCC 
C1-106 GACGGGGCCCTCGTTCAAAAAGAAACACTCATCCGTAAC 
C1-96 GACGGGGCCCACATTTAGAAGCCAGTAATCTTCCATCTTC 
C1-86 GACGGGGCCCCTTCATAGCCAGGTAACGGTTAGCAC 
C1-66 GACGGGGCCCTGCTTGAAGTTGTAGCTTGATGTGAGGG 
C1-56 GACGGGGCCCGCTCTTCTCCCGGACCCCG 
C1-46 GACGGGGCCCGTCGGGGTGGATGCGCAGG 
C1-36 GACGGGGCCCGTTTTTGCAGTACAGCCGCTTGGGG 
Cwt GACGGGGCCCGCTCTTAGCAGACATTGGAAGAAAAAG 
GFPforapaI GACGGGGCCCATGGTGAGCAAGGGCGAGG 
GFPrevsphI ATCGATGCATGCTTAGTGATGGTGATGG 
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2.1.6 Bacteria and Media 
 
The following E.coli strains were used for cloning and amplification. They were grown 
in LB (Luria Bertani) medium or on LB agar plates supplied with ampicillin in a final 
concentration of 100 µg/ml to select for successfully transformed cells carrying 
plasmids containing the appropriate resistance gene. 
 
DH5α      Invitrogen, Karlsruhe 
XL1-Blue supercompetent cells  Stratagene, La Jolla 
 
 
LB medium 
5 -10g NaCl 
10g Tryptone 
5g Yeast extract 
ad 1 l   H2OmilliQ 
 
LBAmp plates 
5 -10g NaCl 
10g Tryptone 
5g Yeast extract 
15g    Agar 
ad 1 l   H2OmilliQ 
 
2.1.7 Eukaryotic Cells and Media 
 
Chinese Hamster Ovary (CHO) cell lines 
 
Several CHO model cell lines expressing different mutated versions of FGF2-GFP in 
a doxicycline dependent manner were generated during this thesis. They were stably 
transduced with the corresponding reporter constructs and were used to function as 
a eukaryotic system to investigate FGF2 in a living cell. For the procedure of 
retroviral transduction see section 2.5.2.   
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Human Embryonic Kidney (HEK) cells 
 
The cell line HEK 293T was used for the production of retroviral particles carrying 
different reporter constructs. 
 
-Modification of the Minimal Essential Medium (-MEM) 
 
The -Modification of the Minimal Essential Medium was used for cultivation of CHO 
cells. The appropriate amount of -MEM powder (Biochrom KG, Berlin) was 
dissolved in 5 l of ultrapure water and 10 g of sodium hydrogen carbonate was added 
to adjust the pH to 7.4. The prepared medium was filter sterilized into autoclaved 
bottles and stored at 4°C. If the medium was stored for more than six weeks, 2 mM 
L-glutamine were added before use. The medium was supplemented with 10% (v/v) 
fetal calf serum (FCS) and 500 U Penicillin/Streptomycin before it was added to 
cultured cells. 
 
Dulbecco´s Modified Eagle Medium (DMEM) 
 
The Dulbecco´s Modified Eagle Medium was used for the cultivation of HEK cells. 
Dry medium (Biochrom KG) was dissolved in 5 l of ultrapure water, and 10g of 
sodium hydrogen carbonate was added to adjust the pH to 7.4. The prepared 
medium is sterile filtered into autoclaved bottles and stored at 4°C. If the medium was 
stored for more than 6 weeks, 2 mM L-glutamine were added before use. Before 
addition to cultured cells, the medium was supplemented with 10% (v/v) fetal calf 
serum (FCS) and 500 U Penicillin/Streptomycin. 
 
Maintaining CHO cells 
 
CHO cells were maintained at 37°C in 5% CO2 (Heraeus incubator), in Minimal 
Essential Medium (-MEM) supplemented with 10% (v/v) fetal calf serum (FCS) and 
500 U Penicillin/Streptomycin. Cells were passaged when confluent by removing the 
old medium and washing the cells with PBS. After trypsinization of the cell monolayer 
with 1 ml trypsin (0.125% trypsin in PBS, 0.5 mM EDTA), the cells were resuspended 
in 10 ml of fresh culture medium and finally seeded into cell culture dishes at desired 
densities, depending on the experiment requirements.  
Material and Methods 
 
36 
Freezing of eukaryotic cells 
 
Frozen stocks for long time use were prepared from cells grown to 100% confluency 
on a 10 cm culture plate. The cells were washed once with PBS and detached using 
1 ml trypsin/EDTA. Subsequently, the cells were resuspended in growth medium, 
transferred to a 10 ml tube and pelleted by low speed centrifugation at 200 g for 5 
min at 4°C. The pellet was carefully resuspended in 2 ml freeze medium and 
transferred to 2 ml cryo tubes which were frozen at -80°C. For long term storage the 
frozen cryo tubes were transferred to liquid nitrogen cell storage tanks. 
   
Freeze medium 
20% FCS (v/v) 
10% DMSO (v/v) 
1 mg/ml Streptomycin/Penicillin 
70% αMem or DMEM 
 
Thawing of eukaryotic cells 
 
To defreeze cells the cryo tube was removed from liquid nitrogen and immediately 
thawn in a water bath at 37°C. The cells were transferred to 20 ml of prewarmed 
culture medium in a 50 ml tube and sedimented by low speed centrifugation (200 g, 5 
min, 4°C). DMSO was removed by discarding the medium followed by resuspension 
of cells using fresh growth medium. The cells were then seeded on culture plates ( Ø 
10 cm) and incubated at 37°C supplemented with 5% CO2. 
 
2.2 Molecular biological methods 
 
2.2.1 Polymerase Chain Reaction (PCR) 
 
2.2.1.1 Random Mutagenesis 
 
A low fidelity PCR based on the addition of MnCl2 was performed to introduce 
randomly distributed base pair alterations into the open reading frame of FGF2. 
(Shafikhani et al., 1997).  
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The used primers were FGF2-MUT-FOR and FGF2-MUT-REV respectively and are 
listed in section 2.1.6. 
PCR reaction mix: 
 
PCR for random Mutagenesis 
30 ng template DNA (PRevTRE2 FGF2-GFP) 
25 pmol FGF2-MUT-FOR 
25 pmol FGF2-MUT-REV 
10 µl 2.5 mM dNTP-Mix 
12 µl  25 mM MgCl2 
10 µl 5 mM MnCl2 
10 µl 10x PCR buffer 
0.5 µl 5 U Ampli-Taq Polymerase 
Ad 100 µl  H2OMilliQ 
 
PCR program: 
 
Start:  2 min at 95°C 
Amplification:  1 min at 94°C Denaturation 
20 cycles  1 min at 50°C Hybridization 
   1 min at 72°C Elongation 
End:    10 min at 72°C 
 
The PCR product was then subjected to an agarose gel electrophoresis, proving 
correct size of the amplified DNA, followed by purification of the PCR product using 
the QIAquick PCR Purification Kit (Qiagen). 
 
 
2.2.1.2 Point mutations 
 
Point mutations were introduced into FGF2 using the QuickChange Site-Directed 
Mutagenesis kit. PCR reactions were performed using PfuTurbo Polymerase, a 
dsDNA vector with the insert of interest (pGEM-T-FGF2-GFP) and two synthetic 
complementary primers containing the desired mutation (see chapter 2.1.6). 
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Incorporation of the oligonucleotide primers generated a mutated plasmid containing 
staggered nicks. 
 
PCR reaction mix: 
 
PCR for point mutations 
50 ng template DNA (PGemT-FGF2-GFP) 
125 pmol Forward primer 
125 pmol Reverse primer 
10 µl 2.5 mM dNTP-Mix 
5 µl 10x PCR buffer 
0.5 µl 5 U PfuTurbo Polymerase 
Ad 50 µl  H2OMilliQ 
 
PCR program: 
 
Start:    1 min at 30°C 
Amplification:  30 s at 95°C  Denaturation  
16 Cycles  1 min at 55°C Hybridization   
   4 min at 68°C Elongation 
End:   store at 4°C 
 
 
The PCR products were treated with 10U of the endonuclease Dpn I for 1h at 37°C, 
which specifically cuts methylated DNA. Dpn I was used to digest the parental DNA 
template derived from a dam methylase containing E.coli strain, therefore selecting 
for mutated newly synthesized DNA. The nicked vectors containing the desired 
mutations were subsequently introduced into DH5α- or XL1-Blue supercompetent 
cells. 
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2.2.1.3 Truncations 
 
Specific primers were used for the generation of N- and C-terminal truncations which 
are listed in section 2.1.6. 
 
PCR reaction mix: 
 
PCR for N- and C-terminal Truncation 
30 ng template DNA (PGemT-FGF2-GFP) 
25 pmol Forward primer 
25 pmol Reverse primer 
10 µl 2.5 mM dNTP-Mix 
10 µl 10x PCR buffer 
0.5 µl 5 U Ampli-Taq Polymerase 
Ad 100 µl  H2OMilliQ 
 
For primers used see chapter 2.1.7 
 
PCR program: 
 
Start:    2 min at 95°C 
Amplification:  1 min at 94°C Denaturation 
35 cycles  1 min at 47°C Hybridization  
   1 min at 72°C Elongation 
End:   10 min at 72°C 
 
The PCR product was then subjected to an agarose gel electrophoresis, proving 
correct size of the amplified DNA, followed by purification of the PCR product using 
the QIAquick PCR Purification Kit (Qiagen). 
 
2.2.2 PCR Purification 
 
PCR products were purified using the QIAquick PCR Purification (Qiagen) according 
to the manufacturers instructions. The DNA was eluted with 30 µl H20MilliQ. 
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2.2.3 Restriction digestion and Dephosphorylation 
 
Restriction digestions of DNA with endonucleases were performed after a procedure 
described by (Maniatis et al., 1989). Reactions were carried out as recommended by 
New England BioLabs. According to used enzymes, the appropriate buffer and 
supplements were used.  About 2-4 U of the corresponding enzyme was used to 
digest 1 µg DNA. The reaction mix was incubated up to 4 h at 37°C.   
To remove 5´-phosphates at the ends of linearised vectors (to prevent self-ligation of 
vector) the restriction product was treated with 1 U calf intestinal alkaline 
phosphatase (CIP, New England Biolabs) per 1 µg DNA for 30 min at 37°C.  
 
2.2.4 Ligation of DNA fragments 
 
Ligations of linearised vectors and inserts digested with the same restriction enzymes 
were conducted using the TAKARA ligation kit. 50 ng of vector were used in the 
reaction, the amount of insert was calculated using the following equation:  
 
amount (ng) vector x size (bp) insert 
                                                            = amount (ng) insert 
              
  size (bp) vector 
 
 
5 µl Solution 1, containing the ligase, was added to the DNA and the reaction mix 
was filled up with H2O to a final volume of 10 µl. The ligation was performed for 3 h at 
37°C or over night at 16°C followed by heat inactivation of the ligase at 60°C for 10 
min. 
 
2.2.5 Transformation of E.coli with plasmid DNA 
 
1-10 ng DNA or 5µl from a ligation reaction were incubated with 30 µl of competent 
E.coli DH5α cells for 30 min on ice, followed by heat shock at 37°C for 20 s and 
incubation on ice for additional 2 min. 1 ml of LB medium was added followed by 
incubation for 1h at 37°C under constant shaking (300 /min). The cells were then 
spread on LB plates containing 100 µg/ml ampicillin and cultivated at 37°C over night. 
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2.2.6 Selection of clones 
 
After incubating LBAmp plates over night, bacteria resistant to ampicillin form colonies 
on the plates. For amplification of single colonies, they were transferred with a pipette 
tip to 5 ml LB medium containing ampicillin (100 µg/ml) and incubated for 12-16 h at 
37°C under constant shaking (200 U/min). 
 
2.2.7 Isolation of plasmid DNA from bacteria 
 
Plasmid DNA from over night cultures incubated with individual colonies from LBAmp 
plates was prepared using kits supplied by Macherey & Nagel or Qiagen according to 
the manufacturers manual. Following alkaline lysis of bacterial cells the DNA was 
bound to a silica-membrane in presence of high salt concentrations. After washing 
the membrane, the purified DNA was eluted using H2OMilliQ. Depending on the 
volume of the over night cultures, the following kits were used: 
 
Volume of bacterial cells Qiagen Kit Machery & Nagel Kit 
5 – 10 ml  QIAprep Spin Miniprep Kit Nucleospin Plasmid 
20 – 150 ml QIAprep Plasmid Midi Kit Nucleobond-PC 100 
More than 150 ml QIAgen Plasmid Maxi Kit Nucleobond-PC 500 
 
2.2.8 Agarose gel electrophoresis 
 
Size and purity of DNA fragments were analyzed by agarose gel electrophoresis. For 
the preparation of agarose gels, 1% (w/v) agarose was dissolved in 1x TAE using a 
microwave and poured in a casting device after addition of ethidiumbromide to a final 
concentration of 0.5 µg/ml. 
 
50x TAE buffer 
242 g Tris 
57.1 ml Glacial acidic acid 
100 ml  EDTA, 0.5 M, pH 8 
ad 1 l   H2OmilliQ 
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After addition of the appropriate amount of sample buffer containing glycerol (30% 
w/v), the samples were loaded on the gel.  
 
5x sample buffer 
0.25% (w/v) Bromphenol blue 
0.25% (w/v) Xylencyanol FF 
30% (w/v) Glycerol 
 
Electrophoresis was conducted in 1x TAE buffer at 100 V for approximately 20 min. 
For visualization BioRad Gel Doc System was used. 
 
2.2.9 DNA extraction from agarose gels 
 
Bands were visualized with UV light (366 nm) and cut out of the agarose gel. The 
extraction of DNA was carried out following the manual from the DNeasy gel 
extraction kit. The DNA was eluted with 30 µl elution buffer or H20MilliQ.  
 
2.2.10 DNA Sequencing 
 
All obtained constructs were verified by DNA-Sequencing. Therefore the demanded 
amount of DNA was sent to specialized companies (Seqlab, Göttingen or GATC, 
Konstanz). Editing, assembly and analysis of DNA sequences was performed using 
LaserGene Software. 
 
2.3 Biochemical Methods 
 
2.3.1 SDS-Polyacrylamid-gel electrophoresis 
 
SDS polyacrylamide gel electrophoresis was performed as described by (Laemmli, 
1970). The Mini-PROTEAN III-Gel system (Bio-Rad) was used. The gels used had a 
size of 80 x 73 mm and a thickness of 0.75 mm, consisting of a separating and a 
stacking gel. 
For preparation of the separating gel the following solutions were mixed and poured 
between two glass plates fixed in the casting device: 
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Separation gel  10 % 13 % 
H2OMilliQ 2 ml 1.68 ml 
1.5 M Tris-HCl pH 8.8 1.25 ml 1.25 ml 
10% (w/v) SDS 50 l 50 l 
Acrylamide/Bis 30% (w/v) 1.66 ml 2 ml 
10 % (w/v) Ammonium persulphate (APS) 25 l 25 l 
N,N,N',N'-Tetramethylendiamin (TEMED) 2.5 l 2.5 l 
 
To achieve an even surface, isopropanol was carefully poured over the not yet 
polymerized gel surface. After polymerization was completed, isopropanol was 
removed with Whatman paper. 
 
For the 4.8 % stacking gel the following solutions were mixed and poured on the 
separation gel: 
 
Stacking Gel   
1.53 ml H2OMilliQ 
0.625 ml 0.5 M Tris-HCl pH 6.8 
25 l 10% (w/v) SDS 
335 l Acrylamide/Bis 30% (w/v) 
12.5 l 25 % (w/v) Ammonium persulphate (APS) 
2.5 l N,N,N',N'-Tetramethylendiamin (TEMED) 
 
The samples were mixed in a ratio of 3:1 with sample buffer and heated for 10 min at 
95°C before loading onto the gel.  
 
4x Sample Buffer   
200 mM Tris-HCl, pH 6.8 
25% (w/v) Glycerol 
2% (w/v) SDS 
0.2% (w/v) Bromphenol blue 
0.7 M -Mercaptoethanol 
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Running Buffer   
25 mM Tris pH 8.3 
192 mM Glycine 
0.1% (w/v) SDS 
 
Electrophoresis was performed in running buffer at 200 V until the bromphenol blue 
marker front reached the end of the gel. 
 
2.3.2 Western Blot Analysis 
 
Western blotting was performed as described by (Towbin et al., 1979). Proteins 
separated by SDS-PAGE were blotted on a polyvinylidene fluoride (PVDF) 
membrane (Immobilon™-P/FL, Millipore) using a wet blotting apparatus (MiniProtean 
Trans Blot®, Bio-Rad). 
 
Solutions: 
 
Blotting / transfer buffer  
192 mM Glycine 
25 mM Tris-Base 
20% (v/v) Methanol 
 
Ponceau S  
0.25% (w/v) Ponceau S 
3% (v/v) TCA 
 
1x PBS 
140 mM Sodium chloride (NaCl) 
2.7 mM Potassium chloride (KCl) 
10 mM Sodium hydrogen phosphate (Na2HPO4) 
1.8 mM Potassium dihydrogen phosphate (KH2PO4) 
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PBS-Tween   
0.05% (w/v) Tween 20 
 PBS 
 
Blocking buffer   
5% (w/v) Milk powder 
 PBS-Tween 
 
Primary antibody buffer   
3% (w/v) Bovine serum albumin (BSA) 
0.02 % (w/v) Sodium azid (NaN3) 
 PBS-Tween 
 
Secondary antibody buffer (HRP system)   
3% (w/v) Milk powder 
 PBS-Tween 
 
Secondary antibody buffer (Licor system)   
3% (w/v) Milk powder 
0.01% SDS 
 PBS-Tween 
 
 
2.3.2.1 Transfer of proteins to polyvinylidene fluoride (PVDF) membrane 
A PVDF membrane sheet of the same dimensions as the gel was prepared, soaked 
in methanol and equilibrated in blotting buffer. Two pieces of filter paper (Whatman 
3MM) of the same size as the gel were soaked in blotting buffer, as well as two 
sponges. The blotting apparatus was assembled, taking care to remove air bubbles, 
and placed in the transfer tank with the PVDF membrane towards the anode. An ice 
block was placed in the tank, which was then filled up with blotting buffer. Protein 
transfer to the PVDF membrane was performed at constant voltage (100 V) for 1h. 
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      Anode (+) 
Sponge 
3 MM Whatman 
PVDF membrane 
SDS gel 
3MM Whatman 
Sponge 
 
  Kathode (-) 
Figure 2.1: Assembly of the Western Blot apparatus  
 
2.3.2.2 Ponceau S staining 
 
Following transfer to the membrane, proteins were visualized by staining with 
Ponceau S for one minute while shaking. Background staining was removed with 
H2OMilliQ until the bands were clearly observed and the position of the molecular 
weight marker proteins was labeled on the membrane. Complete destaining was 
reached by washing the membrane in PBS-Tween. When using the Licor System, 
Ponceau S staining was not performed, since this resulted in an enhanced 
background. 
 
2.3.2.3 Immunochemical detection of proteins (HRP system) 
 
The membrane was treated with blocking buffer for one hour at room temperature or 
overnight at 4°C, and subsequently incubated for 1h with affinity-purified polyclonal 
antibodies directed against the protein of interest. The membrane was washed three 
times with PBS-Tween followed by treatment with the appropriate horseradish 
peroxidase (HRP)-conjugated secondary antibodies for 1h. After three washing steps, 
remaining secondary antibody was removed with PBS-Tween. Visualization was 
performed using the enhanced chemi-luminescence mixture (ECL; Amersham): The 
membrane was incubated for 60 s in the reagent, patted dry, covered in Saran wrap 
and exposed to Super RX Medical X ray film (Fuji) for up to thirty minutes.  
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2.3.2.4 Immunochemical detection of proteins (Licor System) 
 
The membrane was treated with blocking buffer without Tween-20 for one hour at 
room temperature, and subsequently incubated for one hour with affinity-purified 
polyclonal antibodies directed against the protein of interest. The membrane was 
washed four times with PBS-Tween followed by treatment with the appropriate Alexa 
680-conjugated secondary antibodies for 30 min. After four times of washing, 
remaining secondary antibodies were removed using PBS-Tween, followed by one 
washing step using PBS without Tween-20. Visualization was performed by the 
Odyssey System (Licor).  
 
2.3.3 Biochemical assay to estimate the amount of secreted FGF2-GFP 
 
CHO cells were grown on 6-well plates for 48 h at 37°C in the presence of 1 µg/ml 
doxicycline and 125 µg/ml heparin. The medium was removed followed by the 
dissociation of the cells from the culture plates using a protease-free buffer (Cell 
dissociation buffer) supplemented with 125 µg/ml heparin. Following sedimentation of 
cells, the supernatant was combined with the original medium, diluted 1:10 in a Tris 
buffer (10 mM, pH 7.4) containing 1 mM EDTA and 1% (w/v) Triton X-100. The cells 
were lysed in the same buffer. Both the cellular extracts and the corresponding 
supernatants were then subjected to affinity purification using heparin sepharose 
(Amersham Pharmacia). Bound material was eluted with SDS sample buffer followed 
by SDS-PAGE and western blot analysis using affinity-purified anti-GFP antibodies 
and ECL detection. 
 
2.3.4 Isolation of detergent-insoluble microdomains 
 
CHOFGF2-GFP cells were grown on large culture plates (ø 15 cm) for 36 h in the 
presence of doxicycline (1 g/ml). The cells were washed twice with PBS followed by 
the addition of PBS supplemented with 10% (w/v) sucrose. After dissociation from 
the culture plates using a rubber policeman, cell disruption was achieved using a 
Balch homogenizer (Balch and Rothman, 1985). The resulting suspension was 
subjected to differential centrifugation at 1000 g and 5000 g, respectively. The 5000 g 
supernatant was loaded onto a 20% sucrose cushion followed by ultracentrifugation 
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at 100,000 g for 60 min at 4°C. The resulting membrane sediment represents a 
microsomal membrane fraction containing intracellular as well as plasma membranes. 
The preparation of detergent-soluble and –insoluble fractions as well as a flotation 
analysis employing sucrose gradients were performed as described by (Gkantiragas 
et al., 2001).  
 
2.3.5 Biotinylation of proteins associated with the cell surface 
 
Biotinylation was performed as described by Seelenmeyer et al, 2005. Extracellular 
proteins were labeled with a membrane impermeable biotin reagent and in this way 
discriminated from the intracellular fraction. 
 
Solutions: 
PBS Ca2+/Mg2+   
1x PBS 
1 mM MgCl2 
0.1 mM CaCl2 
 
Incubation buffer   
150 mM MgCl2 
10 mM Triethanolamine pH 9 
2 mM CaCl2 
 
Quenching buffer   
 PBS Ca2+/Mg2+ 
100 mM Glycine 
 
Lysis buffer 
62.5 mM EDTA 
50 mM Tris-HCl pH 7.5 
0.4% Deoxycholate 
1% NP-40 
 Protease inhibitor tab (1 in 10 ml) 
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Washing buffer 1 
62.5 mM EDTA 
50 mM Tris-HCl pH 7.5 
0.4% Deoxycholate 
1% NP-40 
0.5 M NaCl 
 
Washing buffer 2 
62.5 mM EDTA 
50 mM Tris-HCl pH 7.5 
0.4% Deoxycholate 
0.1% NP-40 
0.5 M NaCl 
 
The CHO model cell lines were grown on 12-well plates in presence of 1µg/ml 
doxicycline to a confluency of 70%. Cells were washed twice with cold PBS 
Ca2+/Mg2+ and subsequently incubated for 30 min at 4°C with 350 µl of incubation 
buffer containing 0.5mg/ml membrane-impermeable biotin (EZ-link Sulfo-NHS-SS-
biotin, Pierce). To quench remaining biotin reagent, cells were washed with 
Quenching buffer, followed by incubation at 4°C for 20 min with 350 µl Quenching 
buffer. A washing step with PBS was introduced to remove residual Quenching buffer, 
followed by incubation for 10 min at 37°C with 110 µl Lysis buffer. Cells were scraped 
off using a rubber policeman, resuspended and transferred to an Eppendorf tube. 
Cell lysates were produced by sonication in a sonication bath for 3 min, followed by 
incubation for 15 min at RT, pipetting the sample up and down several times. To 
remove insoluble material, a centrifugation at 16,000 g was performed. An aliquot of 
10% was stored as the input material. The remaining lysate was subjected to a 
streptavidin affinity chromatography, using 20 µl packed beads, equilibrated with lysis 
buffer. After incubation of lysates with the beads for 1 h at room temperature under 
constant head-over-head rolling, a centrifugation at 3000 g was performed to pellet 
the beads. The supernatant was discarded. To remove non-specific bound material, 
the pellet was washed three times with Washing Buffer 1, followed by two washing 
steps with Washing Buffer 2. The residual Washing Buffer 2 was carefully removed 
and the biotinylated protein, bound to streptavidin beads was eluted with 20 µl of 
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Sample Buffer. Input and eluate were subsequently analyzed by SDS-PAGE and 
Western blotting using anti-GFP antibodies. 
 
2.3.6 Preparation of cell free supernatant 
 
FGF2-GFP fusion proteins were expressed in CHO cells by incubating the cells in the 
presence of doxicycline (1 g/ml) for 48 h at 37°C. After removing growth medium 
and washing cells with PBS, they were detached from the culture plate using Cell 
Dissociation Buffer. Cells in solution were transferred to an Eppendorf tube und 
submitted to a low speed centrifugation step for 3 min at 200 g to pellet cells. 
Resuspension was carried out by adding 500 µl of PBS. Cell-free supernatants were 
then prepared by homogenization combining freeze-thaw cycles with sonication. 
Membranes were removed in two steps by centrifugation at 14000 g (10 min at 4°C) 
and 100000 g (1h at 4°C) The resulting supernatants were analyzed for the amounts 
of fusion protein based on GFP fluorescence as measured with a fluorescence plate 
reader (Molecular Devices Spectra Max Gemini XS). 
 
2.3.7 Binding of FGF2 to heparin beads 
 
Cell free supernatant was produced as described in 2.3.4. Normalized amounts of 
the supernatant (50 GFP units corresponding to about 0.5 g GFP) were then 
incubated with heparin beads (Sigma), equilibrated with PBS, for 1h at 4°C. An input 
fraction, corresponding to 10% of the total protein was removed prior to binding and 
stored at 4°C. Beads were centrifuged at 800 g and the supernatant (non-bound 
material) was stored at 4°C. Following extensive washing with PBS, bound material 
was eluted using SDS sample buffer. Input, flow-through fraction and SDS eluates 
were analyzed by SDS PAGE and Western blotting using anti-GFP antibodies. 
 
2.3.8 Precipitation of FGF2-GFP from culture media using heparin beads 
 
Medium was removed from the cells which were additionally washed with PBS. 
Heparin beads were equilibrated using PBS. Both, medium and PBS were subjected 
to heparin beads for 1h at 4°C to allow binding of FGF2-GFP, present as a soluble 
protein in the medium, to heparin beads. After centrifugation at 3000 g to pellet 
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beads, the supernatant (non-bound material) was removed. The pellet was 
extensively washed using PBS, followed by eluating bound material from heparin 
beads using SDS-sample buffer. The SDS eluate was then subjected to SDS-PAGE 
and Western blotting using anti-GFP antibodies. 
 
2.3.9 Binding of FGF2-GFP to CHOMCAT/TAM2 Cells 
 
Cell free supernatant was produced as described in 2.3.4. Normalized amounts of 
the supernatant (50 GFP units corresponding to about 0.5 g GFP) were then 
incubated with CHOMCAT/TAM2 cells for 1h at 4°C to allow binding of FGF2-GFP to 
receptors present on the cell surface of the cells. Cells were subsequently washed 
using PBS and prepared for FACS analysis (see 2.4.2). 
 
2.3.10 Immunoprecipitation of FGF2-GFP from growth medium 
 
20 µl of a 1:1 Protein A and CL-4B-sepharose mix were transferred to an Eppendorf 
tube, followed by extensive washing with IP-buffer 1.  
 
IP-buffer 1 
25 mM Tris-HCl 7.4 
150 mM NaCl 
1 mM  EDTA 
0.5% NP-40 
 
To bind antibodies to sepharose, affinity-purified anti-GFP antibodies in IP-buffer 1 
was added to the beads and incubated over night at 4°C under constant shaking. 
Sepharose was then extensively washed using IP buffer 2.  
 
IP-buffer 2 
25 mM Tris-HCl 7.4 
150 mM NaCl 
1 mM  EDTA 
0.5% NP-40 
1%  BSA 
 
Subsequently, the sepharose was pelleted and the supernatant was carefully 
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removed. Growth medium and PBS-wash solution obtained from the corresponding 
CHO model cell lines were added to the sepharose and incubated for 2 h at 4°C. 
After three of washing steps with IP-buffer 0, the protein was eluted using SDS-
containing sample buffer.  
 
 
IP-buffer 0 
25 mM Tris-HCl 7.4 
150 mM NaCl 
1 mM  EDTA 
 
The eluate was then applied to SDS-PAGE and Western blotting using affinity-
purified anti-GFP antibodies. 
 
2.4 FACS Analysis 
 
2.4.1 Antibody labelling of cells in suspension 
 
The following solutions were used during the antibody labelling procedure: 
 
PBS EDTA 
1x PBS 
0.5 mM EDTA 
 
Primary antibody 
 α-MEM (growth medium) 
1:200 Affinity-purified anti-GFP antibodies 
 
Secondary antibody 
 α-MEM (growth medium) 
1:750 Goat anti rabbit IgG coupled to allophycocyanin 
(APC) 
 
Sorting medium 
 α-MEM without FCS 
0.2% FCS 
5% CDB 
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Cells were washed with PBS and detached from the culture plate using Cell 
Dissociation Buffer (Invitrogen) or PBS/EDTA and sedimented by low speed 
centrifugation at 200 g for 3 min. The supernatant was removed and the pellet was 
washed once with PBS. Cells were then incubated with 500 µl of primary antibodies 
for 1h at 4°C. Antibody solution was removed by washing cells two times with PBS. 
500 µl of secondary antibodies was applied to the cells for 30 min at 4°C, followed by 
two washing steps using PBS. Cells were resuspended in 500 µl sorting medium 
subsequently analyzed via flow cytometry (FACS Calibur, Becton Dickinson). 
 
2.4.2 Antibody labelling of Cells Attached to the culture plate 
 
PBS/EDTA 
1x PBS 
0.5 mM EDTA 
 
Primary antibody 
 Alpha-MEM (growth medium) 
1:200 Affinity-purified anti-GFP antibody 
 
Secondary antibody 
 Alpha-MEM (growth medium) 
1:750 Goat anti rabbit IgG coupled to allophycocyanin 
(APC) 
 
Sorting medium 
 Alpha-MEM without FCS 
0.2% FCS 
5% CDB 
 
Cells were washed with PBS followed by incubation with 350µl primary antibodies for 
1h at 4°C. Following one washing step with PBS, secondary antibodies were added 
to attached cells for 30 min at 4°C. To remove free antibodies, cells were extensively 
washed with PBS prior to their detachment of cells using 200 µl cell dissociation 
buffer or PBS/EDTA. Cells were transferred in Eppendorf tubes containing 300 µl 
sorting medium and subsequently analyzed via flow cytometry (FACS Calibur, 
Becton Dickinson). 
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2.5 Production of stable Cell Lines 
 
2.5.1 Retroviral Transduction 
 
CHO cell lines were generated by retroviral transduction of CHOMCATTAM cells with the 
corresponding reporter constructs. All plasmids used are listed in chapter 2.1.6.  
  
Principle of this method:   
HEK 293T cells were cotransfected with the plasmid pVPack Eco encoding a 
retroviral envelope-protein and the reporter construct cloned into pRevTRE2 or pFB-
GFP as a control. The transfected cells produce retroviral particles containing the 
RNA of interest which accumulate in the cell culture medium. The medium is then 
transferred to the CHOMCATTAM target cells that are infected by the retrovirus followed 
by reverse transcription and the integration of the reporter DNA into the host cell 
genome. 
 
Experimental procedure: 
The retroviral transduction was conducted using the MBS Mammalian Transfection 
Kit, (Stratagene) according to the protocol supplied by the manufacturer. In the 
following the procedure is described briefly: On the first day, the required plasmids 
were precipitated and HEK 293T cells were splitted. On the second day, HEK 293T 
cells were transfected with the prepared DNA and production of retroviral particles 
starts. On the next day, CHOMCAT/TAM2 target cells were splitted 1:20. On the fourth 
day, the medium from virus producing HEK 293T cells was sterile filtered and 
transferred to the target CHOMCAT/TAM2 cells. After adding growth medium to medium 
containing virus particles, cells were incubated for another two days prior to FACS 
analysis to prove the expression of the integrated reporter molecules. 
 
2.5.2 FACS Sort 
 
Sorting of cells expressing the desired GFP fusion protein was conducted in 
collaboration with Dr. Blanche Schwappach from the Center of Molecular Biology 
Heidelberg (ZMBH). Transduced cells were induced to synthesize the desired protein 
by adding doxicycline (1µg/ml) for 16 h to the growth medium of transduced cells. 
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Detachment of cells occurred with sterile cell dissociation buffer (Invitrogen), followed 
by addition of 500 µl of sorting medium.  
 
Sorting medium 
 α-MEM without FCS 
0.2% FCS 
5% CDB 
 
Cells were subsequently passed through a cell strainer cap into a sterile round 
bottom FACS tube (Becton Dickinson) and analyzed via flow cytometry (FACS 
Vintage or FACSAria, Becton Dickinson). GFP positive cells were collected in 6-well 
plates and propagated for a week. A second sorting step was conducted without prior 
induction of protein synthesis and cells were collected for negative GFP fluorescence 
on 6-well plates. After propagation of these cells for a week and incubation with 1 
µg/ml doxicycline for 16 h a final sorting step was conducted, sorting cells for 
enhanced GFP-fluorescence. The cells were either sorted as single cell events in a 
96-well plate to generate clonal cell lines or as cell populations in 6-well plates. 
 
2.6 Confocal Microscopy 
 
Cells were grown on cover slips placed in 12 well plates. After washing with PBS, 
cells were fixed without permeabilization for 20 min on ice using 3% 
paraformaldehyde. Remaining PFA was washed away using PBS and cells were 
quenched for 10 min with 50 mM NH4Cl. Unspecific antibody binding was avoided by 
incubating cells with 1% BSA in PBS for 10 min. Subsequently, cells were processed 
with primary antibodies (1:50 affinity-purified anti-GFP antibody, 1h, RT) and 
secondary antibodies (1:250 goat anti-rabbit Alexa 546, 1h, RT). After removing 
antibody solution by multiple washing steps, specimens were mounted in 
Fluoromount G (Southern Biotechnology Associates), sealed and viewed with a Zeiss 
LSM 510 confocal microscope. 
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3 Results 
 
Most of the examples of protein translocation across a membrane (such as the 
import of classical secretory proteins into the endoplasmic reticulum (ER), import of 
proteins into mitochondria and peroxisomes, as well as protein import into and export 
from the nucleus), are understood in great detail. Generally, proteins are targeted to 
the corresponding translocation apparatus by “transport” signals which are specific 
for protein import into distinct organelles. Proteins imported into the ER contain N-
terminal signal peptides directing the protein to the translocation apparatus (Walter et 
al., 1984). Proteins that are translocated over mitochondrial membranes contain 
either N-terminal cleavable signal sequences or internal targeting sequences (Schatz, 
1996; Neupert, 1997; Gordon et al., 2000). Peroxisomal proteins contain peroxisomal 
targeting sequences (PTS) which direct the protein to the peroxisomal transport 
machinery. (Johnson and Olsen, 2001). The nuclear import of proteins into the cell 
nucleus involves the recognition of a nuclear localization signal sequence which is 
recognized by the translocation apparatus of the nuclear transport machinery 
(Christophe et al., 2000).  
In contrast, unconventional protein secretion from eukaryotic cells was discovered 
about 15 years ago, but the transport mechanism is still poorly understood. In 1991, 
Interleukin-1β has been suggested to be exported in an unconventional manner 
(Rubartelli and Sitia, 1991) and only two years later FGF2 has been proposed to be 
exported independently from the classical secretion pathway (Mignatti and Rifkin, 
1991). However, the molecular mechanism and the molecular identity of machinery 
components that mediate this process remain elusive.  An export targeting motif that 
directs unconventional secretory proteins to their translocation machinery has not yet 
been identified.  
This thesis was aimed on identifying such a motif which targets FGF2 to its putative 
transport machinery. Therefore, the open reading frame (ORF) of FGF2 was 
screened for amino acids potentially forming a motif which might interact with the 
machinery of the unconventional secretion pathway. The nature of this motif remains 
elusive and it has to be identified if it is composed of consecutive amino acids, 
thereby building a linear motif, or of amino acids distributed over the open reading 
frame of FGF2, building a three dimensional motif.  
In order to be able to screen for amino acids potentially forming an export targeting 
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motif, a suitable tool for the quantitative analysis of FGF2 secretion had to be 
developed first. Therefore, a model CHO cell line was generated, expressing a 
FGF2-GFP fusion protein in a doxicycline dependent manner. The first part of this 
thesis describes the establishment of an in vivo assay, which allows direct 
quantification of secreted FGF2-GFP based on flow cytometry. Furthermore, 
additional assays were developed allowing the characterization of FGF2 secretion. 
These assays were used in the second part of this thesis to perform a mutational 
analysis of FGF2, in order to elucidate an export targeting motif. Therefore more than 
100 different FGF2 mutants were generated and analyzed with regard to export 
efficiency. The individual mutants were selected by random mutagenesis employing 
low-fidelity PCR, in order to hit a broad range of multiple amino acids, by point 
mutations to hit specific single amino acids and to complete the mutational analysis 
of FGF2, and finally by systematic truncations of the C- and N-terminus of FGF2.  
 
3.1 Generation of model cell lines expressing FGF2-GFP in a 
doxicycline-dependent manner 
 
In order to establish a FGF2 export model system, CHO cells were genetically 
modified to express a GFP-tagged version of FGF2 (FGF2-GFP) and GFP, 
respectively, in a doxicycline-dependent manner.  
The generation procedure of the model cell lines is depicted in figure 3.1: 
 
Figure 3.1: schematic overview of the generation of model cell lines expressing FGF2-GFP in a doxicycline dependent manner.  
CHO cells were first stably transfected with the receptor for an ecotropic virus (MCAT), followed by retroviral transduction with a 
bicistronic Tet-On Transactivator/CD2 construct to facilitate the doxicycline dependent expression. A second retroviral 
transduction with FGF2-GFP inserted the reporter protein into the genomic DNA. Single cell clones were isolated employing 
repeated FACS sortings in the presence and absence of doxicycline. For more detail see Material and Methods, chapter 2.5 
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CHO cells were stably transfected with the mouse cationic amino acid transporter-1 
(MCAT-1; (Albritton et al., 1989; Davey et al., 1997), which serves as a receptor for 
an ecotropic envelope protein of a murine virus carrying appropriate constructs. In a 
second step, cells where transduced with an ecotropic retrovirus carrying a 
bicistronic construct consisting of the doxicycline-sensitive transactivator (rtTA2-M2) 
(Urlinger et al., 2000) and a truncated version of CD2 (Liu et al., 2000) that serves as 
a cell surface marker. A pool of CD2 positive cells was isolated by fluorescence 
activated cell sorting (FACS) sorting and subjected to another round of retroviral 
transduction using a vector carrying a doxicycline/transactivator-dependent promotor 
to generate a cell line expressing FGF2-GFP or GFP, respectively. 
 
To demonstrate the generation of cell lines the results of the sorting procedure 
displayed for the cell line CHOFGF2-GFP-His6 was used as an example in figure 3.2. 
 
 
Figure 3.2: FACS sorting based on GFP fluorescence to generate the reporter cell line FGF2-GFP. 
Cells were detached from culture dishes using cell dissociation buffer and processed for FACS analysis to measure GFP 
fluorescence. Sort 1 displays cells 3 days after viral transduction incubated in the presence of 1 µg/ml doxicycline for 12 h 
(panel A). FL1-H represents the green channel measuring GFP fluorescence, FL3-H shows the red channel displaying 
propidium iodide staining (dead cells). 50000 cells were sorted within the sorting gate (marked area). Sort 2 shows cells grown 
for 7 days in the absence of doxicycline after sort 1 (panel B). Again 50000 cells were sorted within the sorting gate. Sort 3 
shows cells 7 days after sort 2 incubated in the presence of 1 µg/ml doxicycline for 12 h. Single clones were sorted within the 
sorting gate and propagated to generate clonal cell lines or 50000 cells were sorted to generate cell pools expressing the 
reporter constructs in a doxycycline-dependent manner.  
 
Three days after retroviral transduction, 1 µg/ml doxicycline was added to the culture 
medium for 12 h. Following this incubation period, cells were detached from culture 
plates using cell dissociation buffer and processed for flow cytomery. Dead cells 
were excluded by staining with propidium iodide which intercalates into the DNA after 
membrane damage (Crissman et al., 1976).  
Based on GFP fluorescence using a FACSVantage sorting device, 50000 cells from 
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each cell line were isolated (figure 3.2, panel A). The obtained pools of cells were 
incubated for 7 days in the absence of doxicycline followed by the isolation of 50,000 
cells from each population that did not display any GFP fluorescence at this point 
(figure 3.2, panel B). Each population was now cultured for another 7 days including 
12 h in the presence of 1 µg/ml doxicycline at the end of this period (figure 3.2, panel 
C) and single cells were isolated by FACS-sorting based on GFP fluorescence.  
 
 
3.1.1 Verification of the stable integration of FGF2-GFP into the genome of 
CHO cells 
 
After retroviral transduction, the integration of the FGF2-GFP construct into the CHO 
genome was verified.  
 
 
 
Figure 3.3: PCR analysis to verify integration of FGF2-GFP into the genome of CHO cells. 
Genomic DNA was extracted from CHO cells grown on a culture plate (Ø 10 cm) to 100% confluency. After cell lysis a PCR with 
primers complementary to the flanking LTR of the retroviral system was performed. PCR from genomic DNA (10% of total), as 
well as from original plasmid (10% of total, positive control) were subjected to electrophoresis on a 1% agarose gel and 
visualized using the Biorad Geldoc System. 
 
Therefore, the corresponding cells from a 100% confluent culture plate (∅ 10 cm) 
were lysed, the genomic DNA was extracted and a PCR using genomic DNA as a 
template was performed, using specific primers complementary to the long terminal 
repeats (LTR) at the 5´and 3´ends of the retroviral genome.  
As depicted in figure 3.3, the PCR analysis of genomic DNA revealed the presence 
of DNA fragments of the expected size of 1188 bp for FGF2-GFP and 468 bp for 
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GFP, respectively. The same size of PCR products was observed for the control 
reaction using the original vector for retroviral transduction. This experiment 
confirmed the stable integration of FGF2-GFP into the genome of CHO host cells. 
 
3.1.2 Characterization of CHOFGF2-GFP and CHOGFP cells employing 
fluorescence microscopy, Western blotting and FACS analysis 
 
The doxicycline dependent expression of FGF2-GFP was characterized employing 
Fluorescence Microscopy, Western blot and FACS analysis. For all experiments, 
cells were incubated in the presence of doxycyline (1 µg/ml) for 16 h to induce the 
expression of the reporter protein. As a control, cells were grown in the absence of 
doxycyline. 
 
 
 
Figure 3.4: Characterization of CHOFGF2-GFP cells.  
The model cell line generated was characterized with regard to doxicycline dependent protein expression based on 
fluorescence microscopy (A, +dox; panel B, -dox), Western blot analysis of doxycyline dependent protein expression (C) and 
analysis of doxicycline dependent protein expression based on FACS (D). Fluorescence microscopy. Cells were grown on cover 
slips to 50% confluency and incubated for 16 h in presence (A, 1 µg/ml) and absence (B) of doxycyline and analyzed employing 
fluorescence microscopy (oil immersion objective, 63x, identical exposure time). Western blot analysis (C). Total cell lysates 
from a confluent 6-well plate were subjected to SDS-PAGE (20 µg/lane) followed by Western blot analysis employing affinity-
purified anti-GFP antibodies. FACS analysis (D). Cells were grown on 10 cm plates to 90% confluency and incubated in 
absence (grey histogram), and in presence of doxicycline (dark grey histogram), detached by cell dissociation buffer (CDB) and 
analyzed by flow cytometry using affinity-purified anti-GFP antibodies and PE-conjugated mouse anti-rabbit antibodies. 
 
Fluorescence microscopy was performed after fixation of cells grown on cover slips 
to a confluency of about 50%. GFP-derived fluorescence was detectable in the 
presence of doxicycline (A), indicating the expression of the FGF2-GFP fusion 
protein. GFP-derived fluorescence was not detectable in cells not induced with 
doxicycline (B). 
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A western blot analysis was performed after lysis of cells with SDS-containing buffer, 
followed by separation of total cell lysates (20 µg/lane) on an SDS-gel, transfer to a 
PVDF membrane and immunodetection using affinity-purified anti-GFP antibodies. 
After inducing the cells with doxicycline an immunoreactive band with an apparent 
molecular weight of 45 kDa corresponding to the expected size of FGF2-GFP was 
observed (C, +dox). Without induction, FGF2-GFP expression could not be observed 
(C, -dox). 
For FACS experiments, cells were grown on culture plates (∅ 10 cm) to about 90% 
confluency. The cells were detached using cell dissociation buffer (CDB). The 
expression level was detected by exciting GFP with a blue laser at 488 nm. CHOFGF2-
GFP cells not induced to express the fusion protein were used to calibrate the flow 
cytometer. The cells intrinsic fluorescence (autofluorescence) was thereby manually 
set to 10 arbitrary units. Inducing the expression of FGF2-GFP with doxicycline led to 
an approximately 50-100 fold increase of GFP-derived fluorescence as compared to 
autofluorescence (D).  
As demonstrated by all three independent methods, FGF2-GFP expression was 
strictly regulated by the doxicycline-dependent transactivator system, as FGF2-GFP 
was exclusively expressed in the presence of doxicycline.  
 
3.2 Establishing an in vivo system to quantitatively asses 
FGF2-GFP secretion 
 
FGF2 binds to low and high affinity receptors present on the cell surface which 
mediate its role as a growth factor. These molecules are on the one hand high-affinity 
FGF-receptors (FGFR1-4) and on the other hand receptors like heparan sulfate 
proteoglycans (HSPG) and the glycolipid GM1. Since CHO cells lack high affinity 
FGF-receptors (Rusnati et al., 2002), binding of FGF2 to the cell surface is only 
mediated by heparan sulfate proteoglycans and the glycolipid GM1. Following its 
secretion, FGF2 binds to these low affinity receptors and therefore, is detectable with 
specific antibodies on the cell surface of non-permeabilized cells.   
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3.2.1 Secreted FGF2-GFP is detected on the cell surface of CHO cells 
 
Since an intact plasma membrane is impermeable for antibodies, only secreted 
FGF2-GFP, bound to the cell surface is detectable with FGF2- or GFP-antibodies 
and can be quantified using flow cytometry. To verify this detection method, the 
following experiments were performed:  
 
 
 
Figure 3.5: FGF2-GFP is detected on the cell surface of CHO cells.  
Cells were grown for 18 hours at 37° C under the conditions indicated followed by dissociation from the culture plates employing 
a protease free protocol. The cell suspension was then processed for FACS analysis as indicated. Panel A to C represent dot 
blots, blotting total GFP-derived fluorescence against cell surface derived PE fluorescence. Panel A, cells grown in absence of 
doxicycline. Cells grown in presence of doxicycline and processed without (panel B) and with antibodies (panel C, 1:30 anti-
GFP; 1:300 goat-anti-rabbit PE-conjugated). Panel D represents the corresponding histograms of the cell surface staining. The 
colours correspond to the conditions shown in panel A to C. 
 
 
CHOFGF2-GFP cells grown on culture plates (∅ 10 cm) to a confluency of about 90% in 
presence or absence of doxicycline (1 µg/ml) were detached using a protease free 
reagent (cell dissociation buffer, CDB) and processed with primary antibodies 
(affinity-purified anti-GFP antibodies, 1:30, 1h), followed by secondary antibody 
treatment (Phycoerythrin (PE)-coupled, 1:300, 30 min) and FACS analysis. Non-
induced cells do not express the fusion protein and did not show any signal in GFP-
derived fluorescence as well as in cell surface staining (A, white dot plot).  
Cells cultivated with doxicycline (1 µg/ml) were characterized by an increased GFP-
derived fluorescence (50-100 fold) and Phycoerythrin (PE)-derived cell surface 
staining (10-20 fold) as compared to non-induced cells (C, pink dot plot). Without 
antibody processing, GFP-derived fluorescence, but no cell surface staining could be 
detected (B, green dot plot). The data described above are also shown as an overlay 
Results 
 
63 
of histograms (D). 
This experiment confirmed that FGF2-GFP is translocated to the cell surface and can 
be detected by specific antibodies. Accordingly, PE-derived fluorescence 
corresponding to cell surface localized FGF2-GFP could only be observed when 
FGF2-GFP expression was induced by doxicycline, demonstrating the 
monospecificity of the affinity-purified anti-GFP antibodies used. 
 
 
3.2.1.1 Cell surface staining is removable by trypsin and heparin treatment 
 
To ensure that PE-derived fluorescence exclusively represents FGF2-GFP bound to 
the cell surface, a control experiment was conducted. In this experiment, the 
proteolytic activity of trypsin was used to degrade cell surface proteins as for 
example heparan sulfate proteoglycans. 
 
 
 
Figure 3.6: Trypsin treatment of cells expressing FGF2-GFP reduces the signal for fusion protein bound to the cell surface.  
Cells were grown on culture plates (Ø 10 cm) to a confluency of 90%, incubated in absence (panel A) and presence of 
doxicycline (1µg/ml, 18h, panel B-D),  followed by detachment of cells using cell dissociation buffer (A-C) or trypsin/EDTA 
(0.125% (v/v), 10 min). Cells were processed without (panel B) and with anti GFP primary antibodies and PE coupled secondary 
antibodies and analyzed by FACS analysis (panel A, C, D). 
 
Cells were cultivated on culture plates (∅ 10 cm) to a confluency of about 90% in 
absence and presence of doxycyline (1 µg/ml, 18h), detached from the culture plate 
using either cell dissociation buffer (Invitrogen) or 0.125% (v/v) trypsin/EDTA, 
processed with primary and secondary antibodies  and analyzed by flow cytometry (A, 
white dot plot). The cells grown in absence of doxicycline did not show any GFP-
derived fluorescence or cell surface staining (A, white dot plot).  
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However, cells exposed to doxicycline (1 µg/ml) were characterized by increased 
GFP-derived fluorescence (50-100 fold), as well as cell surface staining (10-20 fold), 
if cells were processed with antibodies (C, pink dot plot). Without antibody processing, 
GFP-derived fluorescence, but no cell surface staining was detected (B, green dot 
plot). 
FGF2-GFP bound to the cell surface could be removed from the cell surface by 
trypsin treatment (10 min, 0,125% trypsin/EDTA (v/v), D) since the data obtained 
were quantified as shown in the following figure 3.7: 
 
 
 
figure 3.7: Quantification of cell surface staining. Mean value of fluorescence detected on the cell surface is shown. 
 
The diagram shows a 7fold increase of the signal for cell surface staining upon 
doxycyline incubation. When cells were treated with trypsin, the cell surface signal 
was reduced to background level. Thus, cell surface staining is sensitive to trypsin 
treatment, which implicates that FGF2-GFP is bound to the cell surface and 
removable by proteolytic degradation of cell surface proteins.     
 
A second control experiment was conducted to verify that PE-derived fluorescence 
corresponds to FGF2-GFP bound to the cell surface. Therefore heparin, a low-
molecular-weight compound, was used which is competing with heparin sulfate 
proteoglycans for the binding to FGF2. Addition of heparin to cells should elute 
FGF2-GFP associated with plasma membrane-localized heparan sulfate 
proteoglycans. 
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Figure 3.8: Heparin treatment of cells expressing FGF2-GFP reduces the signal for fusion protein bound to the cell surface. 
Cells were grown on a culture plate (Ø 10 cm) to a confluency of 90%, incubated in absence (panel A) and presence of 
doxicycline (1µg/ml, 18h, panel B-D), followed by detachment of cells using cell dissociation buffer (CDB). During detachment, 
Heparin (125µg/ml) was added to CDB (panel D). Cells were then processed without (panel B) and with antibodies (panel A, C; 
D). 
 
 
Cells were cultivated on culture plates (∅ 10 cm) to a confluency of about 90% in 
absence and presence of doxycyline (1 µg/ml), detached from the culture plate using 
either cell dissociation buffer (Invitrogen) or heparin (125 µg/ml), processed with 
primary and secondary antibodies and analyzed by flow cytometry (A, white dot plot). 
The cells grown in absence of doxicycline did not show any GFP-derived 
fluorescence or cell surface staining (A, white dot plot). However, cells exposed to 
doxicycline (1 µg/ml) demonstrated an increased GFP-derived fluorescence (50-100 
fold), as well as cell surface staining (10-20 fold), if cells were processed with 
antibodies (C, pink dot plot). Without antibody processing, GFP-derived fluorescence, 
but no cell surface staining was detected (B, green dot plot). In conclusion, treating 
cells with heparin (125 µg/ml) during detachment and first antibody incubation 
removed the cell surface signal demonstrating FGF2-GFP bound to the cell surface 
since the data obtained were quantified as shown in the following figure 3.9: 
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figure 3.9: Quantification of cell surface staining. Mean value of the fluorescence detected on the cell surface is shown. 
 
The diagram displays a 7 fold increase of the cell surface signal after inducing fusion 
protein expression with doxycyline. When cells were treated with heparin, the signal 
for cell surface staining was reduced to background level. 
 
3.2.1.2 FGF2-GFP binding capacity to the cell surface 
 
To analyze that the cell surface signal derived from plasma membrane associated 
FGF2-GFP is limited by the amount of binding sites available, the total binding 
capacity of CHOFGF2-GFP cells was analyzed using recombinant His6-FGF2. This His6 
tagged version of FGF2 was generated based on a PCR product corresponding to 
the 18 kDa isoform of FGF2 and the vector pET15b (Novagen). Recombinant His6-
FGF2 were expressed in E. coli BL21 (DE3) cells and purified from a 100000 g 
supernatant of homogenized cells by using Ni-NTA agarose (Qiagen) according to 
standard procedures. 
 
 
Results 
 
67 
 
 
Figure 3.10: Binding capacity of the cell surface as detected in presence of doxycyline.  
CHO-FGF2-GFP cells were cultivated on culture plates (Ø 10 cm) and incubated for 18 h with doxicycline (1µg/ml). The confluent 
culture dish was then divided into 6 equal samples. 30 min before antibody processing (described above) recombinant FGF2 
(His6-tagged) in different quantities (1ng-red, 10ng-green, 50ng-pink, 100ng-blue, and 500ng-orange) was added to the cells. A 
FACS analysis was performed after antibody processing. 
 
Therefore, CHO cells were cultivated on culture plates (∅ 10 cm) in presence of 
doxicycline (1 µg/ml, 18h) to a confluency of about 100% and split into 6 equal 
samples followed by incubation for 30 min at 4°C with recombinant His6-FGF2 in 
different amounts (1ng-red, 10ng-green, 50ng-pink, 100ng-blue, and 500ng-orange). 
Antibody processing with affinity-purified anti-FGF2 antibodies and PE-coupled 
secondary antibodies was performed and the samples were analyzed by flow 
cytometry since the data obtained were quantified as shown in the following figure 
3.11: 
 
 
Figure 3.11: Quantification of binding capacity of exogenously added FGF2 compared to secreted, endogenous FGF2.  
Mean values as arbitrary units of the fluorescence detected on the cell surface are shown. 
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Already the addition of minor amounts of His-FGF2 (1ng, 10 ng) to FGF2-GFP 
secreting cells led to an enhanced signal for cell surface staining, when compared to 
cells secreting FGF2-GFP without addition of recombinant FGF2. A significantly 
higher signal for FGF2 derived cell surface staining was obtained by adding higher 
amounts of recombinant His6-FGF2 to the samples. The cell surface signal for 500ng 
His6-tagged FGF2 was about 10 fold higher when compared to the cell surface signal 
for secreted endogenous FGF2-GFP. This indicates that the binding capacity of 
CHOFGF2-GFP cells for FGF2 is at least 10 times higher than the amount of FGF2-GFP 
externalized from these cells. Therefore, the secretion signal observed for 
endogenous FGF2-GFP is not limited by the amount of heparan sulfate 
proteoglycans available on the cell surface. 
 
3.2.2 Characterization of FGF2-GFP secretion regarding kinetics, 
unspecific release and sensitivity to ouabain 
 
To study the kinetics of FGF2-GFP export, the following experiment was conducted. 
CHOFGF2-GFP cells were cultivated on 6 well plates in presence of doxicycline (1 µg/ml) 
to a confluency of about 90% for different time periods (6 h, 12 h, 24 h, 48 h, 72)  
 
 
 
figure 3.12: Kinetics for cell surface staining mediated by FGF2-GFP.  
CHOFGF2-GFP cells were cultivated on culture plates (Ø 10 cm) to a confluency of 90% and incubated with doxicycline (1 µg/ml) 
for different time periods (6h-red, 12h-green, 24h-pink, 48h-blue, and 72h-orange). After processing with antibodies (1:30 anti-
GFP; 1:300 goat anti-rabbit PE coupled) a FACS analysis was performed. 
 
After detachment from the culture plate using CDB, cells were processed with anti-
GFP and PE-conjugated goat anti-rabbit antibodies, and analyzed by FACS analysis. 
To adjust background levels, CHOMCAT/TAM2 cells were used as a negative control. 
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When cells were exposed to doxicycline (1 µg/ml) for 6 h, the signal for FGF2-GFP 
bound to the cell surface was almost not enhanced, compared to control cells. 
Incubation of cells with doxycyline for 12 h led to a significant signal for cell surface 
staining which was further enhanced by prolonging the doxicycline incubation time up 
to 72 h. The raw data obtained were subjected to a weight curve fit and are 
representative of two individual experiments. 
 
 
 
figure 3.13: Kinetic analysis of FGF2-GFP export. CHOFGF2-GFP cells were grown in the presence of doxicycline for the times 
indicated followed by FACS processing, including antibody treatment, as described in Materials and Methods. The raw data 
have been subjected to a weighted curve fit and are representative of two independent experiments. 
 
The amount of secreted FGF2 increases in a linear manner for 48 hours, but the 
signal reaches saturation levels after an incubation time of 48 h, indicating steady 
state conditions. 
 
To verify that the signal detected on the cell surface does not reflect unspecifically 
released material derived from damaged cells but rather secreted FGF2-GFP the 
following experiments were conducted: Non-induced CHOFGF2-GFP cells were 
incubated with a supernatant derived from homogenized CHOFGF2-GFP cells, which 
were induced to express the fusion protein.   
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Figure 3.14: Biochemical analysis of FGF2 secretion with regard to unspecific release and sensitivity to ouabain. 
CHOFGF2-GFP cells were grown in the absence of doxicycline followed by the addition of various amounts of a supernatant derived 
from homogenized CHOFGF2-GFP cells that were grown on a culture plate (∅ 10 cm) to 100% confluency and incubated for 48 
hours in the presence of doxicycline (lanes 1-5). Based on cell number, 0% (lane 1), 2.5% (lane 2), 5% (lane 3), 7.5% (lane 4) 
and 10% (lane 5) of this supernatant was added to CHOFGF2-GFP cells grown in the absence of doxicycline. The PE-derived 
FGF2-GFP cell surface signal was then compared with the corresponding signal of CHOFGF2-GFP cells grown for 48 hours in the 
presence of doxicycline (set to 100%, lane 6). Lanes 7 and 8 refer to experiments under the same conditions as those in lane 6 
with the exception that during the whole course of the experiment, 1 mM and 5 mM ouabain, respectively, were added to the 
culture medium. The data are representative of two independent experiments. 
 
Defined amounts of this lysate corresponding to 0, 2.5, 5, 7.5 or 10% of 
homogenized cells (lanes 1-5) were added to CHOFGF2-GFP cells not expressing the 
reporter molecule, followed by detachment, antibody processing and FACS analysis. 
The observed signal for cell surface staining of the 10% condition accounted for up to 
40% of the signal detected for secreted fusion protein exported by CHOFGF2-GFP cells 
(lane 6). During all FACS experiments the amount of dead cells was monitored by 
the addition of propidium iodide (PI), a low molecular weight dye that only enters 
damaged cells. Typically, about 2-3% of the total cell population was found to be 
positive for PI. Thus, the population of FGF2-GFP found on the cell surface (lane 6) 
can not be derived from damaged cells but rather was secreted by a specific 
transport mechanism. 
This conclusion is further substantiated by the observation that the appearance of 
FGF2-GFP on the cell surface can be partially inhibited (1mM reduced to 70%; 5mM 
reduced to 55% as compared to wild-type levels) by ouabain (Figure 3.14; lanes 7, 8).  
 
3.2.3 Biochemical analysis of FGF2-GFP secretion 
 
To further characterize the model cell lines, biochemical experiments were conducted 
to analyze the extracellular localization of the reporter proteins. Cells were exposed 
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to doxicycline for 48 hours at 37°C in the presence of heparin (125 µg/ml) in order to 
prevent FGF2 binding to plasma-membrane-associated HSPGs.  
 
 
 
Figure 3.15: Biochemical analysis of FGF2 fusion protein secretion.  
The various cell lines indicated were analyzed biochemically with regard to secretion of the reporter molecules (A). Cells were 
grown on culture plates (Ø 10 cm) in the presence of doxicycline and heparin (125 µg/ml) for 48 hours at 37°C. FGF2-GFP was 
affinity-purified from detergent cell extracts and the medium by using heparin sepharose. 1% (cells) and 15% (medium) of the 
eluates were subjected to SDS-PAGE. In case of CHOGFP cells, 1% of both cells and medium were directly subjected to SDS-
PAGE (the amount of the medium loaded onto the gel had to be reduced to 1% of the total material because of the high protein 
concentration). Affinity-purified anti-GFP antibodies were used to detect the reporter molecules. Even after prolonged exposition, 
no GFP signal could be observed in lane 4. To analyze whether FGF2-GFP is released by a specific mechanism, CHOFGF2-GFP 
cells were grown for 48 hours at 37°C in the presence of doxicycline, 125 µmg/ml heparin and 25 µM ouabain, a drug known to 
inhibit FGF2 export (B). The samples were processed as described for panel A. 
 
After dissociation of cells from the culture plates using cell dissociation buffer, 
residual cell surface-associated FGF2-GFP was removed from the plasma 
membrane by heparin and the corresponding cell-free supernatant was combined 
with the original growth medium. In parallel, detergent extracts from the cellular 
fractions were prepared. FGF2 fusion proteins were affinity-purified from both the 
cellular and the medium fractions using heparin sepharose (for more details see 
Material and Methods, section 2.3.3). FGF2-GFP was then eluted with SDS-
containing sample buffer followed by SDS-PAGE and western blot analysis using 
affinity-purified anti-GFP antibodies and ECL detection as described in section 2.3.2. 
FGF2-GFP derived from CHOFGF2-GFP cells was detectable in the supernatant of 
cultured cells (A, lane 2). Approximately 10% of the total amount of FGF2-GFP fusion 
protein was found to be secreted. In contrast, GFP could not be detected in the 
supernatant (A, lane 4) although GFP was found in the total lysate derived form 
CHOGFP cells (A, lane 3). In a second set of experiments, depicted in panel B, the 
same biochemical assay as described above was used, however, Ouabain (25 µM) 
was added to cells exposed to doxicycline (1 µg/ml) and heparin (125 µg/ml) for 48 h 
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at 37°C. Ouabain, which belongs to the family of G-strophantins (Petersen and 
Poulsen, 1967), is a glycoside, which blocks the sodium-potassium ATPase (Riehle 
et al., 1991), and has been shown to partially inhibit the export of FGF2 (Florkiewicz 
et al., 1998; Dahl et al., 2000). FGF2-GFP secretion from cells incubated with 
ouabain was significantly reduced when compared to FGF2 secretion without 
exposure to ouabain. The ratio of the relative amounts of FGF2-GFP in lanes 1 and 2 
of panel B (control) is clearly higher than the corresponding ratio of lanes 3 and 4 of 
panel B (ouabain). Both experiments demonstrate that the export of FGF2-GFP is 
dependent on the FGF2 part of the fusion protein since GFP is not exported from 
CHO cells and that the export of FGF2-GFP fusion proteins from CHO cells is 
partially inhibited by the glycoside ouabain, indicating that FGF2 is secreted by a 
specific transport mechanism depending on the Na+/K+-ATPase. 
 
3.2.4 Analysis of FGF2-GFP secretion by confocal microscopy 
 
To verify the results obtained by FACS analysis using an independent method, 
experiments based on immunofluorescence confocal microscopy (see Materials and 
Methods) were conducted. CHOFGF2-GFP and CHOGFP cells were grown on glass cover 
slips for 24 hours in absence or presence of doxicycline.  
 
Figure 3.16: Translocation of FGF2-GFP to the surface of the plasma membrane, as determined by confocal microscopy. 
CHOFGF2-GFP and CHOGFP cells were grown on glass cover slips for 24 hours at 37°C in the absence or presence of doxicycline. 
Where indicated, cells were washed with PBS containing 125 µg/ml heparin. Following fixation using 3 % paraformaldehyde, 
cells were processed with affinity-purified anti-GFP antibodies and secondary antibodies coupled to an Alexa546 fluorophore. 
The specimens were embedded using Fluoromount G and viewed with a Zeiss LSM 510 confocal microscope. The results 
shown are representative of four independent experiments. 
 
Samples were washed with PBS or with PBS containing heparin (125 µg/ml) followed 
by a fixation procedure using paraformaldehyde (3%). Samples were then processed 
Results 
 
73 
with affinity-purified anti-GFP antibodies and secondary antibodies coupled to an 
Alexa546 fluorophore. Finally samples were embedded using Fluoromount G and 
visualized with a Zeiss LSM 510 confocal microscope. 
As shown in figure 3.16, cells were analyzed for GFP fluorescence (A-D) and cell 
surface staining (E-H). Without addition of doxicycline, GFP-derived fluorescence 
and cell surface-derived fluorescence was at background levels (A). After induction of 
expression with doxicycline, FGF2-GFP appeared in the cytoplasm and the nucleus 
of CHO cells (B), and was also detected in spots on the cell surface (F). Consistent 
with the FACS experiments shown in figure 3.8, heparin treatment did not influence 
protein expression as the GFP fluorescence in the cytoplasm and nucleus was not 
altered (compare B and C). However, the heparin treatment removed FGF2-GFP 
from the cell surface, resulting in a loss of signal for cell surface staining to 
background levels (G). CHO cells expressing GFP showed a cytoplasmic 
fluorescence (D), but cell surface signals were not detected using anti-GFP 
antibodies (H). These results are fully consistent with the data obtained by FACS 
analysis. 
 
3.2.5 Secreted biosynthetic FGF2-GFP is targeted to non-lipid raft 
microdomains 
 
To assess the structural organization of cell-surface-localized FGF2-GFP in more 
detail, an immunofluorescence confocal microscopy at high magnification was 
performed using the same protocol as in section 3.2.5.  
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Figure 3.17: Identification of FGF2-GFP-positive microdomains on the extracellular surface of CHO cells.  
CHOFGF2-GFP cells were grown on glass cover slips for 24 h at 37°C in the presence of doxicycline (1 µg/ml). Processing for 
confocal microscopy was performed as described in the legend of Fig. 3.15. (A) Merged image of 16 confocal planes spanning 
the whole depth of the cells. (B) A confocal plane close to the bottom of the cells where they are attached to the glass cover 
slips.  
 
As shown in panel A of figure 3.17 (merged image of 16 confocal planes), FGF2-GFP 
did not display a homogenous staining of the plasma membrane but rather appeared 
in bright spots representing distinct microdomains. These microdomains represent 
structures exclusively localized to the cell surface since sequential scanning of focal 
planes (one of which is shown in B) revealed the absence of any intracellular staining. 
 
To analyze whether the observed microdomains are related to lipid rafts, the 
detergent solubility of plasma membrane-associated FGF2-GFP was characterized. 
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figure 3.18: FGF2-GFP-positive microdomains are distinct from lipid rafts.  
CHOFGF2-GFP cells were grown on culture plates (Ø 15 cm) for 48 h at 37°C in the presence of doxicycline (1 µg/ml). Following a 
wash procedure using PBS the cells were scraped off the culture plates in a sucrose-containing buffer. Cell breakage was 
achieved by using a Balch homogenizer followed by differential centrifugation at 1000 g and 5000 g to sediment nuclei and cell 
debris. The resulting supernatant was loaded on top of a 20% (w/v) sucrose cushion and centrifuged for 60 minutes at 100,000 
g in order to collect microsomal membranes freed of cytosolic proteins. The membrane sediment was resuspended in PEN 
buffer containing 1% (w/v) Triton X-100 at 4°C. While being resuspended several times using a 100 µl tip, the membrane 
suspension was kept on ice for 30 minutes. The samples were then divided and either subjected to ultracentrifugation in order to 
sediment detergent-insoluble complexes or adjusted to 40% (w/v) sucrose followed by flotation in a linear sucrose gradient. (A) 
Detergent-soluble fraction (lane 1), detergent-insoluble fraction (lane 2). (B) 14 fractions of the linear flotation gradient (lanes 1-
14) with lane 1 containing the most dense sucrose fraction and lane 14 containing the lightest fraction. In the case of FGF2-GFP 
and p23 detection, 60% of each fraction was TCA-precipitated and applied to the gel; in the case of caveolin-1, 15% of each 
fraction was TCA precipitated and applied to the gel. 
 
CHOFGF2-GFP cells were grown on a culture plate (∅ 15 cm) to a confluency of about 
90% and incubated for 48h with doxicycline (1 µg/ml). After washing with PBS, cells 
were scraped off in sucrose-containing buffer, and were broken using a Balch 
homogenizer, followed by centrifugation at 1000 g and 5000 g in order to pellet nuclei 
and cell debris. The supernatant was loaded on top of a 20% (w/v) sucrose cushion 
and centrifuged for 60 minutes at 100000 g. The sedimented microsomal membranes, 
freed from cell debris, nuclei and soluble proteins were resuspended in PEN buffer 
containing Triton X-100 (1%) at 4°C. The samples were divided and either subjected 
to ultracentrifugation (sedimentation of detergent-insoluble fraction) or adjusted to 
40% (w/v) sucrose followed by flotation in a linear sucrose gradient (A). The Golgi-
localized transmembrane protein p23 (Sohn et al., 1996) was used as a non-lipid raft 
marker (Gkantiragas et al., 2001) and the plasma-membrane localized protein 
caveolin-1 as a classical lipid raft marker (Rothberg et al., 1992; Kurzchalia and 
Parton, 1999). P23 as well as FGF2-GFP could be detected only in the soluble 
fraction (lane 1), whereas caveolin-1 was almost exclusively found in the insoluble 
fraction (lane 2). Moreover, caveolin-1 could be detected in the light fractions, 
corresponding to about 15% (w/v) sucrose, of the flotation gradient (B). In contrast, 
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p23 and FGF2-GFP were exclusively localized to the bottom fractions of the gradient 
demonstrating that the microdomains observed by confocal microscopy were not 
related to lipid rafts. A formal possibility would be that a potential association of 
FGF2-GFP with lipid rafts could not be detected because the interaction of FGF2-
GFP with cell surface HSPGs is detergent-sensitive which, in turn, would cause 
FGF2-GFP to appear in the supernatant of detergent-treated membranes. However, 
as demonstrated in chapter 3.2.4, FGF2-GFP could be affinity-purified from cellular 
detergent extracts by using heparin-sepharose, a method that mimics the interaction 
of FGF2 with heparan sulfate proteoglycans (Burgess and Maciag, 1989).  
 
3.2.6 Intercellular spreading of exported biosynthetic FGF2-GFP 
 
With the in vivo system developed it was possible to visualize and quantify secreted 
FGF2-GFP. In order to distinguish a translocation mechanism that involves a soluble 
intermediate between export and binding to proteoglycans from an integrated 
process where the export machinery directly delivers FGF2 to the proteoglycan 
binding site, a FACS and a confocal microscopy experiment were performed. 
CHOFGF2-GFP cells and CHOMCAT/TAM2 cells were used for FACS analysis. 
CHOMCAT/TAM2 cells lack the FGF2-GFP reporter construct, which allows for 
discrimination between both cell lines based on GFP-derived fluorescence. Cells 
were grown on culture plates (∅ 10 cm) in presence of doxicycline (1 µg/ml, 24 h) to 
a confluency of about 90%, detached and processed with anti-GFP primary 
antibodies and PE-coupled secondary antibodies, followed by FACS analysis. 
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figure 3.19: Intercellular spreading mediated by antibody processing.  
Both cell lines CHOMCAT/TAM2 and CHOFGF2-GFP were cultivated separately on culture plates (Ø 10 cm) to a confluency of 60% and 
incubated with doxicycline for 24 h (1 µg/ml). Cells were processed by antibodies separately and combined prior to FACS 
analysis (A). Both cell lines were cultivated individually and incubated with doxicycline (1µg/ml). Cells were combined and 
processed with antibodies prior to FACS analysis (B). Both Cell lines were cultivated in one culture plate in the presence of 
doxicycline (1µg/ml) at a ratio of 1:1 followed by antibody processing and FACS analysis (C). 
 
When the two different cell lines were cultivated and processed with antibodies 
separately and combined immediately prior to FACS analysis, a striking difference in 
cell surface staining for both cell lines was observed (A). When both cell lines were 
cultivated individually but combined for antibody processing, the signal for cell 
surface staining of both cell lines was still significantly discriminative (B). However, 
CHOMCAT/TAM2 (pink) and CHOFGF2-GFP cells (green) did not differ from each other as 
clearly as in the experimental settings described above. If CHOFGF2-GFP and 
CHOMCAT/TAM2 cells were cultivated together in a ratio of 1:1, followed by antibody 
processing, no difference in cell surface staining was detectable (C). This experiment 
reveals that FGF2-GFP secreted from the expressing cells spread to the cell surface 
of non-expressing cells. 
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A similar experiment was performed and analyzed using confocal microscopy to 
verify the data obtained by FACS analysis. 
 
 
Figure 3.20: Intercellular spreading of secreted FGF2-GFP. CHOFGF2-GFP and CHOMCAT/TAM2 cells were cultured on glass cover 
slips in a 1:1 ratio. Following incubation for 24 hours at 37°C in the presence of doxicycline, the cells were fixed with PFA and 
processed with affinity-purified anti-GFP antibodies. Primary antibodies were detected with anti-rabbit IgG antibodies coupled to 
Alexa546. The specimens were viewed using a Zeiss LSM 510 confocal microscope. 
 
CHOFGF2-GFP and CHOMCAT/TAM2 cells were co-cultivated in presence of doxicycline (1 
µg/ml, 24 h, 37°C) in a ratio of 1:1 on cover slips to a confluency of 50-60%. After 
fixation without permeabilization using paraformaldehyde (3%) the cells were further 
processed with primary affinity-purified anti-GFP and secondary mouse anti-rabbit 
IgG antibodies coupled to Alexa546, embedded with Fluoromount G and visualized 
with a Zeiss LSM 510 confocal microscope. As shown in figure 3.20, CHOMCAT/TAM2 
cells did not express FGF2-GFP and showed no signal for GFP fluorescence but a 
cell surface signal was detected due to HSPG associated FGF2-GFP (marked with 
asterisk). These results implicate that after secretion, FGF2-GFP exists as a soluble 
intermediate, which can be transferred between cells and clusters on HSPGs 
accumulating in cell surface microdomains. 
 
3.2.7 Refinement of FACS processings in order to prevent unspecific 
release 
 
During the preparation for FACS analysis the cells were detached from the culture 
plates using CDB prior to antibody processing. This procedure might lead to an 
unspecific release of FGF2-GFP from damaged cells followed by cell surface binding 
and thus resulting in a falsely increased signal of cell surface staining. Therefore, an 
advanced FACS procedure was established where the antibody treatment was 
performed prior to cell detachment. The advantage over the old procedure is that 
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residual antibodies have been depleted when the cells were detached from the 
culture plate. Therefore, potential unspecifically released FGF2-GFP did not result in 
an APC-derived signal for cell surface staining.  
 
 
 
Figure 3.21: Comparison of standard and refined FACS procedure.  
A GFP fluorescence. B Cell surface staining. CHOFGF2-GFP and CD4 positive CHOGFP cells were grown on 6 well plates to a 
confluency of 50% and incubated with doxicycline (1µg/ml) for 16h at 37°C. Cells were either detached from the culture plate 
using cell dissociation buffer (CDB) prior to antibody staining (black bars) or antibody processing was performed while cells 
were attached to culture plates (red bars). The antibody treatment was equal for both FACS procedures; the only difference was 
the time point of cell detachment. The incubation with first antibody was for 1h at 4°C with affinity-purified anti-GFP antibodies 
followed by an incubation of 30 min at 4°C with a secondary goat anti-rabbit IgG coupled to APC (allophycocyanin).  
 
For the establishment of the advanced FACS assay, CHOFGF2-GFP and CD4 positive 
CHOGFP cells were used. In contrast to FGF2 which is secreted as a soluble protein, 
CD4 is an integral plasma membrane protein. Therefore, these cell lines serve as a 
control to verify if the accessibility of anti-CD4 antibodies is reduced due to steric 
hindrance when cells are attached to the culture plate. Therefore, cell lines were 
grown on 6 well plates to a confluency of 50% in presence of doxicycline (1 µg/ml) for 
16h at 37°C. Both cell surface proteins were then detected by using specific 
antibodies for GFP and CD4. As shown in section 3.2.7, FGF2-GFP is able to spread 
between membranes. In contrast, CD4 is an integral membrane protein, which is not 
transferred between cells. 
The standard protocol was performed by detaching the cells prior to antibody 
processing (affinity-purified anti-GFP antibody (1:50) at 4°C for 1h and secondary 
goat anti-rabbit IgG coupled to APC (1:750) at 4°C for 30 min; black bars). For the 
advanced FACS protocol, cells were processed with antibodies under the same 
conditions as described for standard protocol, but cell detachment was performed 
after antibody processing (red bars). CD4 was detected by an anti CD4 antibody and 
a secondary goat anti-rabbit antibody coupled to APC.  
As shown in figure 3.21 panel A, the signal for GFP-derived fluorescence was slightly 
reduced using plate-labelling (advance protocol, red bars) compared to labelling in 
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suspension (standard protocol, black bars). Figure 3.21 panel B displays the signal 
for FGF2 and CD4 detected on the cell surface of the corresponding cell lines. A 
significant reduction of signal (approximately 50%) for FGF2-GFP bound to the cell 
surface was observed when the plate labelling method was used.  
The signal for CD4 was constant comparing both labelling procedures, showing that 
the procedure does not influence the antibody detection of an integral membrane 
protein. The reduced signal for FGF2-GFP bound to heparan sulfate proteoglycans 
by using the plate labelling method might be caused by less amounts of 
unspecifically released fusion protein detectable on the cell surface by antibodies. 
Moreover, FGF2-GFP bound to the cell surface of cells attached to the culture plate 
is, potentially due to steric hindrance, less accessible to antibodies, than FGF2-GFP 
bound to the cell surface of cells in solution. It is most likely that both reasons might 
lead to the reduction of the signal for FGF2-GFP derived cell surface staining. 
 
3.3 Mutational analysis of FGF2-GFP targeting to its transport 
machinery 
 
In eukaryotic cells classically secreted proteins and proteins transported across other 
membranes possess signals that mediate targeting to their transport machineries. 
This has been reported for peroxisomes, the ER, mitochondria, chloroplasts and the 
nucleus (Walter et al., 1984; Neupert, 1997; Smith and Schnell, 2001). These signals 
have been identified and their motifs consist of amino acids mostly present in the N- 
or C-termini of the protein. In contrast to conventionally secreted proteins, FGF2 
does not contain a signal peptide, and is not exported in an ER/Golgi dependent 
manner but by unconventional means. FGF2 is segregated from cytoplasmatic 
proteins and therefore must contain a signal which is recognized by a so far unknown 
translocation machinery.  
Therefore, a mutational analysis of the FGF2 open reading frame was conducted in 
order to find export deficient mutants and mutants which have a defect in binding to 
HSPGs.  
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3.3.1 Selection and cloning of FGF2 mutants 
 
To determine the signal mediating unconventional secretion of FGF2, several 
experimental approaches were chosen in order to isolate mutants defective with 
regard to FGF2 secretion. 
In a first step, a random mutagenesis was conducted, introducing randomly multiple 
mutations into the open reading frame of FGF2. These mutations were obtained by 
performing an unbiased PCR using 5 mM MnCl2 leading to more frequently mutated 
adenines and thymines than cytosines and guanines (Shafikhani et al., 1997). The 
results from the random mutagenesis were then taken as a basis to further 
investigate the role of distinct point mutations in secretion. Additionally hydrophobic 
protein surface residues which are potentially involved in protein-protein interaction 
were identified by an analysis of the crystal structure and were changed by site-
directed mutagenesis. Moreover, residues at the N-terminus of FGF2 are disordered 
and have not been successfully crystallized. Additionally, amino acids cluster at both 
protein termini which are responsible for the interaction of FGF2 with heparin (Baird 
et al., 1988; Li et al., 1994). Therefore, The N- and the C-terminus of FGF2 were 
stepwise truncated and analyzed with regard to their secretion. In the following 
sections, the cloning strategies for the four different approaches are demonstrated. 
 
3.3.1.1 Random mutagenesis 
 
In order to randomly introduce single and multiple base substitutions, a low fidelity 
PCR using pRevTRE2-FGF2-GFP-His6 as a template was performed, beginning with 
the start codon of FGF2 and ending with an endogenous BamH I restriction site at 
position 406. Both primers were also complementary to an intrinsic BamH I restriction 
site at position -15 and 406.  The cloning strategy is depicted in the following figure 
3.22. 
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Figure 3.22: schematic overview of the cloning strategy for the introduction of multiple random amino acid changes. 
 
The obtained PCR products were purified by gel extraction to dispose the original 
vector and primers used. The DNA fragment and pGEM-T-FGF2-GFP
 
were then 
digested using BamH I, followed by ligation. After transformation of E.coli DH5α, 
DNA was amplified by a mid-scale preparation without selecting single clones in 
order to receive a subset of different mutants. Mutated FGF2-GFP (FGF2-GFPmut) 
was then excised from amplified pGEM-T-FGF2-GFP using Not I and Sph I and 
ligated into pRevTRE2-FGF2-GFP linearized with the same restriction enzymes. 
Following transformation, selection of clones and amplification of plasmid DNA, the 
correct orientation of inserted FGF2-GFPmut was verified by an asymmetric digestion 
analysis using Age I and Sph I. Plasmids with correctly orientated FGF2-GFP were 
finally used for the retroviral transduction of CHOMCAT/TAM2 cells. An overview of all 
mutations obtained is listed in table 3.1. 
 
 
3.3.1.2 Point mutations 
 
The clones obtained by the random mutagenesis described by a different phenotype 
regarding stability of the protein, cell surface staining and binding efficiency to 
heparin where analysed with regard to their multiple mutations, which where then 
introduced as distinct single mutations in the open reading frame of FGF2.  
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As a second approach, an analysis of the three-dimensional structure of FGF2 was 
conducted in collaboration with Dr. Ivo Tews from the group of Prof. Dr. Irmgard 
Sinning by analyzing FGF2 for surface residues which are potentially involved in 
protein-protein interactions. Therefore, hydrophobic amino acids, exposed to the 
protein surface and cysteines responsible for dimerization of FGF2 were chosen as a 
target for site-directed mutagenesis. 
To summarize amino acids changed by site directed, the primary sequence of FGF2 
is depicted in figure 3.23 with amino acids changed by site-directed mutagenesis 
being marked with an asterisk. 
  
        *******    **      * *  *   *  *     ** * *       ** * *   
1  maagsittlpalpedggsgafppghfkDapkrlycknggfflrihpdgrvdgvreksdphi 
 
       *  ** ***  * ** ** * *    ** * *   *     * *       *    * 
61  klqlqaeergvvsikgvcanrylamkedgrllaskcvtdecffferlesnnyntyrsrky  
  
       *     **  **    *             *               
   121 tswyvalkrtgqyklgsktgpgqkailflpmsaks 
 
Figure 3.23: Primary structure of FGF2.  
Amino acids marked with an asterisk were subjected to point mutations. 
 
A detailed list of all amino acid exchanges is provided in table 3.3. 
To visualize the location of the mutated amino acids in the three-dimensional 
structure of FGF2, the following figure 3.24 was generated.  
 
Figure 3.24: Three-dimensional structure of FGF2.  
Red areas represent amino acids changed by site-directed mutagenesis of FGF2. Right picture is turned 90° compared to left 
picture. The picture was created using protein explorer 2.45 beta on the PDB entry domain 1ev2. 
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The picture was painted using protein explorer software and the PDB entry domain 
1ev2. The red areas represent amino acids changes obtained by site-directed 
mutagenesis of FGF2. As depicted in figure 3.24, most mutations are localized in the 
β-sheets contributing to the overall structure of FGF2. 
 
The cloning strategy for the generation of point mutations is depicted in the following 
figure 3.25. 
 
 
Figure 3.25: schematic overview of the cloning strategy for the introduction of site-directed mutations. 
 
Point mutations were introduced into the open reading frame of FGF2 using the 
QuickChange Site-Directed Mutagenesis Kit (Stratagene). The PCR reactions were 
performed according to the manufacturer’s instructions using pGEM-T-FGF2-GFP-
His6 as a template and primers containing the desired mutations (see section 2.2.1.2). 
The primers used are listed in chapter materials and methods, section 2.1.6. After 
introducing the PCR constructs into DH5α or supercompetent XL-1 blue bacterial 
cells, clones were selected and plasmid DNA was prepared from bacterial cells. 
Point-mutated FGF2-GFP was excised from pGEM-T-FGF2-GFP with Not I and Sph I 
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and ligated into pRevTRE2-FGF2-GFP-His6 digested with the same enzymes. 
Following transformation into DH5α cells, selection of clones, amplification and 
preparation of plasmid DNA, the insert was sequenced to verify the mutation. Correct 
constructs were used for retroviral transductions of CHOMCAT/TAM2 cells. An overview 
of all mutations is listed in table 3.3. 
 
3.3.1.3 Truncations  
 
To complete the structural analysis, FGF2 was truncated from both the N-terminus 
and the C-terminus. The heparin binding sites of FGF2 were identified to cluster at 
the C-terminus from amino acid 128-138 (Li et al., 1994), as well as at the N-terminus 
(Baird et al., 1988). 
 
N-terminal Truncation 
 
The first 15 amino acids of FGF2 are part of a flexible region of unknown structure 
(Eriksson et al., 1991; Plotnikov et al., 1999), which might be potentially involved in 
protein-protein interactions as it is known for secretory proteins, which do have an N-
terminal signal sequence which targets the protein to the transport machinery of the 
classical secretory pathway. Additionally, the heparin binding sites proposed to be 
present in the N-terminal region might also play a role in the transport process. It was 
shown for galectin-1 that binding to its counter-receptor is a prerequisite for its export 
(Seelenmeyer et al., 2005). To avoid binding of FGF2 to heparan sulfate 
proteoglycans, heparin binding regions of FGF2 were deleted. Therefore, several 
truncated versions of FGF2-GFP were generated, lacking the N-terminal 10, 20, 30, 
40 and 50 amino acids. The cloning strategy is depicted in the following figure 3.26. 
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Figure 3.26: schematic overview of the cloning strategy for N-terminal truncations. 
 
In order to obtain the desired truncated DNA fragments of FGF2, PCRs were 
conducted with two specific primers flanked by a 5´ Not I and a 3` BamH I cleavage 
site. The Kozak sequence is the consensus sequence for the initiation of translation 
in vertebrates. This sequence is essential, because it has to be expressed from 
mammalian CHO cells. The PCR products and pGEM-T-FGF2-GFP were then 
digested using Not I and BamH I, followed by ligation, transformation, selection of 
clones and preparation of plasmid DNA. The FGF2-GFP open reading frame was 
subsequently excised from pGEM-T-FGF2-GFP using Not I and Sph I and ligated 
with pRevTRE2, linearised by the same restriction enzymes. After verifying the final 
constructs by DNA sequencing, these vectors were used for retroviral transduction. 
 
 
3.3.1.4 C-terminal Truncations  
 
The C-terminal truncations were conducted to complete the mutational analysis of 
FGF2. Since secretion of Galectin-1 depends on its interaction with galactose 
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containing counter receptors on the cell surface (Seelenmeyer et al., 2005), it is also 
well possible that secretion of FGF2 depends on its interaction with HSPGs present 
on the cell surface. The main part of the heparin binding site of FGF2 is localized 
close to the C-terminus at position 128 – 138 (Li et al., 1994). Therefore, several 
truncated versions of FGF2-GFP were generated, lacking the C-terminal 10, 20, 30, 
40, 50, 60, 70, 90, 100, 110 and 120 amino acids. The cloning strategy is depicted in 
the following figure 3.27. 
 
Figure 3.27: schematic overview of cloning strategy for C-terminal truncations. 
 
In order to obtain the desired truncated DNA fragments of FGF2 PCRs were 
conducted with two specific primers flanked by a 5´ Not I and a 3` Age I cleavage site. 
With an additional PCR an Apa I restriction site was introduced to the 5´ end of GFP. 
The DNA fragments were subsequently digested with Not I/Apa I (FGF2) and Apa 
I/Sph I (GFP) and subjected to a triple ligation with pGEM-T-FGF2-GFP cut with Not 
I/Sph I, followed by transformation, selection of clones and preparation of plasmid 
DNA. The constructs were then verified by sequencing. FGF2-GFP was 
subsequently excised using Not I and Sph I and ligated into PRevTRE2 linearised 
with the same restriction enzymes. These final constructs were used for retroviral 
transduction of CHO cells. 
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3.3.2 Characterisation of FGF2 mutants with regard to export efficiency, 
binding to heparan sulfate proteoglycans in vivo and to heparin in 
vitro 
 
All generated FGF2-GFP mutants were characterized regarding export efficiency as 
well as with regard to their ability to bind to heparin and HSPG by the following in 
vivo and in vitro assays.  
 
1. In vitro binding assay using heparin beads. 
2. In vivo binding assay using CHO cells. 
3. FACS-based expression and secretion assay. 
4. Biochemical secretion assay using a biotin reagent. 
 
In this chapter, wild-type FGF2-GFP was used as a positive and GFP as a negative 
control to establish the assays described above. 
 
3.3.2.1 In vitro binding of FGF2 using heparin beads 
 
Distinct amino acid clusters are widely distributed over the structure of FGF2 and 
mediate binding to heparin-derived oligosaccharides (Faham et al., 1996). Therefore 
an assay using heparin coupled to sepharose beads was developed to analyze 
mutants with regard to their heparin-binding properties in vitro.  
 
 
Figure 3.28: In vitro binding of FGF2-GFP to heparin beads.  
Cell free supernatants prepared from CHOFGF2-GFP and CHOGFP cells respectively incubated on a culture plate (Ø 15 cm) with 
doxicycline (1 µg/ml) for 24 h at 37°C, resulting in a confluency of 100% were normalized for GFP fluorescence and incubated 
with heparin beads for 1h at 4°C. The non-bound fraction was separated and, following extensive washing, bound material was 
eluted with SDS sample buffer. Input (lane 1; 5%), non-bound material (lane 2; 5%) and bound material (lane 3; 5%) were 
analyzed by SDS PAGE and Western blotting using affinity-purified anti-GFP antibodies. 
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CHOFGF2-GFP and CHOGFP cells were grown on culture plates (∅ 15 cm) in presence 
of doxicycline (1 µg/ml) for 24 h at 37 °C, resulting in a confluency of about 100%. 
After washing and detachment, cells were broken up by combining freeze-thaw 
cycles with sonication and membranes were removed by ultracentrifugation (see 
Material and Methods, chapter 2.3.6). The obtained cell free supernatants were 
normalized for GFP-fluorescence and incubated with heparin beads for 1h at 4°C, 
followed by washing steps in buffer containing Triton X-100 and elution of bound 
material with SDS-containing sample buffer. Input, flowthrough and eluate were 
analyzed by SDS-PAGE and Western blotting using anti-GFP antibodies. For more 
detail see materials and methods, section 2.3.7. 
As shown in figure 3.28, the 45 kDa FGF2-GFPwt fusion protein was present in the 
input (lane 1) and the eluate (lane 3). In the flowthrough fraction (lane 2), 
representing non-bound material, the protein band representing the fusion protein 
could not be observed. However, GFP was found in input (lane 4) and flowthrough 
(lane 5), but not in the eluate (lane 6). These results show that FGF2-GFP binds 
specifically to heparin in vitro mediated by the FGF2 domain and not by the GFP 
domain of the fusion protein.  
 
 
 
3.3.2.2 In vivo binding of FGF2 to CHO cells 
 
CHO cells lack high affinity FGF2 receptors but provide the low affinity receptors 
heparan sulfate proteoglycans and glycolipids GM1 on their surface which can be 
occupied by FGF2. To analyze the cell-binding capacity of mutated FGF2 in vivo, an 
assay was developed where the protein of interest was exogenously added to CHO 
cells, followed by FACS-based detection and quantification of FGF2-GFP bound to 
the cell surface.  
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Figure 3.29: In vivo binding of the fusion protein to the cell surface of CHO cells.  
The FGF2-GFP fusion proteins and GFP respectively were expressed in CHO cells. Cell free supernatants were prepared and 
normalized for GFP fluorescence. The various supernatants were then incubated with CHO cells for 1h at 4°C to allow cell 
surface binding. Following treatment with affinity-purified anti-GFP antibodies (1:50) and APC-conjugated secondary antibodies 
(1:750), cell surface binding was quantified by flow cytometry using a FACSCalibur system from Becton Dickinson (n=3). Cell 
surface staining of FGF2-GFPwt was set to 100%. 
 
A cell free supernatant, produced as described in chapter 2.3.6 and normalized for 
GFP fluorescence (50 GFP units corresponding to about 0,5 g GFP, Molecular 
Devices SpectraMax Gemini XS) was diluted 1:10 with growth medium and 
incubated with CHOMCAT/TAM2 cells for 1h at 4°C in order to allow FGF2-GFP fusion 
proteins to bind to the cell surface. After washing cells with PBS, they were 
processed for analyzed using a Becton Dickinson FACSCalibur flow cytometry. 
As expected, the wild-type form of FGF2-GFP was detectable on the cell surface, 
because the FGF2 part of the fusion protein binds to heparan sulfate proteoglycans. 
For GFP alone, as expected a cell surface signal could not be detected. 
 
 
3.3.2.3 Quantification of FGF2-GFP export by flow cytometry 
 
This described in vivo assay (see chapter 3.1) was performed to quantify the amount 
of expressed and secreted FGF2-GFP fusion protein.  
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Figure 3.30: Quantitative analysis of secreted proteins from CHO cells employing flow cytometry.  
CHO cells were grown on 6-well plates to a final confluency of 60% and induced with doxicycline for 16 h at 37°C to express the 
proteins indicated. Following removal of the medium, cells were washed and labelled with affinity-purified anti-GFP antibodies 
and APC-conjugated secondary antibodies while they were still attached to the culture dishes. After detachment of the cells 
using PBS/EDTA, GFP (expression level; black bars) and APC-derived fluorescence (cell surface; red) were quantified by flow 
cytometry using a Becton Dickinson FACSCalibur system (n=3). GFP fluorescence and cell surface staining of FGF2-GFPwt was 
set to 100%. 
 
CHO cells induced to express FGF2-GFPwt and GFP respectively were grown on a 6-
well plates to a confluency of about 60 % at 37°C. After a washing step with PBS, 
cells were processed for FACS analysis as described in materials and methods, 
section 2.4.2.  
The signal for FGF2-GFP expression level (GFP fluorescence, black bars) and cell 
surface staining (APC derived fluorescence, red bars) was set to 100%, respectively. 
CHOGFP cells displayed an enhanced GFP fluorescence (160%) when compared to 
CHOFGF2-GFPwt cells, indicating a higher expression level of GFP. The signal for cell 
surface staining of GFP cells was reduced to background levels (5%) when 
compared to FGF2-GFP.  
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3.3.2.4 Biochemical secretion assay using botin to analyze FGF2 export from CHO 
cells  
 
This assay was developed to allow a biochemical quantification of FGF2-GFP 
secretion from CHO cells. Biotin (EZ-link Sulfo-NHS-SS-Biotin; Pierce), a membrane-
impermeable low molecular weight reagent was covalently bound to proteins present 
on the cell surface. The secreted population of FGF2-GFP (bound to plasma 
membrane-associated heparin sulfate proteoglycans) is therefore well distinguishable 
from overall expressed fusion protein. After cell lysis biotinylated (extracellular) 
proteins were separated employing streptavidin beads and analyzed by western 
blotting. 
 
 
 
Figure 3.31: Biochemical analysis of FGF2-GFP and GFP export respectively from CHO cells employing cell surface 
biotinylation.  
The indicated proteins were expressed in CHO cells for 16 h at 37°C (6-well plates; 70% confluency). Following removal of the 
medium, cells were treated with a membrane-impermeable biotinylation reagent. Following detergent-mediated cell lysis 
biotinylated and nonbiotinylated proteins were separated employing streptavidin beads. Aliquots from the input material (lane 1; 
2.5% from total cell lysate) and the biotinylated fraction (lane 2; 50%) were analyzed by SDS-PAGE and Western blotting using 
affinity-purified anti-GFP antibodies. 
 
FGF2-GFP and GFP were expressed in CHO cells (6 well plates, 70% confluency) 
by incubation in the presence of doxicycline (1 g/ml) for 16 h at 37°C. Cells were 
then treated with a membrane-impermeable biotinylation reagent (EZ-Link Sulfo-
NHS-SS-Biotin; Pierce) for 1h at 4°C, followed by cell lysis and affinity-purification 
using streptavidin beads. For more details see Material and Methods, chapter 2.3.5. 
The input (2.5% from total cell lysate) as well as proteins eluted from streptavidin 
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beads (50%) were analyzed by SDS PAGE and western blotting. For FGF2-GFPwt 
cells, a band was detected in both input (lane 1) and eluate (lane 2). In GFP 
expressing cells, a signal for GFP could be detected only in the input material (lane 3) 
but not in the eluate fraction (lane 4). This leads to the conclusion, that FGF2-GFP is 
secreted and bound to the cell surface. Moreover GFP could not be detected in the 
eluate, showing that the biotin reagent is not able to cross the plasma membrane. 
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3.3.3 Analysis of mutants obtained by performing random Mutagenesis 
 
Performing a random mutagenesis of the open reading frame of FGF2 resulted in 
clones with different subsets of mutated versions of FGF2. 100 distinct mutants were 
analyzed by flow cytometry regarding FGF2-GFP expression and cell surface 
staining. 18 from 100 clones were chosen based on altered cell surface staining 
when compared to wild-type FGF2-GFP. They were also characterized with regard to 
their ability to bind to heparin.  
 
3.3.3.1 Overview of mutations with regard to their amino acid changes  
 
The low fidelity PCR resulted in randomly distributed mutations within the open 
reading frame of FGF2. The created mutants are listed with regard to their individual 
mutations in the following table. 
 
Mutant Mutations Number of mutations 
25 A3S, E14D, R42H, K61H, V72A, R90K 6 
26 G18S, D58G, G89V, R90G, L91F, W123R 6 
30 P23S, K55R, E68A, E87D 4 
32 G19S, L32Q, R90S, F103L, E105G, N110S 6 
63 A20V, R81C 2 
71 E14G, F103L 2 
151 A2V, T8I, S122G 3 
156 E87K, K128E, R129Q 3 
193 R81C, L135F 2 
201 P13H, F21I, F40L, K55T, L64P, C78S, Y133H 7 
210 H59P, E68G, I74T 3 
239 A3S, P13L, K61E 3 
265 K30E, E67V, C78S 3 
284 V77A, N110S 2 
315 F21L, R42K, G89V 3 
331 D15Y, K35I 2 
346 K35R, S56C, N111Y, Y120H 4 
365 F39L, V52A, K75I, Q132R 4 
 
Table 3.1: List of mutations for individual clones created by a random mutagenesis. 
Abbreviations used are international standards for the identification of amino acids. The first abbreviation is used for the original 
amino acid present in FGF2, the following number represents the position of the changed amino acid in the sequence of FGF2. 
The following abbreviation represents the newly generated amino acid. 
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The assays described in section 3.3.2 were used to analyze the binding ability of the 
mutants in vivo and in vitro. The amount of secreted FGF2-GFP was quantified by 
performing flow cytometry and cell surface biotinylation.  
 
 
3.3.3.2 Experimental data for FGF2 mutants not impaired regarding export 
efficiency and binding to heparin 
 
In this section, the FGF2 mutants generated by random mutagenesis are depicted 
which are comparable to wild-type FGF2-GFP with regard to secretion efficiency and 
binding capability to heparin and heparan sulfate proteoglycans. Moreover, their 
amino acid changes are shown and a summary of the experimental data is provided. 
For a detailed view on the assays used, please refer to chapter 3.3.2. 
 
Mutant rM 26 contains 6 amino acid changes: G18S, D58G, G89V, R90G, L91F, 
W123R. 
 
 
Figure 3.32: Random mutagenesis; 6 amino acid changes: G18S, D58G, G89V, R90G, L91F, W123R A FACS analysis of cell 
free supernatant bound to the surface of CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of 
cell free supernatant to heparin beads. Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound 
(flowthrough, 10%) and bound material (eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative 
analysis of export employing flow cytometry.  Expression level (black bars) and secreted protein detected on the cell surface 
(red bars) is shown. FGF2-GFPwt was set to 100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-
impermeable biotin reagent. After cell lysis biotinylated and non-biotinylated proteins were separated by streptavidin beads. 
Total material (input, 5%) and the biotinylated fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. 
All results shown represent an average of at least 3 different experiments. For further details see „Material and Methods“ and 
explanation of assays in chapter 3.3.2. As a result, this clone does not show any difference to wild-type cells.  
 
As demonstrated in figure 3.32, mutant rM 26 showed a slightly reduced ability to 
bind in vivo to heparan sulfate proteoglycans as compared to wild-type FGF2-GFP 
(panel A). However, the mutant rM 26 and FGF-GFPwt showed the same affinity to 
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heparin in vitro (panel B). As demonstrated in panel C, the expression level of FGF2-
GFPrM 26 was enhanced to about 160% ± 10% as compared to FGF2-GFPwt. 
Additionally, the amount of secreted FGF2-GFPrM 26 detected on the cell surface was 
enhanced to about 110% ± 50%. However, the ratio between expressed and 
secreted protein remained comparable to wild-type protein, indicating unchanged 
secretion efficiency. The data obtained by flow cytometry was confirmed by the 
biotinylation assay (panel D).  
 
 
Mutant rM 63 contains 2 amino acid changes: A20V and R81C 
 
 
 
Figure 3.33: Random mutagenesis; 2 amino acid changes: A20V, R81C A FACS analysis of cell free supernatant bound to the 
surface of CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin 
beads. Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound 
material (eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow 
cytometry.  Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt 
was set to 100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After 
cell lysis biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the 
biotinylated fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average 
of at least 3 different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. As 
a result, this clone does not show any difference to wild-type cells. 
 
As demonstrated in figure 3.33, the mutant rM 63 showed a reduced ability to bind to 
heparan sulfate proteoglycans in vivo (about 60%; panel A), but the affinity to heparin 
in vitro was comparable to FGF2-GFPwt. The expression level and the cell surface 
staining of FGF2-GFPrM 63 were reduced (panel C), but the ratio between expressed 
and secreted protein remained comparable to wild-type protein, indicating unchanged 
secretion efficiency. The data obtained by flow cytometry was confirmed by the 
biotinylation assay (panel D). These experiments demonstrate that mutant rM 63 
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does not differ from wild-type FGF2-GFP with regard to secretion efficiency, affinity to 
heparin and heparan sulfate proteoglycans. 
 
 
Mutant rM 151 contains 3 amino acid changes: A2V, T8I and S122G. 
 
 
 
Figure 3.34: Random mutagenesis; 3 amino acid changes: A2V, T8I, S122G A FACS analysis of cell free supernatant bound to 
the surface of CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to 
heparin beads. Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and 
bound material (eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing 
flow cytometry.  Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-
GFPwt was set to 100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin 
reagent. After cell lysis biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 
5%) and the biotinylated fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent 
an average of at least 3 different experiments. For further details see „Material and Methods“ and explanation of assays in 
chapter 3.3.2. As a result, this clone does not show any difference to wild-type cells. 
 
As demonstrated in figure 3.34, the mutant rM 151 showed a reduced ability to bind 
to heparan sulfate proteoglycans in vivo (about 80%; panel A), but the affinity to 
heparin in vitro was comparable to FGF2-GFPwt. The expression level and the cell 
surface staining of FGF2-GFPrM 151 were reduced (panel C), but the ratio between 
expressed and secreted protein remained comparable to wild-type protein, indicating 
unchanged secretion efficiency. The data obtained by flow cytometry was confirmed 
by the biotinylation assay (panel D). These experiments demonstrate that the mutant 
rM 151 does not differ from wild-type FGF2-GFP with regard to secretion efficiency, 
affinity to heparin and heparan sulfate proteoglycans.  
Results 
 
98 
Mutant rM 239 contains 3 amino acid changes: A3S, P13L and K61E. 
 
 
 
Figure 3.35: Random mutagenesis; 3 amino acid changes: A3S, P13L, K61E A FACS analysis of cell free supernatant bound to 
the surface of CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to 
heparin beads. Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and 
bound material (eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing 
flow cytometry.  Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-
GFPwt was set to 100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin 
reagent. After cell lysis biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 
5%) and the biotinylated fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent 
an average of at least 3 different experiments. For further details see „Material and Methods“ and explanation of assays in 
chapter 3.3.2. As a result, this clone does not show any difference to wild-type cells.  
 
As demonstrated in figure 3.35, the mutant rM 239 showed an enhanced ability to 
bind to heparan sulfate proteoglycans in vivo (about 120%; panel A), but the affinity 
to heparin in vitro was comparable to FGF2-GFPwt. The expression level and the cell 
surface staining of FGF2-GFPrM 239 were also enhanced (panel C), but the ratio 
between expressed and secreted protein remained comparable to wild-type protein, 
indicating unchanged secretion efficiency. The data obtained by flow cytometry was 
confirmed by the biotinylation assay (panel D). These experiments demonstrate that 
the mutant rM 239 does not differ from wild-type FGF2-GFP with regard to secretion 
efficiency. 
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Mutant rM 265 contains 3 amino acid changes: K30E, E67V and C78S. 
 
 
 
Figure 3.36.: Random mutagenesis; 3 amino acid changes: K30E, E67V, C78S A FACS analysis of cell free supernatant bound 
to the surface of CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to 
heparin beads. Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and 
bound material (eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing 
flow cytometry.  Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-
GFPwt was set to 100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin 
reagent. After cell lysis biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 
5%) and the biotinylated fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent 
an average of at least 3 different experiments. For further details see „Material and Methods“ and explanation of assays in 
chapter 3.3.2. As a result, this clone does not show any difference to wild-type cells.  
 
As demonstrated in figure 3.36, the affinity of FGF2-GFPrM 265 to heparan sulfate 
proteoglycans in vivo (panel A) and to heparin in vitro (panel B) was comparable to 
FGF2-GFPwt. The expression level of FGF2-GFPrM 265 was enhanced to about 120 % 
and the signal for secreted fusion protein showed about 160% ± 60% (panel C). The 
biotinylation assay showed slightly decreased secretion efficiency when compared to 
FGF2-GFPwt (panel D). These experiments demonstrate that the mutant rM 265 does 
not differ from wild-type FGF2-GFP with regard to binding efficiency to heparan 
sulfate proteoglycans and heparin. The secretion efficiency of FGF2-GFPrM 265 was 
shown to be slightly different as analyzed with both secretion assays. However, since 
both assays do not detect a significant reduction of secretion efficiency, this clone 
belongs to the group of mutants showing no phenotype. 
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Mutant rM 284 contains 2 amino acid changes: V77A, N110S. 
 
 
 
 
Figure 3.37: Random mutagenesis; 2 amino acid changes: V77A, N110S A FACS analysis of cell free supernatant bound to the 
surface of CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin 
beads. Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound 
material (eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow 
cytometry.  Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt 
was set to 100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After 
cell lysis biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the 
biotinylated fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average 
of at least 3 different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. As 
a result, this clone does not show any difference to wild-type cells.  
 
As demonstrated in figure 3.37, the affinity of FGF2-GFPrM 284 to heparan sulfate 
proteoglycans in vivo (panel A) and to heparin in vitro (panel B) was comparable to 
FGF2-GFPwt. The expression level of FGF2-GFPrM 284 was enhanced to about 200 % 
and the signal for secreted fusion protein showed about 100% ± 50% (panel C). The 
biotinylation assay confirmed the result obtained by flow cytometry (panel D). These 
experiments demonstrate that the mutant rM 284 does not differ from wild-type 
FGF2-GFP with regard to secretion efficiency and binding efficiency to heparan 
sulfate proteoglycans or heparin. Since both assays do not detect a clear reduction of 
secretion efficiency, this clone belongs to the group of mutants showing no 
phenotype. 
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Mutant rM 315 contains 3 amino acid changes: F21L, R42K and G89V. 
 
 
 
Figure 3.38: Random mutagenesis; 3 amino acid changes: F21L, R42K, G89V A FACS analysis of cell free supernatant bound 
to the surface of CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to 
heparin beads. Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and 
bound material (eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing 
flow cytometry.  Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-
GFPwt was set to 100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin 
reagent. After cell lysis biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 
5%) and the biotinylated fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent 
an average of at least 3 different experiments. For further details see „Material and Methods“ and explanation of assays in 
chapter 3.3.2. As a result, this clone does not show any difference to wild-type cells.  
 
As demonstrated in figure 3.38, the mutant rM 315 showed an enhanced ability to 
bind to heparan sulfate proteoglycans in vivo (about 190%; panel A), but the affinity 
to heparin in vitro was comparable to FGF2-GFPwt. The expression level of FGF2-
GFPrM 315 was enhanced to about 120 % and the signal for secreted fusion protein 
showed about 80% ± 30% (panel C). The biotinylation assay showed confirmed the 
result obtained by flow cytometry (panel D). These experiments demonstrate that the 
mutant rM 315 does not differ from wild-type FGF2-GFP with regard to export 
efficiency, although the binding efficiency to heparan sulfate proteoglycans is 
enhanced. Since both secretion assays do not detect a clear reduction of export 
efficiency, this clone belongs to the group of mutants showing no phenotype. 
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Mutant rM 331 contains 2 amino acid changes: D15Y and K35I. 
 
 
 
Figure 3.39: Random mutagenesis; 2 amino acid changes: D15Y, K35I A FACS analysis of cell free supernatant bound to the 
surface of CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin 
beads. Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound 
material (eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow 
cytometry.  Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt 
was set to 100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After 
cell lysis biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the 
biotinylated fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average 
of at least 3 different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. As 
a result, this clone does not show any difference to wild-type cells.  
 
As demonstrated in figure 3.39, the mutant rM 331 showed a reduced ability to bind 
to heparan sulfate proteoglycans in vivo (about 50% ± 50%; panel A), but the affinity 
to heparin in vitro was comparable to FGF2-GFPwt. The expression level of FGF2-
GFPrM 331 was enhanced to about 150 % and the signal for secreted fusion protein 
showed about 80% ± 40% (panel C). The biotinylation assay confirmed the result 
obtained by flow cytometry (panel D). These experiments demonstrate that the 
mutant rM 331 does not differ from wild-type FGF2-GFP with regard to secretion 
efficiency and binding efficiency to heparan sulfate proteoglycans or heparin. Since 
both secretion assays do not detect a clear reduction of secretion efficiency, this 
clone belongs to the group of mutants showing no phenotype. 
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Mutant RM 346 contains 4 amino acid changes: K35R, S56C, N111Y and Y120H. 
 
 
 
Figure 3.40: Random mutagenesis; 4 amino acid changes: K35R, S56C, N111Y, Y120H A FACS analysis of cell free 
supernatant bound to the surface of CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell 
free supernatant to heparin beads. Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound 
(flowthrough, 10%) and bound material (eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative 
analysis of export employing flow cytometry.  Expression level (black bars) and secreted protein detected on the cell surface 
(red bars) is shown. FGF2-GFPwt was set to 100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-
impermeable biotin reagent. After cell lysis biotinylated and non-biotinylated proteins were separated by streptavidin beads. 
Total material (input, 5%) and the biotinylated fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. 
All results shown represent an average of at least 3 different experiments. For further details see „Material and Methods“ and 
explanation of assays in chapter 3.3.2. As a result, this clone does not show any difference to wild-type cells.  
 
As demonstrated in figure 3.40, the mutant rM 346 showed a slightly reduced ability 
to bind to heparan sulfate proteoglycans in vivo (about 80% ± 20%; panel A), which 
is confirmed by the ability to bind to heparin in vitro (panel B). The expression level 
and the cell surface staining of FGF2-GFPrM 346 were reduced (panel C), but the ratio 
between expressed and secreted protein was comparable to wild-type protein, 
indicating unchanged secretion efficiency. This result could not be confirmed by the 
biotinylation assay, which showed reduced expression level (lane 3) and less 
secreted FGF2-GFP fusion protein when compared to wild-type FGF2-GFP (lane 1 
and 2; panel D). These experiments demonstrate that the ability of mutant rM 346 to 
bind to heparin and to heparan sulfate proteoglycans is slightly reduced. However, 
since both secretion assays fail to detect a clear reduction of secretion efficiency, this 
clone belongs to the group of mutants showing no phenotype. 
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Mutant RM 365 contains 4 amino acid changes: K35R, S56C, N111Y and Y120H. 
 
 
 
 
Figure 3.41: Random mutagenesis; 4 amino acid changes: F39L, V52A, K75I, Q132R A FACS analysis of cell free supernatant 
bound to the surface of CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free 
supernatant to heparin beads. Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound 
(flowthrough, 10%) and bound material (eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative 
analysis of export employing flow cytometry.  Expression level (black bars) and secreted protein detected on the cell surface 
(red bars) is shown. FGF2-GFPwt was set to 100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-
impermeable biotin reagent. After cell lysis biotinylated and non-biotinylated proteins were separated by streptavidin beads. 
Total material (input, 5%) and the biotinylated fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. 
All results shown represent an average of at least 3 different experiments. For further details see „Material and Methods“ and 
explanation of assays in chapter 3.3.2. As a result, this clone does not show any difference to wild-type cells.  
 
As demonstrated in figure 3.41, the mutant rM 365 showed a reduced ability to bind 
to heparan sulfate proteoglycans in vivo (about 50% ± 30%; panel A), but the affinity 
to heparin in vitro was comparable to FGF2-GFPwt (panel B). The expression level 
and the cell surface staining of FGF2-GFPrM 365 were reduced (panel C), but the ratio 
between expressed and secreted protein remained comparable to wild-type protein, 
indicating unchanged secretion efficiency. As detected by the biotinylation assay 
(panel D), the mutant rM 365 shows the same expression level of the fusion protein 
(lane 3) as compared to FGF2-GFPwt (lane 1). Additionally, the amount of secreted 
FGF2-GFPrM 365 (lane 4) is reduced when compared to FGF2-GFPwt (lane 2). Taken 
these results together, this mutant does not show a secretion deficiency and its 
binding ability to heparin is not impaired.   
 
The mutants listed in this section do not demonstrate decreased secretion efficiency 
and reduced affinity to heparin or heparan sulfate proteoglycans when compared to 
wild-type FGF2-GFP. Therefore, they were termed “no phenotype”. 
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3.3.3.3 Experimental data for FGF2 mutants impaired in binding and protein 
stability 
 
In this section, FGF2 mutants generated by random mutagenesis are depicted which 
show reduced affinity to heparin in vitro and to heparan sulfate proteoglycans in vivo. 
Additionally, they demonstrate reduced expression levels of intracellular FGF2-GFP 
fusion protein. Moreover, their amino acid changes are shown and a summary of the 
experimental data is provided. For a detailed view on the assays used, please refer 
to chapter 3.3.2. 
 
Mutant rM 25 contains 6 amino acid changes: A3S, E14D, R42H, K61H, V72A and 
R90K 
 
 
Figure 3.42: Random mutagenesis; 6 amino acid changes: A3S, E14D, R42H, K61H, V72A, R90K A FACS analysis of cell free 
supernatant bound to the surface of CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell 
free supernatant to heparin beads. Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound 
(flowthrough, 10%) and bound material (eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative 
analysis of export employing flow cytometry.  Expression level (black bars) and secreted protein detected on the cell surface 
(red bars) is shown. FGF2-GFPwt was set to 100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-
impermeable biotin reagent. After cell lysis biotinylated and non-biotinylated proteins were separated by streptavidin beads. 
Total material (input, 5%) and the biotinylated fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All 
results shown represent an average of at least 3 different experiments. For further details see „Material and Methods“ and 
explanation of assays in chapter 3.3.2. As a result, this clone shows a binding deficiency in both binding assays. Both secretion 
assays reveal that the reduced signal for secreted FGF2 is resulting from the low amount of expressed reporter protein and the 
impaired binding ability to heparan sulfate proteoglycans. 
 
As demonstrated in figure 3.42, mutant rM 25 showed a reduced ability to bind to 
heparan sulfate proteoglycans in vivo (panel A) as well as to heparin in vitro (panel B) 
when compared to FGF2-GFPwt. The expression level and cell surface staining of 
FGF2-GFPrM 25 is strongly reduced compared to wild-type FGF2-GFP as shown by 
flow cytometry (panel C) and biotinylation assay (panel D). The combined data 
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obtained demonstrate that the mutations of FGF2-GFPrM 25 cause impaired binding to 
heparin and heparan sulfate proteoglycans as well as an instable fusion protein. 
 
 
Mutant rM 30 contains 6 amino acid changes: G18S, D58G, G89V, R90G, L91F and 
W123R. 
 
Figure 3.43: Random mutagenesis; 6 amino acid changes: G18S, D58G, G89V, R90G, L91F, W123R A FACS analysis of cell 
free supernatant bound to the surface of CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of 
cell free supernatant to heparin beads. Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound 
(flowthrough, 10%) and bound material (eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative 
analysis of export employing flow cytometry.  Expression level (black bars) and secreted protein detected on the cell surface 
(red bars) is shown. FGF2-GFPwt was set to 100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-
impermeable biotin reagent. After cell lysis biotinylated and non-biotinylated proteins were separated by streptavidin beads. 
Total material (input, 5%) and the biotinylated fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All 
results shown represent an average of at least 3 different experiments. For further details see „Material and Methods“ and 
explanation of assays in chapter 3.3.2. As a result, this clone shows a binding deficiency in both binding assays. Both secretion 
assays reveal that the reduced signal for secreted FGF2 is resulting from the low amount of expressed reporter protein and the 
impaired binding ability to heparan sulfate proteoglycans. 
 
As demonstrated in figure 3.43, mutant rM 30 showed a reduced ability to bind to 
heparan sulfate proteoglycans in vivo (panel A) as well as to heparin in vitro (panel B) 
when compared to FGF2-GFPwt. The expression level and cell surface staining of 
FGF2-GFPrM 30 is strongly reduced compared to wild-type FGF2-GFP as shown by 
flow cytometry (panel C) and biotinylation assay (panel D). The combined data 
obtained demonstrate that the mutations of FGF2-GFPrM 30 cause impaired binding to 
heparin and heparan sulfate proteoglycans as well as an instable fusion protein. 
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Mutant rM 32 contains 4 amino acid changes: P23S, K55R, E68A, E87D. 
 
 
 
Figure 3.44: Random mutagenesis; 4 amino acid changes: P23S, K55R, E68A, E87D A FACS analysis of cell free supernatant 
bound to the surface of CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free 
supernatant to heparin beads. Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound 
(flowthrough, 10%) and bound material (eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative 
analysis of export employing flow cytometry.  Expression level (black bars) and secreted protein detected on the cell surface 
(red bars) is shown. FGF2-GFPwt was set to 100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-
impermeable biotin reagent. After cell lysis biotinylated and non-biotinylated proteins were separated by streptavidin beads. 
Total material (input, 5%) and the biotinylated fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All 
results shown represent an average of at least 3 different experiments. For further details see „Material and Methods“ and 
explanation of assays in chapter 3.3.2. As a result this clone shows a binding deficiency in both binding assays. Both secretion 
assays reveal that the reduced signal for secreted FGF2 is resulting from the low amount of expressed reporter protein and the 
impaired binding ability to heparan sulfate proteoglycans. 
  
As demonstrated in figure 3.44, mutant rM 32 showed a reduced ability to bind to 
heparan sulfate proteoglycans in vivo (panel A) as well as to heparin in vitro (panel B) 
when compared to FGF2-GFPwt. The expression level and cell surface staining of 
FGF2-GFPrM 32 is strongly reduced compared to wild-type FGF2-GFP as shown by 
flow cytometry (panel C) and biotinylation assay (panel D). The combined data 
obtained demonstrate that the mutations of FGF2-GFPrM 32 cause impaired binding to 
heparin and heparan sulfate proteoglycans as well as an instable fusion protein. 
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Mutant rM 71 contains 6 amino acid changes: A3S, E14D, R42H, K61H, V72A and 
R90K. 
 
 
 
Figure 3.45: Random mutagenesis; 6 amino acid changes: A3S, E14D, R42H, K61H, V72A, R90K A FACS analysis of cell free 
supernatant bound to the surface of CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell 
free supernatant to heparin beads. Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound 
(flowthrough, 10%) and bound material (eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative 
analysis of export employing flow cytometry.  Expression level (black bars) and secreted protein detected on the cell surface 
(red bars) is shown. FGF2-GFPwt was set to 100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-
impermeable biotin reagent. After cell lysis biotinylated and non-biotinylated proteins were separated by streptavidin beads. 
Total material (input, 5%) and the biotinylated fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All 
results shown represent an average of at least 3 different experiments. For further details see Materials and Methods.  As a 
result, this clone shows a binding deficiency in both binding assays. Both secretion assays reveal that the reduced signal for 
secreted FGF2 is resulting from the low amount of expressed reporter protein and the impaired binding ability to heparan sulfate 
proteoglycans. 
 
As demonstrated in figure 3.45, mutant rM 71 showed a reduced ability to bind to 
heparan sulfate proteoglycans in vivo (panel A) as well as to heparin in vitro (panel B) 
when compared to FGF2-GFPwt. The expression level and cell surface staining of 
FGF2-GFPrM 71 is strongly reduced compared to wild-type FGF2-GFP as shown by 
flow cytometry (panel C) and biotinylation assay (panel D). The combined data 
obtained demonstrate that the mutations of FGF2-GFPrM 71 cause impaired binding to 
heparin and heparan sulfate proteoglycans as well as an instable fusion protein. 
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 Mutant rM 193 exhibits 2 amino acid changes: R81C and L135F. 
 
 
 
Figure 3.46: Random mutagenesis; 2 amino acid changes: R81C, L135F A FACS analysis of cell free supernatant bound to the 
surface of CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin 
beads. Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound 
material (eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow 
cytometry.  Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt 
was set to 100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After 
cell lysis biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the 
biotinylated fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average 
of at least 3 different experiments. For further details see Materials and Methods. As a result, this clone shows a binding 
deficiency in both binding assays Both secretion assays reveal that the reduced signal for secreted FGF2 is resulting from the 
low amount of expressed reporter protein and the impaired binding ability to heparan sulfate proteoglycans. 
 
As demonstrated in figure 3.46, mutant rM 193 showed a reduced ability to bind to 
heparan sulfate proteoglycans in vivo (panel A) when compared to FGF2-GFPwt, but 
its affinity to bind to heparin in vitro (panel B) was not impaired. The expression level 
and of FGF2-GFPrM 193 is strongly reduced as shown by flow cytometry (panel C), but 
as detected by the biotinylation assay (panel D), the mutant rM 193 showed the 
same expression level of fusion protein (lane 3) as compared to FGF2-GFPwt (lane 1). 
However, the amount of secreted FGF2-GFPrM 193 was comparable to FGF2-GFPwt. 
Although the combined data obtained are not consistent, FGF2-GFPrM 193 shows 
impaired binding to heparan sulfate proteoglycans and an instable fusion protein. 
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Mutant rM 201 contains 7 amino acid changes: P13H, F21I, F40L, K55T, L64P, 
C78S and Y133H. 
 
 
 
Figure 3.47: Random mutagenesis; 7 amino acid changes: P13H, F21I, F40L, K55T, L64P, C78S, Y133H A FACS analysis of 
cell free supernatant bound to the surface of CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding 
of cell free supernatant to heparin beads. Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-
bound (flowthrough, 10%) and bound material (eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative 
analysis of export employing flow cytometry.  Expression level (black bars) and secreted protein detected on the cell surface 
(red bars) is shown. FGF2-GFPwt was set to 100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-
impermeable biotin reagent. After cell lysis biotinylated and non-biotinylated proteins were separated by streptavidin beads. 
Total material (input, 5%) and the biotinylated fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All 
results shown represent an average of at least 3 different experiments. For further details see Materials and Methods. As a 
result, this clone shows a binding deficiency in both binding assays. Both secretion assays reveal that the reduced signal for 
secreted FGF2 is resulting from the low amount of expressed reporter protein. 
 
As demonstrated in figure 3.47, mutant rM 201 showed a reduced ability to bind to 
heparan sulfate proteoglycans in vivo (panel A) as well as to heparin in vitro (panel B) 
when compared to FGF2-GFPwt. The expression level and cell surface staining of 
FGF2-GFPrM 201 is strongly reduced compared to wild-type FGF2-GFP as shown by 
flow cytometry (panel C) and biotinylation assay (panel D). The combined data 
obtained demonstrate that the mutations of FGF2-GFPrM 201 cause impaired binding 
to heparin and heparan sulfate proteoglycans as well as an instable fusion protein. 
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Mutant RM 210 contains 3 amino acid changes: H59P, E68G and I74T. 
 
 
 
Figure 3.48: Random mutagenesis; 3 amino acid changes: H59P, E68G, I74T A FACS analysis of cell free supernatant bound 
to the surface of CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to 
heparin beads. Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and 
bound material (eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing 
flow cytometry.  Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-
GFPwt was set to 100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin 
reagent. After cell lysis biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 
5%) and the biotinylated fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent 
an average of at least 3 different experiments. For further details see Materials and Methods. As a result, this clone shows a 
binding deficiency in both binding assays. Both secretion assays reveal that the reduced signal for secreted FGF2 is resulting 
from the low amount of expressed reporter protein. 
 
As demonstrated in figure 3.48, mutant rM 210 showed a reduced ability to bind to 
heparan sulfate proteoglycans in vivo (panel A) as well as to heparin in vitro (panel B) 
when compared to FGF2-GFPwt. The expression level and cell surface staining of 
FGF2-GFPrM 210 is reduced compared to wild-type FGF2-GFP as shown by flow 
cytometry (panel C) and biotinylation assay (panel D). The combined data obtained 
demonstrate that the mutations of FGF2-GFPrM 210 cause impaired binding to heparin 
and heparan sulfate proteoglycans as well as an instable fusion protein. 
 
The mutants listed in this section demonstrate an impaired binding to heparin in vitro 
and heparan-sulfate proteoglycans in vivo. Additionally, the expression level of the 
various versions of FGF2-GFP is strongly reduced, indicating a potentionally 
misfolded proteins which is rapidly degraded or reduced translation rates. As a 
consequence thereof, these mutants were termed “low expressed and impaired in 
binding”. 
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3.3.3.4 Experimental data for a secretion deficient FGF2 mutant  
 
The mutant depicted in this section was shown to be secretion deficient using the 
standard assays described in section 3.3.2. 
 
 
Mutant rM156 contains 3 amino acid changes: E87K, K128E and R129Q. 
 
 
 
Figure 3.49: Random mutagenesis; 3 amino acid changes: E87K, K128E, R129Q A FACS analysis of cell free supernatant 
bound to the surface of CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free 
supernatant to heparin beads. Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound 
(flowthrough, 10%) and bound material (eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative 
analysis of export employing flow cytometry.  Expression level (black bars) and secreted protein detected on the cell surface 
(red bars) is shown. FGF2-GFPwt was set to 100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-
impermeable biotin reagent. After cell lysis biotinylated and non-biotinylated proteins were separated by streptavidin beads. 
Total material (input, 5%) and the biotinylated fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All 
results shown represent an average of at least 3 different experiments. For further details see „Material and Methods“ and 
explanation of assays in chapter 3.3.2. As a result, this clone shows a reduced signal for protein presented on the cell surface. 
The result for binding differs. FGF2-GFPRM156 was able to bind to heparin beads in vitro, but could not be bound to the Cell 
Surface of CHOMCAT/TAM2 cells. This clone was subject of further characterizations. 
 
As demonstrated in figure 3.49, the mutant rM156 displayed a constant FGF2-GFP 
expression level but a reduced signal for secreted FGF2-GFP bound to the cell 
surface when compared to FGF2-GFPwt as shown by flow cytometry and cell surface 
biotinylation, indicating that these mutations influence unconventional secretion of 
FGF2-GFP. Additionally it was shown that the protein is able to bind in vitro to 
heparin, but its binding in vivo to the cell surface of CHO cells is impaired. The 
combined data obtained for mutant rM 156 are not consistent. It remains elusive if 
the impaired binding to heparan sulfate proteoglycans results in the reduced amount 
of secreted FGF2-GFP bound to the cell surface. Therefore, this mutant was 
characterized in more detail as described in chapter 3.4.2. 
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3.3.3.5 Classification of FGF2-GFP mutants obtained by random mutagenesis with 
regard to secretion efficiency, protein stability and binding to heparin 
 
The results obtained for the different versions of FGF2-GFP mutants as analyzed by 
the standard assays are summarized in table 3.2: 
 
classification Clones 
No phenotype 26 
 63 
 151 
 239 
 265 
 284 
 315 
 331 
 346 
 365 
Reduced expression level and impaired binding 25 
 30 
 32 
 193 
 201 
 210 
Secretion mutant and impaired in binding 156 
Table 3.2: Classifications made for clones created by random mutagenesis.  
 
The results obtained by characterization of mutants generated by random 
mutagenesis show that most of the generated clones have phenotype characteristics 
with regard to secretion and heparin binding (10). Additionally mutants with impaired 
heparin binding ability show low expression levels of FGF2-GFP in the cytosol (7). 
One mutant was observed, which shows a reduced signal for secreted fusion protein. 
Strikingly, this fusion protein fails to bind to CHO cells in vivo, although binding to 
heparin beads in vitro occurs efficiently. This mutant was further characterized as 
described in section 3.4.2. 
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3.3.4 Analysis of mutants obtained by site-directed mutagenesis  
 
In this approach single amino acids of FGF2 were exchanged by site-directed 
mutagenesis. The mutated amino acids were selected based on the following criteria: 
 
1. Random mutagenesis: Mutants bearing multiple randomly introduced amino 
acid changes showing an impaired heparin binding ability or altered secretion 
of FGF2 were further characterized by exchanging every mutated amino acid 
individually to determine the role of a single amino acid in binding and 
secretion.  
 
2. Three-dimensional structure: Based on the crystal structure, hydrophobic 
surface residues of FGF2-GFP were chosen for mutation, which are 
potentially involved in protein-protein interactions, thus mediating interactions 
with the translocation machinery. 
 
 
3. N-terminus: Numerous examples for N-terminal export motifs were shown in 
the literature. Classical secretory proteins contain an N-terminal signal peptide 
(Walter et al., 1984) and proteins localized to mitochondria contain an N-
terminal cleavable signal sequence (Neupert, 1997). Moreover, it might be 
possible that co- and/or posttranslational processings of amino acids might be 
involved in the export process. Side-directed mutations were introduced into 
the N-terminus to verify if N-terminal residues might be involved in the 
secretion of FGF2.  
 
4. Dimerization: It has been shown for FGF-1, that the protein is released in an 
unconventional manner in response to temperature stress as a latent 
homodimer (Tarantini et al., 1995). Additionally it was shown that dimerization 
is a prerequisite for FGF2 mediated signalling (Kwan et al., 2001). Therefore 
two cysteines, potentially mediating dimerization of FGF2 (Kwan et al., 2001), 
were mutated individually and in combination. 
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The individual mutations and the criteria for choosing the distinct point mutations are 
listed in the following table: 
 
Clone Approach Clone  Approach 
A3V Random Mutagenesis 25 E67V Random Mutagenesis 265 
G4A N-terminal mutation E68A Random Mutagenesis 26 
S5A N-terminal mutation E68G Random Mutagenesis 210 
I6T N-terminal mutation R69A 3-D structure 
T7A N-terminal mutation V72A Random Mutagenesis 25 
T7E N-terminal mutation I74T Random Mutagenesis 210 
T7D N-terminal mutation K75I Random Mutagenesis 365 
T8M Random Mutagenesis 217 V77A Random Mutagenesis 284 
E14D Random Mutagenesis 25 C78A Dimerization  
F21I Random Mutagenesis 201 N80A 3-D structure 
P23S Random Mutagenesis Y82A 3-D structure 
F26A 3-D structure E87K Random Mutagenesis 156 
K30E Random Mutagenesis 265 D88A 3-D structure 
Y33A 3-D structure L92A 3-D structure 
F39L Random Mutagenesis 365 C96A Dimerization 
F39A 3-D structure  F102A 3-D structure 
F40L Random Mutagenesis 201 F104A 3-D structure 
R42H Random Mutagenesis 25 Y112A 3-D structure 
R53H 3-D structure  S122A 3-D structure 
K55T Random Mutagenesis 201 K128E Random Mutagenesis 156 
K55R Random Mutagenesis 26 R129Q Random Mutagenesis 156 
H59P Random Mutagenesis 210 Q132R Random Mutagenesis 365 
K61E Random Mutagenesis 239 Y133H Random Mutagenesis 201 
L64P Random Mutagenesis 201 Y133A 3-D structure 
Q65A 3-D structure S152A 3-D structure 
CC78/96AA Dimerization   
Table 3.3: Overview of the selection procedure for the construction of point mutations  
 
As listed in table 3.3, 25 point mutations were selected based on the analysis of 
random mutagenesis, 16 were selected based on crystal structure study, 3 were 
selected based on their ability to dimerize FGF2 and 6 were chosen based on their 
location at the N-terminus. 
The experimental data for point mutations is shown in the following section, including 
in vivo and in vitro binding assays and secretion assays. 
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3.3.4.1 Experimental data for mutants showing no phenotype regarding secretion 
efficiency and affinity to heparin 
 
In this section, the FGF2 mutants generated by site-directed mutagenesis are 
depicted which are comparable to wild-type FGF2-GFP with regard to secretion 
efficiency and binding capability to heparin and heparan sulfate proteoglycans. 
Moreover, their amino acid changes are shown and a summary of the experimental 
data is provided. For a detailed view on the assays used, please refer to chapter 
3.3.2. 
 
The following mutant contains a mutation at position 3 changing alanine to valine. 
 
 
 
Figure 3.50: Point mutation; amino acid change: A3V A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not differ from observations made for wild type FGF2-GFP.  
 
As demonstrated in figure 3.50, the affinities of FGF2-GFPA3V to heparan sulfate 
proteoglycans in vivo (panel A) and to heparin in vitro (panel B) was comparable to 
those of FGF2-GFPwt. As detected by flow cytometry (panel C), the expression level 
of FGF2-GFPA3V was slightly reduced as compared to FGF2-GFPwt, but the amount 
of secreted fusion protein
 
detected on the cell surface did not vary from wild-type 
level, in contrast to the result obtained by the biotinylation assay (panel D), which 
showed slightly reduced secretion efficiency of the mutant when compared to FGF2-
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GFPwt cells. However, the combined data obtained for this mutant demonstrate that 
A3V is not deficient in secretion or impaired in heparin binding and does not show a 
phenotype which is different from FGF2-GFPwt cells.  
 
 
The following mutant contains a mutation at position 4, changing glycine to alanine. 
 
 
 
 
Figure 3.51: Point mutation; amino acid change: G4A A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not alter from observations made for wild-type FGF2-GFP.  
 
As demonstrated in figure 3.51, the mutant G4A showed an enhanced ability to bind 
to heparan sulfate proteoglycans in vivo (about 150% ± 100%; panel A), but its 
affinity to heparin in vitro was comparable to FGF2-GFPwt heparin affinity. As 
detected by flow cytometry (panel C), the expression level of FGF2-GFPG4A was 
slightly reduced as compared to FGF2-GFPwt, but the amount of secreted fusion 
protein
 
detected on the cell surface did not vary from wild-type level. The data 
obtained by flow cytometry were confirmed by the biotinylation assay (panel D). 
These experiments demonstrate that the mutant G4A does not differ from wild-type 
FGF2-GFP with regard to secretion efficiency, affinity to heparin and heparan sulfate 
proteoglycans. 
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The following mutant contains a mutation at position 5, changing serine to alanine. 
 
 
 
Figure 3.52: Point mutation; amino acid change: S5A A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not alter from observations made for wild-type FGF2-GFP.  
 
As demonstrated in figure 3.52, the affinities of FGF2-GFPS5A to heparan sulfate 
proteoglycans in vivo (panel A) and to heparin in vitro (panel B) was comparable to 
those of FGF2-GFPwt. As detected by flow cytometry (panel C), the expression level 
of FGF2-GFPS5A was slightly reduced as compared to FGF2-GFPwt, but the amount 
of secreted fusion protein
 
detected on the cell surface did not vary from wild-type 
level, in contrast to the result obtained by the biotinylation assay (panel D), which 
showed slightly reduced secretion efficiency of the mutant when compared to FGF2-
GFPwt cells. However, the combined data obtained for this mutant demonstrate that 
S5A is not deficient in secretion or impaired in heparin binding and does not show a 
phenotype which is different from FGF2-GFPwt cells. 
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The following mutant contains a mutation at position 6, changing isoleucine to 
alanine. 
 
 
 
Figure 3.53: Point mutation; amino acid change: I6A A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not alter from observations made for wild-type FGF2-GFP.  
 
As demonstrated in figure 3.53, the affinities of FGF2-GFPI6A to heparan sulfate 
proteoglycans in vivo (panel A) and to heparin in vitro (panel B) was comparable to 
those ofFGF2-GFPwt. As detected by flow cytometry (panel C), both the expression 
level and the cell surface staining of FGF2-GFPI6A did not vary from wild-type level, in 
contrast to the result obtained by the biotinylation assay (panel D), which showed 
slightly reduced secretion efficiency of the mutant when compared to FGF2-GFPwt 
cells. However, the combined data obtained for this mutant demonstrate that I6A is 
not deficient in secretion or impaired in heparin binding and does not show a 
phenotype which is different from FGF2-GFPwt cells. 
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The following mutant contains a mutation at position 7, changing threonine to alanine. 
 
 
 
Figure 3.54: Point mutation; amino acid change: T7A A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not alter from observations made for wild-type FGF2-GFP.  
 
As demonstrated in figure 3.54, the affinities of FGF2-GFPT7A to heparan sulfate 
proteoglycans in vivo (panel A) and to heparin in vitro (panel B) was comparable to 
those of FGF2-GFPwt. As detected by flow cytometry (panel C), both the expression 
level and the cell surface staining of FGF2-GFPT7A did not vary from wild-type level, 
in contrast to the result obtained by the biotinylation assay (panel D), which showed 
slightly reduced secretion efficiency of the mutant when compared to FGF2-GFPwt 
cells. However, the combined data obtained for this mutant demonstrate that T7A is 
not deficient in secretion or impaired in heparin binding and does not show a 
phenotype which is different from FGF2-GFPwt cells. 
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The following mutant contains a mutation at position 7, changing threonine to 
glutamic acid. 
 
 
 
Figure 3.55: Point mutation; amino acid change: T7E A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not alter from observations made for wild-type FGF2-GFP.  
 
As demonstrated in figure 3.55, the affinities of FGF2-GFPT7E to heparan sulfate 
proteoglycans in vivo (panel A) and to heparin in vitro (panel B) was comparable to 
those of FGF2-GFPwt. As detected by flow cytometry (panel C), both the expression 
level and the cell surface staining of FGF2-GFPT7E did not vary from wild-type level, 
in contrast to the result obtained by the biotinylation assay (panel D), which showed 
slightly reduced secretion efficiency of the mutant when compared to FGF2-GFPwt 
cells. However, the combined data obtained for this mutant demonstrate that T7E is 
not deficient in secretion or impaired in heparin binding and does not show a 
phenotype which is different from FGF2-GFPwt cells. 
Results 
 
122 
The following mutant contains a mutation at position 7, changing threonine to 
aspartic acid. 
 
 
 
Figure 3.56: Point mutation; amino acid change: T7D A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not alter from observations made for wild-type FGF2-GFP.  
 
As demonstrated in figure 3.56, the affinity of FGF2-GFPT7D to heparan sulfate 
proteoglycans in vivo (panel A) and its affinity to heparin in vitro (panel B) was 
comparable to FGF2-GFPwt heparin affinity. As detected by flow cytometry (panel C), 
both the expression level and the cell surface staining of FGF2-GFPT7D did not vary 
from wild-type level. This result was confirmed by performing a biotinylation assay 
(panel D). The combined data obtained for this mutant demonstrate that T7D is not 
deficient in secretion or impaired in heparin binding and does not show a phenotype 
which is different from FGF2-GFPwt cells. 
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The following mutant contains a mutation at position 8, changing threonine to 
methionine. 
 
 
 
Figure 3.57: Point mutation; amino acid change: T8M A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not alter from observations made for wild-type FGF2-GFP.  
 
As demonstrated in figure 3.57, the affinity of FGF2-GFPT8M to heparan sulfate 
proteoglycans in vivo (panel A) was enhanced (about 200% ± 40%), but its affinity to 
heparin in vitro (panel B) was comparable to FGF2-GFPwt heparin affinity. As 
detected by flow cytometry (panel C), both the expression level and the cell surface 
staining of FGF2-GFPT8M did not vary from wild-type level. This result was confirmed 
by performing the biotinylation assay (panel D). The combined data obtained for this 
mutant demonstrate that T8M is not deficient in secretion or impaired in heparin 
binding and does not show a phenotype which is different from FGF2-GFPwt cells. 
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The following mutant contains a mutation at position 14, changing glutamic acid to 
aspartic acid. 
 
 
 
Figure 3.58: Point mutation; amino acid change: E14D A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not alter from observations made for wild-type FGF2-GFP.  
 
As demonstrated in figure 3.58, the affinity of FGF2-GFPE14D to heparan sulfate 
proteoglycans in vivo (panel A) and its affinity to heparin in vitro (panel B) was 
comparable to FGF2-GFPwt heparin affinity. As detected by flow cytometry (panel C), 
both the expression level and the cell surface staining of FGF2-GFPE14D did not vary 
from wild-type level. This result was confirmed by performing a biotinylation assay 
(panel D). The combined data obtained for this mutant demonstrate that E14D is not 
deficient in secretion or impaired in heparin binding and does not show a phenotype 
which is different from FGF2-GFPwt cells. 
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The following mutant contains a mutation at position 21, changing phenylalanine to 
isoleucine. 
 
 
 
Figure 3.59: Point mutation; amino acid change: F21I A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not alter from observations made for wild-type FGF2-GFP.  
 
As demonstrated in figure 3.59, the affinity of FGF2-GFPF21I to heparan sulfate 
proteoglycans in vivo (panel A) and its affinity to heparin in vitro (panel B) was 
comparable to FGF2-GFPwt heparin affinity. As detected by flow cytometry (panel C), 
both the expression level and the cell surface staining of FGF2-GFPF21I did not vary 
from wild-type level. This result was confirmed by performing a biotinylation assay 
(panel D). The combined data obtained for this mutant demonstrate that F21I is not 
deficient in secretion or impaired in heparin binding and does not show a phenotype 
which is different from FGF2-GFPwt cells. 
Results 
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The following mutant contains a mutation at position 23, changing proline to serine. 
 
 
 
Figure 3.60: Point mutation; amino acid change: P23S A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not alter from observations made for wild-type FGF2-GFP.  
 
As demonstrated in figure 3.60, the affinity of FGF2-GFPP23S to heparan sulfate 
proteoglycans in vivo (panel A) and its affinity to heparin in vitro (panel B) was 
comparable to FGF2-GFPwt heparin affinity. As detected by flow cytometry (panel C), 
the expression level of FGF2-GFPP23S was slightly reduced as compared to FGF2-
GFPwt, but the amount of secreted fusion protein detected on the cell surface did not 
vary from wild-type level, in contrast to the result obtained by the biotinylation assay 
(panel D), which showed slightly reduced secretion efficiency of the mutant when 
compared to FGF2-GFPwt. However, the combined data obtained for this mutant 
demonstrate that P23S is not deficient in secretion or impaired in heparin binding and 
does not show a phenotype which is different from FGF2-GFPwt cells. 
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The following mutant contains a mutation at position 26, changing phenylalanine to 
alanine. 
 
 
 
Figure 3.61: Point mutation; amino acid change: F26A A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not alter from observations made for wild-type FGF2-GFP. 
 
As demonstrated in figure 3.61, the affinity of FGF2-GFPF26A to heparan sulfate 
proteoglycans in vivo (panel A) was enhanced (about 180%), but its affinity to 
heparin in vitro (panel B) was comparable to FGF2-GFPwt heparin affinity. As 
detected by flow cytometry (panel C), the expression level of FGF2-GFPF26A was 
slightly reduced as compared to FGF2-GFPwt, but the amount of secreted fusion 
protein
 
detected on the cell surface did not vary from wild-type level. This result was 
confirmed by performing the biotinylation assay (panel D). The combined data 
obtained for this mutant demonstrate that F26A is not deficient in secretion or 
impaired in heparin binding and does not show a phenotype which is different from 
FGF2-GFPwt cells. 
Results 
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The following mutant contains a mutation at position 30, changing lysine to glutamic 
acid. 
 
 
 
Figure 3.62: Point mutation; amino acid change: K30E A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not alter from observations made for wild-type FGF2-GFP. 
 
As demonstrated in figure 3.62, the affinity of FGF2-GFPK30E to heparan sulfate 
proteoglycans in vivo (panel A) is reduced (about 60% ± 20%), but its affinity to 
heparin in vitro (panel B) was comparable to FGF2-GFPwt heparin affinity. As 
detected by flow cytometry (panel C), the expression level of FGF2-GFPK30E was 
slightly reduced as compared to FGF2-GFPwt, but the amount of secreted fusion 
protein
 
detected on the cell surface did not vary from wild-type level. This result was 
confirmed by performing the biotinylation assay (panel D). The combined data 
obtained for this mutant demonstrate that K30E is not deficient in secretion or 
impaired in heparin binding and does not show a phenotype which is different from 
FGF2-GFPwt cells. 
Results 
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The following mutant contains a mutation at position 33, changing tyrosine to alanine. 
 
 
 
Figure 3.63: Point mutation; amino acid change: Y33A A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not alter from observations made for wild-type FGF2-GFP. 
 
As demonstrated in figure 3.63, the affinity of FGF2-GFPY33A to heparan sulfate 
proteoglycans in vivo (panel A) was enhanced (about 150% ± 60 %), but its affinity to 
heparin in vitro (panel B) was comparable to FGF2-GFPwt heparin affinity. As 
detected by flow cytometry (panel C), both the expression level and the cell surface 
staining of FGF2-GFPY33A did not vary from wild-type level. This result was confirmed 
by performing the biotinylation assay (panel D). The combined data obtained for this 
mutant demonstrate that Y33A is not deficient in secretion or impaired in heparin 
binding and does not show a phenotype which is different from FGF2-GFPwt cells. 
Results 
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The following mutant contains a mutation at position 39, changing phenylalanine to 
leucine. 
 
 
 
Figure 3.64: Point mutation; amino acid change: F39L A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not alter from observations made for wild-type FGF2-GFP. 
 
As demonstrated in figure 3.64, the affinity of FGF2-GFPF39L to heparan sulfate 
proteoglycans in vivo (panel A) is reduced (about 40%) but its affinity to heparin in 
vitro (panel B) was comparable to FGF2-GFPwt heparin affinity. As detected by flow 
cytometry (panel C), the expression level of FGF2-GFPF39L was slightly reduced as 
compared to FGF2-GFPwt, but the amount of secreted fusion protein detected on the 
cell surface did not vary from wild-type level. The result obtained by the biotinylation 
assay (panel D) demonstrated slightly reduced secretion efficiency of the mutant 
when compared to FGF2-GFPwt. The combined data obtained for this mutant 
demonstrate that F39L is not deficient in secretion or impaired in heparin binding and 
does not show a phenotype which is different from FGF2-GFPwt cells. 
Results 
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The following mutant contains a mutation at position 39, changing phenylalanine to 
alanine. 
 
 
 
Figure 3.65: Point mutation; amino acid change: F39A A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not alter from observations made for wild-type FGF2-GFP. 
 
As demonstrated in figure 3.65, the affinities of FGF2-GFPF39A to heparan sulfate 
proteoglycans in vivo (panel A) and heparin in vitro (panel B) was comparable to 
those of FGF2-GFPwt. As detected by flow cytometry (panel C), the expression level 
of FGF2-GFPF39A was slightly reduced as compared to FGF2-GFPwt, but the amount 
of secreted fusion protein
 
detected on the cell surface did not vary from wild-type 
level.  This result was confirmed by performing the biotinylation assay (panel D). The 
combined data obtained for this mutant demonstrate that F39A is not deficient in 
secretion or impaired in heparin binding and does not show a phenotype which is 
different from FGF2-GFPwt cells. 
Results 
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The following mutant contains a mutation at position 53, changing arginine to 
histidine. 
 
 
 
Figure 3.66: Point mutation; amino acid change: R53H A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not alter from observations made for wild-type FGF2-GFP. 
 
As demonstrated in figure 3.66, the affinities of FGF2-GFPR53H to heparan sulfate 
proteoglycans in vivo (panel A) and to heparin in vitro (panel B) was comparable to 
FGF2-GFPwt heparin affinity. As detected by flow cytometry (panel C), the expression 
level of FGF2-GFPR53H was slightly reduced as compared to FGF2-GFPwt, but the 
amount of secreted fusion protein
 
detected on the cell surface did not vary from wild-
type level. As detected by the biotinylation assay (panel D), the mutant R53H 
demonstrated an enhanced amount of fusion protein (lane 3) as compared to FGF2-
GFPwt cells (lane 1). However, this mutant does not secrete the fusion protein more 
efficiently (compare the ration of lane 1 and 2 with the ratio of lane 3 and 4) than wild-
type FGF2-GFP cells. The combined data obtained for this mutant demonstrate that 
R53H is not deficient in secretion or impaired in heparin binding and does not show a 
phenotype which is different from FGF2-GFPwt cells. 
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The following mutant contains a mutation at position 55, changing lysine to threonine. 
 
 
 
Figure 3.67: Point mutation; amino acid change: K55T A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not alter from observations made for wild-type FGF2-GFP. 
 
As demonstrated in figure 3.67, the affinity of FGF2-GFPK55T to heparan sulfate 
proteoglycans in vivo (panel A) was enhanced (about 140% ± 50 %), but its affinity to 
heparin in vitro (panel B) was slightly reduced when compared to FGF2-GFPwt 
heparin affinity. As detected by flow cytometry (panel C), both the expression level 
and the cell surface staining of FGF2-GFPK55T did not vary from wild-type level, in 
contrast to the result obtained by the biotinylation assay (panel D), which 
demonstrated slightly reduced secretion efficiency of the mutant when compared to 
FGF2-GFPwt cells. However, the combined data obtained for this mutant demonstrate 
that K55T is not deficient in secretion or impaired in heparin binding and does not 
show a phenotype which is different from FGF2-GFPwt cells. 
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The following mutant contains a mutation at position 55, changing lysine to arginine. 
 
 
 
Figure 3.68: Point mutation; amino acid change: K55R A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not alter from observations made for wild-type FGF2-GFP. 
 
As demonstrated in figure 3.68, the affinity of FGF2-GFPK55R to heparan sulfate 
proteoglycans in vivo (panel A) was enhanced (about 150% ± 70 %), but its affinity to 
heparin in vitro (panel B) was comparable to FGF2-GFPwt heparin affinity. As 
detected by flow cytometry (panel C), both the expression level and the cell surface 
staining of FGF2-GFPK55T did not vary from wild-type level, in contrast to the result 
obtained by the biotinylation assay (panel D), which demonstrated slightly reduced 
secretion efficiency of the mutant when compared to FGF2-GFPwt cells. However, the 
combined data obtained for this mutant demonstrate that K55T is not deficient in 
secretion or impaired in heparin binding and does not show a phenotype which is 
different from FGF2-GFPwt cells. 
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The following mutant contains a mutation at position 59, changing histidine to proline. 
 
 
 
Figure 3.69: Point mutation; amino acid change: H59P A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not alter from observations made for wild-type FGF2-GFP. 
 
As demonstrated in figure 3.69, the affinity of FGF2-GFPH59P to heparan sulfate 
proteoglycans in vivo (panel A) was enhanced (about 160% ± 30 %), but its affinity to 
heparin in vitro (panel B) was comparable to FGF2-GFPwt heparin affinity. As 
detected by flow cytometry (panel C), both the expression level and the cell surface 
staining of FGF2-GFPH59P did not vary from wild-type level, in contrast to the result 
obtained by the biotinylation assay (panel D), which demonstrated slightly reduced 
secretion efficiency of the mutant when compared to FGF2-GFPwt cells. However, the 
combined data obtained for this mutant demonstrate that the mutant H59P is not 
deficient in secretion or impaired in heparin binding and does not show a phenotype 
which is different from FGF2-GFPwt cells. 
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The following mutant contains a mutation at position 61, changing lysine to glutamic 
acid. 
 
 
 
Figure 3.70: Point mutation; amino acid change: K61E A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not alter from observations made for wild-type FGF2-GFP. 
 
As demonstrated in figure 3.70, the affinity of FGF2-GFPK61E to heparan sulfate 
proteoglycans in vivo (panel A) was enhanced (about 150% ± 50 %), but its affinity to 
heparin in vitro (panel B) was comparable to FGF2-GFPwt heparin affinity. As 
detected by flow cytometry (panel C), both the expression level and the cell surface 
staining of FGF2-GFPK61E were reduced to about 60% when compared to FGF2-
GFPwt cells, indicating that this mutation does not have an effect on secretion 
efficiency. This result was confirmed by the biotinylation assay (panel D). The 
combined data obtained for this mutant demonstrate that K61E is not deficient in 
secretion or impaired in heparin binding and does not show a phenotype which is 
different from FGF2-GFPwt cells. 
Results 
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The following mutant contains a mutation at position 65, changing glutamine to 
alanine. 
 
 
 
Figure 3.71: Point mutation; amino acid change: Q65A A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not alter from observations made for wild-type FGF2-GFP. 
 
As demonstrated in figure 3.71, the affinities of FGF2-GFPQ65A to heparan sulfate 
proteoglycans in vivo (panel A) and to heparin in vitro (panel B) was comparable to 
FGF2-GFPwt heparin affinity. As detected by flow cytometry (panel C), the expression 
level of FGF2-GFPQ65A was slightly reduced as compared to FGF2-GFPwt, but the 
amount of secreted fusion protein
 
detected on the cell surface did not vary from wild-
type level. This result was confirmed by the biotinylation assay (panel D). The 
combined data obtained for this mutant demonstrate that Q65A is not deficient in 
secretion or impaired in heparin binding and does not show a phenotype which is 
different from FGF2-GFPwt cells. 
Results 
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The following mutant contains a mutation at position 67, changing glutamic acid to 
valine. 
 
 
 
Figure 3.72: Point mutation; amino acid change: E67V A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not alter from observations made for wild-type FGF2-GFP. 
 
As demonstrated in figure 3.72, the affinities of FGF2-GFPE67V to heparan sulfate 
proteoglycans in vivo (panel A) and to heparin in vitro (panel B) was comparable to 
FGF2-GFPwt heparin affinity. As detected by flow cytometry (panel C), both the 
expression level and the cell surface staining of FGF2-GFPE67V did not vary from 
wild-type level. This result was confirmed by the biotinylation assay (panel D). The 
combined data obtained for this mutant demonstrate that E67V is not deficient in 
secretion or impaired in heparin binding and does not show a phenotype which is 
different from FGF2-GFPwt cells. 
Results 
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The following mutant contains a mutation at position 68, changing glutamic acid to 
alanine. 
 
 
 
Figure 3.73: Point mutation; amino acid change: E68A A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with Heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not alter from observations made for wild-type FGF2-GFP. 
 
As demonstrated in figure 3.73, the affinities of FGF2-GFPE68A to heparan sulfate 
proteoglycans in vivo (panel A) and to heparin in vitro (panel B) was comparable to 
FGF2-GFPwt heparin affinity. As detected by flow cytometry (panel C), both the 
expression level and the cell surface staining of FGF2-GFPE68A did not vary from 
wild-type level. This result was confirmed by the biotinylation assay (panel D). The 
combined data obtained for this mutant demonstrate that E68A is not deficient in 
secretion or impaired in heparin binding and does not show a phenotype which is 
different from FGF2-GFPwt cells. 
Results 
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The following mutant contains a mutation at position 68, changing glutamic acid to 
glutamine. 
 
 
 
Figure 3.74: Point mutation; amino acid change: E68G A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not alter from observations made for wild-type FGF2-GFP. 
 
As demonstrated in figure 3.74, the affinities of FGF2-GFPE68G to heparan sulfate 
proteoglycans in vivo (panel A) and to heparin in vitro (panel B) was comparable to 
FGF2-GFPwt heparin affinity. As detected by flow cytometry (panel C), both the 
expression level and the cell surface staining of FGF2-GFPE68G did not vary from 
wild-type level. This result was confirmed by the biotinylation assay (panel D). The 
combined data obtained for this mutant demonstrate that E68G is not deficient in 
secretion or impaired in heparin binding and does not show a phenotype which is 
different from FGF2-GFPwt cells. 
Results 
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The following mutant contains a mutation at position 69, changing arginine to alanine. 
 
 
 
Figure 3.75: Point mutation; amino acid change: R69A A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not alter from observations made for wild-type FGF2-GFP. 
 
As demonstrated in figure 3.75, the affinity of FGF2-GFPR69A to heparan sulfate 
proteoglycans in vivo (panel A) was enhanced (about 180% ± 30 %), but its affinity to 
heparin in vitro (panel B) was slightly reduced when compared to FGF2-GFPwt 
heparin affinity. As shown by flow cytometry (panel C), both the expression level and 
the cell surface staining of FGF2-GFPR69A did not vary from wild-type level. This 
result was confirmed by the biotinylation assay (panel D). The combined data 
obtained for this mutant demonstrate that E68G is not deficient in secretion or 
impaired in heparin binding and does not show a phenotype which is different from 
FGF2-GFPwt cells. 
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The following mutant contains a mutation at position 75, changing lysine to isoleucine. 
 
 
 
Figure 3.76: Point mutation; amino acid change: K75I A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not alter from observations made for wild-type FGF2-GFP. 
 
As demonstrated in figure 3.76, the affinity of FGF2-GFPK75E to heparan sulfate 
proteoglycans in vivo (panel A) was enhanced (about 150% ± 30 %), but its affinity to 
heparin in vitro (panel B) was comparable to FGF2-GFPwt heparin affinity. As 
detected by flow cytometry (panel C), both the expression level and the cell surface 
staining of FGF2-GFPK75E did not vary from wild-type level. This result was confirmed 
by the biotinylation assay (panel D). The combined data obtained for this mutant 
demonstrate that K75E is not deficient in secretion or impaired in heparin binding and 
does not show a phenotype which is different from FGF2-GFPwt cells. 
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The following mutant contains a mutation at position 77, changing valine to alanine. 
 
 
 
Figure 3.77: Point mutation; amino acid change: V77A A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not alter from observations made for wild-type FGF2-GFP. 
 
As demonstrated in figure 3.77, the affinity of FGF2-GFPV77A to heparan sulfate 
proteoglycans in vivo (panel A) is reduced (about 50%), but its affinity to heparin in 
vitro (panel B) was comparable to FGF2-GFPwt heparin affinity.  As shown by flow 
cytometry (panel C), both the expression level and the cell surface staining of FGF2-
GFPV77A was slightly reduced as compared to FGF2-GFPwt. As analyzed by the 
biotinylation assay (panel D), the mutant V77A did not secrete the fusion protein 
more efficiently (compare the ration of lane 1 and 2 with the ratio of lane 3 and 4) 
than wild-type FGF2-GFP cells. The combined data obtained for this mutant 
demonstrate that V77A is not deficient in secretion or impaired in heparin binding and 
does not show a phenotype which is different from FGF2-GFPwt cells. 
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The following mutant contains a mutation at position 78, changing cysteine to alanine. 
 
 
 
 
 
Figure 3.78: Point mutation; amino acid change: C78A A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not alter from observations made for wild-type FGF2-GFP. 
 
As demonstrated in figure 3.78, the affinities of FGF2-GFPC78A to heparan sulfate 
proteoglycans in vivo (panel A) and to heparin in vitro (panel B) was comparable to 
FGF2-GFPwt heparin affinity. As detected by flow cytometry (panel C), both the 
expression level and the cell surface staining of FGF2-GFPC78A did not vary from 
wild-type level. This result was confirmed by the biotinylation assay (panel D). The 
combined data obtained for this mutant demonstrate that C78A is not deficient in 
secretion or impaired in heparin binding and does not show a phenotype which is 
different from FGF2-GFPwt cells. 
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The following mutant contains a mutation at position 80, changing asparagine to 
alanine. 
 
 
 
Figure 3.79: Point mutation; amino acid change: N80A A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not alter from observations made for wild-type FGF2-GFP. 
 
As demonstrated in figure 3.79, the affinity of FGF2-GFPN80A to heparan sulfate 
proteoglycans in vivo (panel A) was enhanced (about 180 %), but its affinity to 
heparin in vitro (panel B) was comparable to FGF2-GFPwt heparin affinity. As shown 
by flow cytometry (panel C), the expression level of FGF2-GFPN80A was slightly 
reduced as compared to FGF2-GFPwt, but the amount of secreted fusion protein 
detected on the cell surface did not vary from wild-type level. As analyzed by the 
biotinylation assay (panel D), the mutant N80A did not secrete the fusion protein 
more efficiently (compare the ration of lane 1 and 2 with the ratio of lane 3 and 4) 
than wild-type FGF2-GFP cells. The combined data obtained for this mutant 
demonstrate that N80A is not deficient in secretion or impaired in heparin binding and 
does not show a phenotype which is different from FGF2-GFPwt cells. 
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The following mutant contains a mutation at position 87, changing glutamic acid to 
lysine. 
 
 
 
Figure 3.80: Point mutation; amino acid change: E87K A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not alter from observations made for wild-type FGF2-GFP. 
 
As demonstrated in figure 3.80, the affinities of FGF2-GFPE87K to heparan sulfate 
proteoglycans in vivo (panel A) and to heparin in vitro (panel B) was comparable to 
FGF2-GFPwt heparin affinity. As detected by flow cytometry (panel C), both the 
expression level and the cell surface staining of FGF2-GFPE87K did not vary from 
wild-type level. This result was confirmed by the biotinylation assay (panel D). The 
combined data obtained for this mutant demonstrate that E87K is not deficient in 
secretion or impaired in heparin binding and does not show a phenotype which is 
different from FGF2-GFPwt cells. 
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The following mutant contains a mutation at position 92, changing leucine to alanine 
 
 
 
Figure 3.81: Point mutation; amino acid change: L92A A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not alter from observations made for wild-type FGF2-GFP. 
 
As demonstrated in figure 3.81, the affinity of FGF2-GFPL92A to heparan sulfate 
proteoglycans in vivo (panel A) was enhanced (about 200 % ± 50%), but its affinity to 
heparin in vitro (panel B) was comparable to FGF2-GFPwt heparin affinity. As 
analyzed by flow cytometry (panel C), the signal for cell surface staining for FGF2-
GFPL92A was enhanced to about 170% when compared to FGF2-GFPwt, whereas its 
expression level was shown to be at wild-type levels. However, this result was not 
confirmed by the biotinylation assay, which demonstrated that mutant L92A did not 
secrete the fusion protein more efficiently (compare the ration of lane 1 and 2 with 
the ratio of lane 3 and 4) than wild-type FGF2-GFP cells. Although the data obtained 
by the secretion assay were inconsistent, L92A is shown to be not deficient in 
secretion or impaired in heparin binding and does not show a phenotype which is 
different from FGF2-GFPwt cells. 
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The following mutant contains a mutation at position 96, changing cysteine to alanine. 
 
 
 
Figure 3.82: Point mutation; amino acid change: C96A A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not alter from observations made for wild-type FGF2-GFP. 
 
As demonstrated in figure 3.82, the affinities of FGF2-GFPC96A to heparan sulfate 
proteoglycans in vivo (panel A) and to heparin in vitro (panel B) was comparable to 
FGF2-GFPwt heparin affinity. As detected by flow cytometry (panel C), both the 
expression level and the cell surface staining of FGF2-GFPC96A did not vary from 
wild-type level. This result was confirmed by the biotinylation assay (panel D). The 
combined data obtained for this mutant demonstrate that C96A is not deficient in 
secretion or impaired in heparin binding and does not show a phenotype which is 
different from FGF2-GFPwt cells. 
Results 
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The following mutant contains a mutation at position 102, changing phenylalanine to 
alanine. 
 
 
 
Figure 3.83: Point mutation; amino acid change: F102A A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not alter from observations made for wild-type FGF2-GFP. 
 
As demonstrated in figure 3.83, the affinity of FGF2-GFPF102A to heparan sulfate 
proteoglycans in vivo (panel A) was comparable to FGF2-GFPwt. In contrast, its 
affinity to heparin in vitro (panel B) was reduced when compared to FGF2-GFPwt 
heparin affinity. As shown by flow cytometry (panel C), both the expression level as 
well as the signal for cell surface staining for FGF2-GFPF102A were reduced. This 
result was not confirmed by the biotinylation assay, which demonstrated that mutant 
F102A did not secrete the fusion protein more efficiently (compare the ration of lane 
1 and 2 with the ratio of lane 3 and 4) than wild-type FGF2-GFP cells. However, the 
combined data obtained for this mutant demonstrate that F102A is not deficient in 
secretion or impaired in heparin binding and does not show a phenotype which is 
different from FGF2-GFPwt cells. 
Results 
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The following mutant contains a mutation at position 104, changing phenylalanine to 
alanine. 
 
 
 
Figure 3.84: Point mutation; amino acid change: F104A A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not alter from observations made for wild-type FGF2-GFP. 
 
As demonstrated in figure 3.84, the affinity of FGF2-GFPF104A to heparan sulfate 
proteoglycans in vivo (panel A) was slightly enhanced (140% ± 10 %), whereas its 
affinity to heparin in vitro (panel B) was reduced when compared to FGF2-GFPwt.  As 
shown by flow cytometry (panel C), both the expression level as well as the signal for 
FGF2-GFPF104A detected on the cell surface staining were reduced. This result was 
not confirmed by the biotinylation assay, which demonstrated that mutant F104A did 
not secrete the fusion protein more efficiently (compare the ration of lane 1 and 2 
with the ratio of lane 3 and 4) than wild-type FGF2-GFP cells. However, the 
combined data obtained for this mutant demonstrate that F104A is not deficient in 
secretion or impaired in heparin binding and does not show a phenotype which is 
different from FGF2-GFPwt cells. 
Results 
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The following mutant contains a mutation at position 112, changing tyrosine to 
alanine. 
 
 
 
Figure 3.85: Point mutation; amino acid change: Y112A A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not alter from observations made for wild-type FGF2-GFP. 
 
As demonstrated in figure 3.85, the affinity of FGF2-GFPY112A to heparan sulfate 
proteoglycans in vivo (panel A) is reduced (about 40% ± 10%), but its affinity to 
heparin in vitro (panel B) was comparable to FGF2-GFPwt heparin affinity. As shown 
by flow cytometry (panel C), the expression level of FGF2-GFPY112A was slightly 
reduced as compared to FGF2-GFPwt, but the amount of secreted fusion protein 
detected on the cell surface did not vary from wild-type level. As analyzed by the 
biotinylation assay (panel D), the mutant Y112A did not secrete the fusion protein 
more efficiently (compare the ration of lane 1 and 2 with the ratio of lane 3 and 4) 
than wild-type FGF2-GFP cells. The combined data obtained for this mutant 
demonstrate that Y112A is not deficient in secretion or impaired in heparin binding 
and does not show a phenotype which is different from FGF2-GFPwt cells. 
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The following mutant contains a mutation at position 122, changing serine to alanine. 
 
 
 
Figure 3.86: Point mutation; amino acid change: S122A A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not alter from observations made for wild-type FGF2-GFP. 
 
As demonstrated in figure 3.86, the affinities of FGF2-GFPS122A to heparan sulfate 
proteoglycans in vivo (panel A) and to heparin in vitro (panel B) was comparable to 
FGF2-GFPwt heparin affinity. As detected by flow cytometry (panel C), both the 
expression level and the cell surface staining of FGF2-GFPS122A did not vary from 
wild-type level. This result was confirmed by the biotinylation assay (panel D). The 
combined data obtained for this mutant demonstrate that S122A is not deficient in 
secretion or impaired in heparin binding and does not show a phenotype which is 
different from FGF2-GFPwt cells. 
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The following mutant contains a mutation at position 128, changing lysine to glutamic 
acid. 
 
 
 
Figure 3.87: Point mutation; amino acid change: K128E A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not alter from observations made for wild-type FGF2-GFP. 
 
As demonstrated in figure 3.87, the affinities of FGF2-GFPK128E to heparan sulfate 
proteoglycans in vivo (panel A) and to heparin in vitro (panel B) was comparable to 
FGF2-GFPwt heparin affinity. As detected by flow cytometry (panel C), both the 
expression level and the cell surface staining of FGF2-GFPK128E did not vary from 
wild-type level. This result was confirmed by the biotinylation assay (panel D). The 
combined data obtained for this mutant demonstrate that K128E is not deficient in 
secretion or impaired in heparin binding and does not show a phenotype which is 
different from FGF2-GFPwt cells. 
Results 
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The following mutant contains a mutation at position 129, changing arginine to 
glutamine. 
 
 
 
figure 3.88: Point mutation; amino acid change: R129Q A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not alter from observations made for wild-type FGF2-GFP. 
 
As demonstrated in figure 3.88, the affinities of FGF2-GFPR129Q to heparan sulfate 
proteoglycans in vivo (panel A) and to heparin in vitro (panel B) was comparable to 
FGF2-GFPwt heparin affinity. As detected by flow cytometry (panel C), both the 
expression level and the cell surface staining of FGF2-GFPR129Q did not vary from 
wild-type level. This result was confirmed by the biotinylation assay (panel D). The 
combined data obtained for this mutant demonstrate that R129Q is not deficient in 
secretion or impaired in heparin binding and does not show a phenotype which is 
different from FGF2-GFPwt cells. 
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The following mutant contains a mutation at position 132, changing glutamine to 
arginine. 
 
 
 
Figure 3.89: Point mutation; amino acid change: Q132R A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not alter from observations made for wild-type FGF2-GFP. 
 
As demonstrated in figure 3.89, the affinity of FGF2-GFPQ132R to heparan sulfate 
proteoglycans in vivo (panel A) was enhanced (170% ± 80 %), whereas its affinity to 
heparin in vitro (panel B) was reduced when compared to FGF2-GFPwt.  As shown by 
flow cytometry (panel C), both the expression level as well as the signal for FGF2-
GFPQ132R detected on the cell surface staining were reduced. This result was not 
confirmed by the biotinylation assay (panel D), which demonstrated that mutant 
Q132R did not secrete the fusion protein more efficiently than wild-type FGF2-GFP 
cells. However, the combined data obtained for this mutant demonstrate that Q132R 
is not deficient in secretion or impaired in heparin binding and does not show a 
phenotype which is different from FGF2-GFPwt cells. 
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The following mutant contains a mutation at position 133, changing tyrosine to 
histidine. 
 
 
 
Figure 3.90: Point mutation; amino acid change: Y133H A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not alter from observations made for wild-type FGF2-GFP. 
 
As demonstrated in figure 3.90, the affinities of FGF2-GFPY133H to heparan sulfate 
proteoglycans in vivo (panel A) and to heparin in vitro (panel B) was comparable to 
FGF2-GFPwt heparin affinity. As detected by flow cytometry (panel C), both the 
expression level and the cell surface staining of FGF2-GFPY133H did not vary from 
wild-type level. This result was confirmed by the biotinylation assay (panel D). The 
combined data obtained for this mutant demonstrate that Y133H is not deficient in 
secretion or impaired in heparin binding and does not show a phenotype which is 
different from FGF2-GFPwt cells. 
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The following mutant contains a mutation at position 133, changing tyrosine to 
arginine. 
 
 
 
Figure 3.91: Point mutation; amino acid change: Y133A A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not alter from observations made for wild-type FGF2-GFP. 
 
As demonstrated in figure 3.91, the affinities of FGF2-GFPY133A
 
to heparan sulfate 
proteoglycans in vivo (panel A) and to heparin in vitro (panel B) was comparable to 
FGF2-GFPwt heparin affinity. As detected by flow cytometry (panel C), both the 
expression level and the cell surface staining of FGF2-GFPY133A did not vary from 
wild-type level. This result was confirmed by the biotinylation assay (panel D). The 
combined data obtained for this mutant demonstrate that Y133A is not deficient in 
secretion or impaired in heparin binding and does not show a phenotype which is 
different from FGF2-GFPwt cells. 
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The following mutant contains a mutation at position 152, changing serine to arginine. 
 
 
 
Figure 3.92: Point mutation; amino acid change: S152A A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, this clone does not alter from observations made for wild-type FGF2-GFP. 
 
As demonstrated in figure 3.92, the affinity of FGF2-GFPS152A to heparan sulfate 
proteoglycans in vivo (panel A) was enhanced (about 150% ± 90 %), but its affinity to 
heparin in vitro (panel B) was comparable to FGF2-GFPwt affinity. As detected by flow 
cytometry (panel C), both the expression level and the cell surface staining of FGF2-
GFPS152A did not vary from wild-type level. This result was confirmed by the 
biotinylation assay (panel D). The combined data obtained for this mutant 
demonstrate that S152A is not deficient in secretion or impaired in heparin binding 
and does not show a phenotype which is different from FGF2-GFPwt cells. 
 
To summarize, 43 mutants were shown to be comparable to FGF2-GFPwt cells, 
regarding their secretion efficiency, protein stability, affinity to heparan sulfate 
proteoglycans and to heparin. Therefore, they were termed “no phenotype” 
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3.3.4.2 Experimental data for FGF2 mutants showing a reduced expression level 
of FGF2-GFP 
 
In this section, the FGF2-GFP mutants generated by site-directed mutagenesis are 
depicted which demonstrate a reduced expression level, suggesting that the protein 
might be misfolded and rapidly degraded or that its translation rates are reduced. 
Moreover, their amino acid changes are shown and a summary of the experimental 
data is provided. For a detailed view on the assays used, please refer to chapter 
3.3.2. 
 
 
The following mutant contains a mutation at position 40, changing phenylalanine to  
leucine. 
 
 
figure 3.93: Point mutation; amino acid change: F40L A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, the mutated protein is instable in the cytoplasm, but its affinities to heparin and HSPGs are comparable to 
wild-type FGF2-GFP. 
 
As demonstrated in figure 3.93, the affinity of FGF2-GFPF40L to heparan sulfate 
proteoglycans in vivo (panel A) was comparable to FGF2-GFPwt. In contrast, its 
affinity to heparin in vitro (panel B) was reduced when compared to FGF2-GFPwt. As 
detected by flow cytometry (panel C), the expression level of the mutated fusion 
protein is strongly reduced to under 20% of wild-type level. The signal for FGF2-
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GFPF40L bound to the cell surface is reduced to the same amount as it was shown for 
the expression level of this mutant, suggesting that the secretion efficiency is not 
reduced, since the ratio of fusion protein expression to secretion remains constant in 
comparison to FGF2-GFPwt. This result is confirmed by the biotinylation assay (panel 
D). 
 
The following mutant contains a mutation at position 42, changing arginine to 
histidine. 
 
 
Figure 3.94: Point mutation; amino acid change: R42H A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, the mutated protein is instable in the cytoplasm, but is, concerning binding characteristics, comparable to 
wild-type FGF2-GFP. 
 
As demonstrated in figure 3.94, the affinities of FGF2-GFPR42H
 
to heparan sulfate 
proteoglycans in vivo (panel A) and to heparin in vitro (panel B) was comparable to 
FGF2-GFPwt heparin affinity. As detected by flow cytometry (panel C), the expression 
level of the mutated fusion protein is strongly reduced to under 20% of wild-type level. 
The signal for FGF2-GFPR42H bound to the cell surface is reduced to the same 
amount as it was shown for the expression level of this mutant, suggesting that the 
secretion efficiency is not reduced, since the ratio of fusion protein expression to 
secretion remains constant in comparison to FGF2-GFPwt. This result is confirmed by 
the biotinylation assay (panel D). 
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The following mutant contains a mutation at position 72, changing valine to alanine. 
 
 
 
Figure 3.95: Point mutation; amino acid change: V72A A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, the mutated protein is instable in the cytoplasm, but is, concerning binding characteristics, comparable to 
wild-type FGF2-GFP. 
 
As demonstrated in figure 3.95, the affinities of FGF2-GFPV72A
 
to heparan sulfate 
proteoglycans in vivo (panel A) and to heparin in vitro (panel B) was comparable to 
FGF2-GFPwt heparin affinity. As detected by flow cytometry (panel C), the expression 
level of the mutated fusion protein is strongly reduced to under 20% of wild-type level. 
The signal for FGF2-GFPV72A bound to the cell surface is reduced to the same 
amount as it was shown for the expression level of this mutant, suggesting that the 
secretion efficiency is not reduced, since the ratio of fusion protein expression to 
secretion remains constant in comparison to FGF2-GFPwt. This result is confirmed by 
the biotinylation assay (panel D). 
The three mutants listed in this section demonstrate reduced expression level of the 
various versions of FGF2-GFP, indicating either rapid degradation due to misfolded 
proteins or less expressed fusion protein. Therefore, it is questionable if a 
quantification of the amount of secreted FGF2-GFP is possible. The affinities to 
heparin and to heparan sulfate proteoglycans are not impaired. As a consequence 
thereof, these mutants were termed “instable protein”. 
Results 
 
162 
3.3.4.3 Experimental data for FGF2 mutants impaired in protein stability, binding to 
heparin and to heparan sulfate proteoglycans 
 
In this section, the FGF2-GFP mutants generated by site-directed mutagenesis are 
depicted which demonstrate an instable intracellular fusion protein, an impaired 
binding to heparin and to heparan sulfate proteoglycans. Moreover, their amino acid 
changes are shown and a summary of the experimental data is provided. For a 
detailed view on the assays used, please refer to chapter 3.3.2. 
 
The following mutant contains a mutation at position 64, changing leucine to proline. 
 
 
Figure 3.96: Point mutation; amino acid change: L64P A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, the mutated protein is instable in the cytoplasm, and is, concerning binding characteristics, reduced 
compared to wild-type FGF2-GFP. 
 
As demonstrated in figure 3.96, the affinities of FGF2-GFPL64P to heparan sulfate 
proteoglycans in vivo and to heparin in vitro were reduced. As detected by flow 
cytometry (panel C), the expression level of the mutated fusion protein is strongly 
reduced to under 20% of wild-type level. The signal for FGF2-GFPL64P bound to the 
cell surface is reduced to the same amount as it was shown for the expression level 
of this mutant. The secretion efficiency is not reduced, since the ratio of fusion 
protein expression to secretion remains constant in comparison to FGF2-GFPwt cells. 
This result is confirmed by the biotinylation assay (panel D). 
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The following mutant contains a mutation at position 74, changing isoleucine to 
threonine. 
 
 
 
Figure 3.97: Point mutation; amino acid change: I74T A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, the mutated protein is instable in the cytoplasm, and is, concerning binding characteristics, reduced 
compared to wild-type FGF2-GFP. 
 
As demonstrated in figure 3.97, the affinities of FGF2-GFPI74T to heparan sulfate 
proteoglycans in vivo and to heparin in vitro were reduced. As detected by flow 
cytometry (panel C), the expression level of the mutated fusion protein is strongly 
reduced to under 20% of wild-type level. The signal for FGF2-GFPI74T bound to the 
cell surface is reduced to the same amount as it was shown for the expression level 
of this mutant. The secretion efficiency is not reduced, since the ratio of fusion 
protein expression to secretion remains constant in comparison to FGF2-GFPwt cells. 
This result is confirmed by the biotinylation assay (panel D). 
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The following mutant contains a mutation at position 82, changing tyrosine to alanine. 
 
 
 
Figure 3.98: Point mutation; amino acid change: Y82A A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, the mutated protein is instable in the cytoplasm, and is, concerning binding characteristics, reduced 
compared to wild-type FGF2-GFP. 
 
As demonstrated in figure 3.98, the affinities of FGF2-GFPY82A to heparan sulfate 
proteoglycans in vivo and to heparin in vitro were reduced. As detected by flow 
cytometry (panel C), the expression level of the mutated fusion protein is strongly 
reduced to under 20% of wild-type level. The signal for FGF2-GFPY82A bound to the 
cell surface is reduced to the same amount as it was shown for the expression level 
of this mutant. The secretion efficiency is not reduced, since the ratio of fusion 
protein expression to secretion remains constant in comparison to FGF2-GFPwt cells. 
This result is confirmed by the biotinylation assay (panel D). 
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The following mutant contains a mutation at position 88, changing aspartic acid to 
alanine. 
 
Figure 3.99: Point mutation; amino acid change: D88A A FACS analysis of cell free supernatant bound to the surface of 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. To summarize 
the obtained data, the mutated protein is instable in the cytoplasm, and is, concerning binding characteristics, reduced 
compared to wild-type FGF2-GFP. 
 
As demonstrated in figure 3.99, the affinities of FGF2-GFPD88A to heparan sulfate 
proteoglycans in vivo and to heparin in vitro were reduced. As detected by flow 
cytometry (panel C), the expression level of the mutated fusion protein is strongly 
reduced to under 20% of wild-type level. The signal for FGF2-GFPD88A bound to the 
cell surface is reduced to the same amount as it was shown for the expression level 
of this mutant. The secretion efficiency is not reduced, since the ratio of fusion 
protein expression to secretion remains constant in comparison to FGF2-GFPwt cells. 
This result is confirmed by the biotinylation assay (panel D). 
 
The mutants listed in this section demonstrate an impaired binding to heparin in vitro 
and to heparan-sulfate proteoglycans in vivo. Additionally, the expression level of the 
various versions of FGF2-GFP is strongly reduced, indicating either rapid 
degradation due to misfolded proteins or reduced expression of the fusion protein. 
Therefore, it is questionable if a quantification of the amount of secreted FGF2-GFP 
is possible. As a consequence thereof, these mutants were termed “instable protein 
and impaired in binding”. 
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3.3.4.4 Experimental data for a double cysteine FGF2 mutant potentially deficient 
in secretion  
 
The following mutant displays two altered amino acid at position 78 and 96, changing 
two cysteines to two alanines. 
 
 
 
figure 3.100: Point mutation; amino acid changes: CC78/96AA A FACS analysis of cell free supernatant bound to the surface 
CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free supernatant to heparin beads. 
Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound (flowthrough, 10%) and bound material 
(eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative analysis of export employing flow cytometry.  
Expression level (black bars) and secreted protein detected on the cell surface (red bars) is shown. FGF2-GFPwt was set to 
100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-impermeable biotin reagent. After cell lysis 
biotinylated and non-biotinylated proteins were separated by streptavidin beads. Total material (input, 5%) and the biotinylated 
fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All results shown represent an average of at least 3 
different experiments. For further details see „Material and Methods“ and explanation of assays in chapter 3.3.2. This double 
mutant is positive for both binding in vivo and in vitro. The FACS assay shows a secreted population of FGF2 present on the cell 
surface staining. In contrast to this observation, the amount of secreted protein as detected by biotinylation is significantly 
reduced compared to wild-type FGF2-GFP. 
 
As demonstrated in figure 3.100, the affinity of FGF2-GFPCC78/96AA to heparan sulfate 
proteoglycans in vivo (panel A) and to heparin in vitro (panel B) was comparable to 
FGF2-GFPwt heparin affinity. Results obtained by flow cytometry show that 
expression level and cell surface staining are not reduced when compared to wild-
type FGF2-GFP. Strikingly, biotinylation of cell surface proteins results in a 
significantly reduced streptavidin-bound fraction of mutated protein, indicating a 
reduction in secretion of FGF2-GFPCC78/96AA. However, this discrepancy between 
FACS analysis and cell surface biotinylation remains unclear. 
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3.3.4.5 Overview of mutants obtained by point mutation with regard to secretion 
efficiency, affinity to heparin and protein stability 
 
The generated mutants were analyzed by standard assays as previously described in 
chapter 3.3.2. As a result, the observations made are listed in the following table:   
 
 
Mutant Classification Mutant Classification 
A3V No Phenotype E67V No Phenotype 
G4A No Phenotype E68A No Phenotype 
S5A No Phenotype E68G No Phenotype 
I6T No Phenotype R69A No Phenotype 
T7A No Phenotype V72A Instable Protein 
T7E No Phenotype I74T Instable Protein / Impaired Binding 
T7D No Phenotype K75I No Phenotype 
T8M No Phenotype V77A No Phenotype 
E14D No Phenotype C78A No Phenotype 
F21I No Phenotype N80A No Phenotype 
P23S No Phenotype Y82A Instable Protein / Impaired Binding 
F26A No Phenotype E87K No Phenotype 
K30E No Phenotype D88A Instable Protein / Impaired Binding 
Y33A No Phenotype L92A No Phenotype 
F39L No Phenotype C96A No Phenotype 
F39A No Phenotype F102A No Phenotype 
F40L Instable Protein F104A No Phenotype 
R42H Instable Protein Y112A No Phenotype 
R53H No Phenotype S122A No Phenotype 
K55T No Phenotype K128E No Phenotype 
K55R No Phenotype R129Q No Phenotype 
H59P No Phenotype Q132R No Phenotype 
K61E No Phenotype Y133H No Phenotype 
L64P Instable Protein / Impaired Binding Y133A No Phenotype 
Q65A No Phenotype S152A No Phenotype 
CC78/96AA Negative in Biotinylation   
Table 3.4: Overview of classifications made for point mutations with regard to secretion and heparin binding ability.  
 
The results obtained by characterization of point mutations showed that most of the 
generated clones are comparable to FGF2-GFPwt with regard to protein stability, 
secretion efficiency and affinity to heparin or heparan sulfate proteoglycans (44). 
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Additionally, mutants showing reduced expression levels of FGF2-GFP in the cytosol 
(7) also mainly demonstrate an impaired binding ability of their fusion protein to 
heparin and heparan sulfate proteoglycans (4). Moreover, a mutant (CC78/96AA) 
was observed, which displayed a reduced signal for secreted fusion protein present 
on the surface as detected by cell surface biotinylation, but this could not be 
confirmed by flow cytometry and will be further characterized in our laboratory. 
3.3.5 Truncations of N- and C-Terminus 
 
In order to elucidate a potential export motif that might be present at the very ends of 
FGF2, both the N- and C-terminus were truncated. 
 
3.3.5.1 Functional analysis of FGF2 mutants with N-terminal Truncations 
 
Although the crystal structure of FGF2 has been resolved in 1991 (Ago et al., 1991), 
the disordered N-terminal residues of FGF2 remain of unknown structure. 
Additionally a small heparin binding region appears to be present at the N-terminus 
at position 20-40 (Baird et al., 1988; Ogura et al., 1999). To investigate the effect of 
the flexible region and the N-terminal heparin binding sites with regard to 
unconventional secretion of FGF2, up to 50 amino acids from the N-terminus were 
systematically deleted in steps of 10 amino acids. After stably introducing the cDNA 
into the genome of CHO cells, the cells were analyzed regarding export efficiency of 
FGF2. An overview of the mutants is listed in the following table 3.4. 
 
Mutant Truncation 
∆N10-FGF2 10 amino acids from N-terminus deleted 
∆N20-FGF2 20 amino acids from N-terminus deleted 
∆N30-FGF2 30 amino acids from N-terminus deleted 
∆N40-FGF2 40 amino acids from N-terminus deleted 
∆N50-FGF2 50 amino acids from N-terminus deleted 
 
Table 3.5: overview of N-terminal truncations. 
 
The N-terminal truncations of FGF2-GFP were analyzed with regard to secretion 
efficiency, fusion protein stability, affinity to heparin and to heparan sulfate 
proteoglycans. Moreover, a summary of the experimental data is provided. For a 
detailed view on the assays used, please refer to chapter 3.3.2. 
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Truncation ∆N-10-FGF2-GFP lacks the N-terminal 10 amino acids. 
 
 
Figure 3.101: N-terminal truncations; 10 amino acids form the N-terminus deleted A FACS analysis of cell free supernatant 
bound to the surface of CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free 
supernatant to heparin beads. Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound 
(flowthrough, 10%) and bound material (eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative 
analysis of export employing flow cytometry.  Expression level (black bars) and secreted protein detected on the cell surface 
(red bars) is shown. FGF2-GFPwt was set to 100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-
impermeable biotin reagent. After cell lysis biotinylated and non-biotinylated proteins were separated by streptavidin beads. 
Total material (input, 5%) and the biotinylated fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All 
results shown represent an average of at least 3 different experiments. For further details see „Material and Methods“ and 
explanation of assays in chapter 3.3.2. To summarize the obtained data, this truncation does not differ from observations made 
for wild-type FGF2-GFP. 
 
 
As demonstrated in figure 3.101, the affinities of ∆N-10-FGF2-GFP to heparan 
sulfate proteoglycans in vivo (panel A) and to heparin in vitro (panel B) was 
comparable to FGF2-GFPwt heparin affinity. As shown by flow cytometry, the 
expression level of the truncated fusion protein
 
was enhanced to about 150 % as 
compared to wild-type FGF2-GFP. The signal for the secreted truncated version of 
the fusion protein bound to the cell surface was comparable to the amount of 
secreted cell surface associated FGF2-GFPwt. (panel C). The biotinylation assay 
showed that the secretion efficiency is not reduced, since the ratio of fusion protein 
expression to secretion remains constant in comparison to FGF2-GFPwt cells. The 
combined data obtained for this mutant demonstrate that ∆N-20-FGF2-GFP is not 
deficient in secretion or impaired in heparin binding and does not show a phenotype 
which is different from FGF2-GFPwt cells. 
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Truncation ∆N-20-FGF2-GFP lacks the N-terminal 20 amino acids. 
 
 
 
Figure 3.102: N-terminal Truncations; 20 amino acids form the N-terminus deleted A FACS analysis of cell free supernatant 
bound to the surface of CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free 
supernatant to heparin beads. Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound 
(flowthrough, 10%) and bound material (eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative 
analysis of export employing flow cytometry.  Expression level (black bars) and secreted protein detected on the cell surface 
(red bars) is shown. FGF2-GFPwt was set to 100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-
impermeable biotin reagent. After cell lysis biotinylated and non-biotinylated proteins were separated by streptavidin beads. 
Total material (input, 5%) and the biotinylated fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All 
results shown represent an average of at least 3 different experiments. For further details see „Material and Methods“ and 
explanation of assays in chapter 3.3.2. To summarize the obtained data, this truncation does not alter from observations made 
for wild-type FGF2-GFP. 
 
As demonstrated in figure 3.102, the affinities of ∆N-20-FGF2-GFP to heparan 
sulfate proteoglycans in vivo (panel A) and to heparin in vitro (panel B) was 
comparable to FGF2-GFPwt heparin affinity. As detected by flow cytometry (panel C), 
both the expression level and the cell surface staining of the truncated version of 
FGF2-GFP did not vary from wild-type level. This result was confirmed by the 
biotinylation assay (panel D). The combined data obtained for this mutant 
demonstrate that ∆N-20-FGF2-GFP is not deficient in secretion or impaired in 
heparin binding and does not show a phenotype which is different from FGF2-GFPwt 
cells. 
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Truncation ∆N-30-FGF2-GFP lacks the N-terminal 30 amino acids. 
 
 
 
Figure 3.103: N-terminal Truncations;30 amino acids form the N-terminus deleted A FACS analysis of cell free supernatant 
bound to the surface of CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free 
supernatant to heparin beads. Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound 
(flowthrough, 10%) and bound material (eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative 
analysis of export employing flow cytometry.  Expression level (black bars) and secreted protein detected on the cell surface 
(red bars) is shown. FGF2-GFPwt was set to 100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-
impermeable biotin reagent. After cell lysis biotinylated and non-biotinylated proteins were separated by streptavidin beads. 
Total material (input, 5%) and the biotinylated fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All 
results shown represent an average of at least 3 different experiments. For further details see „Material and Methods“ and 
explanation of assays in chapter 3.3.2. To summarize the obtained data, this truncation shows a total loss of binding in vivo and 
in vitro. Additionally, the expression level is significantly reduced compared to FGF2-GFPwt. 
 
As demonstrated in figure 3.103, the affinities of ∆N-30-FGF2-GFP to heparan 
sulfate proteoglycans in vivo (panel A) and to heparin in vitro (panel B) was lost by 
truncating 30 N-terminal amino acids. Moreover, as detected by flow cytometry 
(panel C), both the expression level and the cell surface staining of the truncated 
version of FGF2-GFP were reduced to less than 10%. This result was confirmed by 
the biotinylation assay (panel D). The combined data obtained for this mutant 
demonstrate that ∆N-30-FGF2-GFP is the binding to heparin or heparan sulfate 
proteoglycans is strongly impaired and that its expression is heavily reduced. 
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Truncation ∆N-40-FGF2-GFP lacks the N-terminal 40 amino acids. 
 
 
 
Figure 3.104: N-terminal Truncations; 40 amino acids form the N-terminus deleted A FACS analysis of cell free supernatant 
bound to the surface of CHO CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free 
supernatant to heparin beads. Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound 
(flowthrough, 10%) and bound material (eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative 
analysis of export employing flow cytometry.  Expression level (black bars) and secreted protein detected on the cell surface 
(red bars) is shown. FGF2-GFPwt was set to 100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-
impermeable biotin reagent. After cell lysis biotinylated and non-biotinylated proteins were separated by streptavidin beads. 
Total material (input, 5%) and the biotinylated fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All 
results shown represent an average of at least 3 different experiments. For further details see „Material and Methods“ and 
explanation of assays in chapter 3.3.2. To summarize the obtained data, this truncation shows a total loss of binding in vivo and 
in vitro. Additionally, the expression level is significantly reduced compared to FGF2-GFPwt. 
 
As demonstrated in figure 3.104, the affinities of ∆N-40-FGF2-GFP to heparan 
sulfate proteoglycans in vivo (panel A) and to heparin in vitro (panel B) was lost by 
truncating 40 N-terminal amino acids. Moreover, as detected by flow cytometry 
(panel C), both the expression level and the cell surface staining of the truncated 
version of FGF2-GFP were reduced to less than 10%. This result was confirmed by 
the biotinylation assay (panel D). The combined data obtained for this mutant 
demonstrate that ∆N-40-FGF2-GFP is the binding to heparin or heparan sulfate 
proteoglycans is strongly impaired and that its expression is heavily reduced. 
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Truncation ∆N-50-FGF2-GFP lacks the N-terminal 50 amino acids. 
 
 
 
Figure 3.105: N-terminal Truncations; 50 amino acids form the N-terminus deleted A FACS analysis of cell free supernatant 
bound to the surface of CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free 
supernatant to heparin beads. Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound 
(flowthrough, 10%) and bound material (eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative 
analysis of export employing flow cytometry.  Expression level (black bars) and secreted protein detected on the cell surface 
(red bars) is shown. FGF2-GFPwt was set to 100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-
impermeable biotin reagent. After cell lysis biotinylated and non-biotinylated proteins were separated by streptavidin beads. 
Total material (input, 5%) and the biotinylated fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All 
results shown represent an average of at least 3 different experiments. For further details see „Material and Methods“ and 
explanation of assays in chapter 3.3.2. To summarize the obtained data, this truncation shows a total loss of binding in vivo and 
in vitro. Additionally, the expression level is significantly reduced compared to FGF2-GFPwt. 
 
As demonstrated in figure 3.105, the affinities of ∆N-50-FGF2-GFP to heparan 
sulfate proteoglycans in vivo (panel A) and to heparin in vitro (panel B) was lost by 
truncating 50 N-terminal amino acids. Moreover, as detected by flow cytometry 
(panel C), both the expression level and the cell surface staining of the truncated 
version of FGF2-GFP were reduced to less than 10%. This result was confirmed by 
the biotinylation assay (panel D). The combined data obtained for this mutant 
demonstrate that ∆N-50-FGF2-GFP is the binding to heparin or heparan sulfate 
proteoglycans is strongly impaired and that its expression is heavily reduced. 
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The data obtained allows the classification of truncations with regard to export 
efficiency of their fusion protein, stability of the fusion protein and its binding affinity to 
heparin and to heparan sulfate proteoglycans.  
 
Mutant Classification 
∆N10 No Phenotype 
∆N20 No Phenotype 
∆N30 Instable Protein / Impaired in binding 
∆N40 Instable Protein / Impaired in binding 
∆N50 Instable Protein / Impaired in binding 
 
Table 3.6: Overview of classifications mad for truncations 
 
The first 20 amino acids, featuring the flexible region of FGF2, did not have any 
impact on export efficiency of FGF2. Deleting more than 20 amino acids from the N-
terminus led to a reduced expression level of the fusion protein, as indicated by the 
low signal for GFP-fluorescence observed in the FACS analysis, suggesting an 
instable fusion protein which might be incorrectly folded and therefore rapidly 
degraded or synthesized with lower translation rates as FGF2-GFPwt. Additionally, 
the truncated versions of FGF2-GPF with more than 20 deleted residues showed an 
impaired ability to bind to CHO cells in vivo and to heparin in vitro. 
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3.3.5.2 Functional analysis of FGF2 mutants with C-terminal Truncations  
 
FGF2 binding to heparin is mediated by amino acids distributed throughout the 
protein (Wong and Burgess, 1998). Strikingly, a heparin binding cluster of 10 amino 
acids (position 128-138) (Li et al., 1994; Ogura et al., 1999) is found to be present at 
the C-terminus. It has been reported that a basic cluster around the amino acid 
asparagine at position 102 might mediate binding to heparin as well (Faham et al., 
1996). Therefore, FGF2 was systematically truncated from the C-terminus in steps of 
10 amino acids up to a deletion of 119 amino acids.  
 
Mutant Truncation 
Cwt Serves as wt control 
C1-146 9 aa form C-terminus deleted 
C1-136 19 aa form C-terminus deleted 
C1-126 29 aa form C-terminus deleted 
C1-116 39 aa form C-terminus deleted 
C1-106 49 aa form C-terminus deleted 
C1-96 59 aa form C-terminus deleted 
C1-86 69 aa form C-terminus deleted 
C1-66 89 aa form C-terminus deleted 
C1-56 99 aa form C-terminus deleted 
C1-46 109 aa form C-terminus deleted 
C1-36 119 aa form C-terminus deleted 
Table 3.7: overview for C-terminal truncations 
 
 
The cells were analyzed regarding export efficiency, fusion protein stability, binding 
to heparin in vitro and to heparan sulfate proteoglycans in vivo.  
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Cwt – wild-type control 
 
 
 
Figure 3.106: C-terminal Truncations; 2 amino acids as linker between FGF2 and GFP; serves as wt-control A FACS analysis of 
cell free supernatant bound to the surface of CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding 
of cell free supernatant to heparin beads. Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-
bound (flowthrough, 10%) and bound material (eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative 
analysis of export employing flow cytometry.  Expression level (black bars) and secreted protein detected on the cell surface 
(red bars) is shown. FGF2-GFPwt was set to 100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-
impermeable biotin reagent. After cell lysis biotinylated and non-biotinylated proteins were separated by streptavidin beads. 
Total material (input, 5%) and the biotinylated fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All 
results shown represent an average of at least 3 different experiments. For further details see „Material and Methods“ and 
explanation of assays in chapter 3.3.2. To summarize the obtained data, this truncation does not alter from observations made 
for wild-type FGF2-GFP. 
 
The addition of two amino acids as a linker between FGF2-GFP did not influence 
unconventional secretion and binding to heparin and CHO cells as compared to wild-
type FGF2-GFP. Therefore, this clone Cwt was used as a positive control for the 
analysis of all C-terminal truncations.    
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C1-146 – Deletion of 9 amino acids from the C-terminus 
 
Figure 3.107: C-terminal Truncations; 9 amino acids form the C-terminus deleted A FACS analysis of cell free supernatant 
bound to the surface of CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free 
supernatant to heparin beads. Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound 
(flowthrough, 10%) and bound material (eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative 
analysis of export employing flow cytometry.  Expression level (black bars) and secreted protein detected on the cell surface 
(red bars) is shown. FGF2-GFPwt was set to 100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-
impermeable biotin reagent. After cell lysis biotinylated and non-biotinylated proteins were separated by streptavidin beads. 
Total material (input, 5%) and the biotinylated fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All 
results shown represent an average of at least 3 different experiments. For further details see „Material and Methods“ and 
explanation of assays in chapter 3.3.2. To summarize the obtained data, this truncation shows a binding deficiency in vivo. In 
contrast, the truncated protein binds in vitro quantitatively to heparin beads. The expression level is significantly reduced, 
indicating rapid degradation of the protein. 
 
Deleting 9 amino acids from the C-terminus led to a significant reduction of the ability 
to bind to HSPGs present on CHOMCAT/TAM2 cells. In contrast, binding to heparin 
beads in vitro was not impaired. The expression level of the truncated protein was 
significantly reduced, indicating a rapid degradation in the cytoplasm or lowered 
translation rates. Extracellular protein bound to the plasma membrane was not 
detectable by FACS analysis due to reduced amount of fusion protein present in the 
cytoplasm. The biotinylation of cell surface protein showed minor amounts of fusion 
protein bound to the cell surface as it could be eluted from streptavidin beads using 
SDS-containing sample buffer.  
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C1-136 – Deletion of 19 amino acids from the C-terminus 
 
 
 
Figure 3.108: C-terminal Truncations; 19 amino acids form the C-terminus deleted A FACS analysis of cell free supernatant 
bound to the surface of CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free 
supernatant to heparin beads. Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound 
(flowthrough, 10%) and bound material (eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative 
analysis of export employing flow cytometry.  Expression level (black bars) and secreted protein detected on the cell surface 
(red bars) is shown. FGF2-GFPwt was set to 100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-
impermeable biotin reagent. After cell lysis biotinylated and non-biotinylated proteins were separated by streptavidin beads. 
Total material (input, 5%) and the biotinylated fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All 
results shown represent an average of at least 3 different experiments. For further details see „Material and Methods“ and 
explanation of assays in chapter 3.3.2. To summarize the obtained data, this truncation shows a binding deficiency in vivo. In 
contrast, the truncated protein binds in vitro quantitatively to heparin beads. The expression level is significantly reduced, 
indicating rapid degradation of the protein. 
 
Deleting 19 amino acids from the C-terminus led to a significant reduction of the 
ability to bind to HSPGs present on CHOMCAT/TAM2 cells. In contrast, binding to 
heparin beads in vitro was not impaired. The expression level of the truncated protein 
was significantly reduced, indicating a rapid degradation in the cytoplasm or lowered 
translation rates. Extracellular protein bound to the plasma membrane was not 
detectable by FACS analysis due to reduced amount of fusion protein present in the 
cytoplasm. The biotinylation of cell surface protein showed minor amounts of fusion 
protein bound to the cell surface as it could be eluted from streptavidin beads using 
SDS-containing sample buffer. 
 
 
Results 
 
179 
C1-126 – Deletion of 29 amino acids from the C-terminus 
 
 
 
Figure 3.109: C-terminal Truncations; 29 amino acids form the C-terminus deleted A FACS analysis of cell free supernatant 
bound to the surface of CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free 
supernatant to heparin beads. Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound 
(flowthrough, 10%) and bound material (eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative 
analysis of export employing flow cytometry.  Expression level (black bars) and secreted protein detected on the cell surface 
(red bars) is shown. FGF2-GFPwt was set to 100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-
impermeable biotin reagent. After cell lysis biotinylated and non-biotinylated proteins were separated by streptavidin beads. 
Total material (input, 5%) and the biotinylated fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All 
results shown represent an average of at least 3 different experiments. For further details see „Material and Methods“ and 
explanation of assays in chapter 3.3.2. To summarize the obtained data, this truncation shows a binding deficiency in vivo. The 
protein binds in vitro to heparin beads, but not as quantitative as truncations described earlier. The expression level is 
significantly reduced. 
 
Deleting 29 amino acids from the C-terminus led to a significant reduction of the 
ability to bind to HSPGs present on CHOMCAT/TAM2 cells. This fusion protein showed, 
in contrast to less truncated versions of FGF2-GFP, an impaired affinity to heparin. 
Only 60% of the input fraction was eluted from heparin beads, whereas 40% were 
present in the non-bound flowthrough fraction. The expression level of the truncated 
protein was significantly reduced, indicating a rapid degradation in the cytoplasm. 
Extracellular protein bound to the plasma membrane was not detectable by FACS 
analysis due to reduced amount of fusion protein present in the cytoplasm. The 
biotinylation of cell surface protein showed minor amounts of fusion protein bound to 
the cell surface as it could be eluted from streptavidin beads using SDS-containing 
sample buffer. 
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C1-116 – Deletion of 39 amino acids from the C-terminus 
 
 
 
 
Figure 3.110: C-terminal Truncations; 39 amino acids form the C-terminus deleted A FACS analysis of cell free supernatant 
bound to the surface of CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free 
supernatant to heparin beads. Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound 
(flowthrough, 10%) and bound material (eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative 
analysis of export employing flow cytometry.  Expression level (black bars) and secreted protein detected on the cell surface 
(red bars) is shown. FGF2-GFPwt was set to 100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-
impermeable biotin reagent. After cell lysis biotinylated and non-biotinylated proteins were separated by streptavidin beads. 
Total material (input, 5%) and the biotinylated fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All 
results shown represent an average of at least 3 different experiments. For further details see „Material and Methods“ and 
explanation of assays in chapter 3.3.2. To summarize the obtained data, this truncation shows a binding deficiency in vivo. The 
protein binds in vitro marginally to heparin beads, the majority of the protein is not able to bind in vitro. The expression level is 
significantly reduced. 
  
Deleting 39 amino acids from the C-terminus led to a significant reduction of the 
ability to bind to HSPGs present on CHOMCAT/TAM2 cells. This fusion protein showed, 
in contrast to less truncated versions of FGF2-GFP, an impaired affinity to heparin. 
Only minor amount of fusion protein was found in the input fraction, whereas a vast 
majority was found in the non-bound flowthrough fraction. The expression level of the 
truncated protein was significantly reduced, indicating a rapid degradation in the 
cytoplasm. Extracellular protein bound to the plasma membrane was not detectable 
by FACS analysis due to reduced amount of fusion protein present in the cytoplasm. 
The biotinylation of cell surface protein showed almost no fusion protein bound to the 
cell surface as it could be eluted only in minor amounts from streptavidin beads using 
SDS-containing sample buffer. 
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C1-106 – Deletion of 49 amino acids from the C-terminus 
 
 
 
Figure 3.111: C-terminal Truncations; 49 amino acids form the C-terminus deleted A FACS analysis of cell free supernatant 
bound to the surface of CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free 
supernatant to heparin beads. Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound 
(flowthrough, 10%) and bound material (eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative 
analysis of export employing flow cytometry.  Expression level (black bars) and secreted protein detected on the cell surface 
(red bars) is shown. FGF2-GFPwt was set to 100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-
impermeable biotin reagent. After cell lysis biotinylated and non-biotinylated proteins were separated by streptavidin beads. 
Total material (input, 5%) and the biotinylated fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All 
results shown represent an average of at least 3 different experiments. For further details see „Material and Methods“ and 
explanation of assays in chapter 3.3.2. To summarize the obtained data, this truncation shows a binding deficiency in vivo. The 
protein binds in vitro marginally to heparin beads, the majority of the protein is not able to bind in vitro. The expression level is 
significantly reduced. 
 
Deleting 49 amino acids from the C-terminus led to a significant reduction of the 
ability to bind to HSPGs present on CHOMCAT/TAM2 cells. This fusion protein showed, 
in contrast to less truncated versions of FGF2-GFP, an impaired affinity to heparin. 
Only minor amount of fusion protein was found in the input fraction, whereas a vast 
majority was found in the non-bound flowthrough fraction. The affinity of FGF2 to 
heparin is reduced when compared to C1-116.The expression level of the truncated 
protein was significantly reduced, indicating a rapid degradation in the cytoplasm. 
Extracellular protein bound to the plasma membrane was not detectable by FACS 
analysis due to the reduced amount of fusion protein present in the cytoplasm. The 
biotinylation of cell surface protein showed almost no fusion protein bound to the cell 
surface as it could be eluted only in minor amounts from streptavidin beads using 
SDS-containing sample buffer. 
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C1-96 – Deletion of 59 amino acids from the C-terminus 
 
 
 
Figure 3.112: C-terminal Truncations; 59 amino acids form the C-terminus deleted A FACS analysis of cell free supernatant 
bound to the surface of CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free 
supernatant to heparin beads. Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound 
(flowthrough, 10%) and bound material (eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative 
analysis of export employing flow cytometry.  Expression level (black bars) and secreted protein detected on the cell surface 
(red bars) is shown. FGF2-GFPwt was set to 100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-
impermeable biotin reagent. After cell lysis biotinylated and non-biotinylated proteins were separated by streptavidin beads. 
Total material (input, 5%) and the biotinylated fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All 
results shown represent an average of at least 3 different experiments. For further details see „Material and Methods“ and 
explanation of assays in chapter 3.3.2. To summarize the obtained data, this truncation shows a binding deficiency in vivo. The 
protein binds in vitro marginally to heparin beads, the majority of the protein is not able to bind in vitro. The expression level is 
significantly reduced. 
 
Deleting 59 amino acids from the C-terminus led to a significant reduction of the 
ability to bind to HSPGs present on CHOMCAT/TAM2 cells. This fusion protein showed, 
in contrast to less truncated versions of FGF2-GFP, an impaired affinity to heparin. 
Only minor amount of fusion protein was found in the input fraction, whereas a vast 
majority was found in the non-bound flowthrough fraction. The affinity of FGF2 to 
heparin is reduced when compared to C1-106.The expression level of the truncated 
protein was significantly reduced, indicating a rapid degradation in the cytoplasm. 
Extracellular protein bound to the plasma membrane was not detectable by FACS 
analysis due to the reduced amount of fusion protein present in the cytoplasm. The 
biotinylation of cell surface protein showed almost no fusion protein bound to the cell 
surface as it could be eluted only in minor amounts from streptavidin beads using 
SDS-containing sample buffer. 
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C1-86 – Deletion of 69 amino acids from the C-terminus 
 
 
 
Figure 3.113: C-terminal Truncations; 69 amino acids form the C-terminus deleted A FACS analysis of cell free supernatant 
bound to the surface of CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free 
supernatant to heparin beads. Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound 
(flowthrough, 10%) and bound material (eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative 
analysis of export employing flow cytometry.  Expression level (black bars) and secreted protein detected on the cell surface 
(red bars) is shown. FGF2-GFPwt was set to 100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-
impermeable biotin reagent. After cell lysis biotinylated and non-biotinylated proteins were separated by streptavidin beads. 
Total material (input, 5%) and the biotinylated fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All 
results shown represent an average of at least 3 different experiments. For further details see „Material and Methods“ and 
explanation of assays in chapter 3.3.2. To summarize the obtained data, this truncation shows a binding deficiency in vivo. From 
this point of degradation, the protein also fails to bind to heparin beads in vivo. The expression level is significantly reduced. 
 
Deleting 69 amino acids from the C-terminus led to a significant reduction of the 
ability to bind to HSPGs present on CHOMCAT/TAM2 cells. A deletion of 69 amino acids 
results in a total loss of the ability for FGF2-GFP to bind to heparin in vitro. Less 
truncated versions of the fusion protein were still able, although partly in minor 
amounts, to bind to heparin. It was not possible to detect the fusion protein in the 
input fraction, but truncated FGF2-GFP was found exclusively in the non-bound 
flowthrough fraction. The expression level of this truncated protein was significantly 
reduced as compared to wild-type level, indicating a rapid degradation in the 
cytoplasm. Extracellular protein bound to the plasma membrane was not detectable 
by FACS analysis due to reduced amount of fusion protein present in the cytoplasm. 
The biotinylation of cell surface protein showed almost no fusion protein bound to the 
cell surface as it could be eluted only in minor amounts from streptavidin beads using 
SDS-containing sample buffer. 
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C1-66 – Deletion of 89 amino acids from the C-terminus 
 
 
Figure 3.114: C-terminal Truncations; 89 amino acids form the C-terminus deleted A FACS analysis of cell free supernatant 
bound to the surface of CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free 
supernatant to heparin beads. Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound 
(flowthrough, 10%) and bound material (eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative 
analysis of export employing flow cytometry.  Expression level (black bars) and secreted protein detected on the cell surface 
(red bars) is shown. FGF2-GFPwt was set to 100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-
impermeable biotin reagent. After cell lysis biotinylated and non-biotinylated proteins were separated by streptavidin beads. 
Total material (input, 5%) and the biotinylated fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All 
results shown represent an average of at least 3 different experiments. For further details see „Material and Methods“ and 
explanation of assays in chapter 3.3.2. To summarize the obtained data, this truncation shows a binding deficiency in vivo. From 
this point of degradation, the protein also fails to bind to heparin beads in vivo. The expression level is significantly reduced. 
 
Deleting 89 amino acids from the C-terminus led to a significant reduction of the 
ability to bind to HSPGs present on CHOMCAT/TAM2 cells. In the assay for binding of 
FGF2-GFP to bind to heparin in vitro, it was not possible to detect fusion protein in 
the eluate fraction, but truncated FGF2-GFP was found exclusively in the non-bound 
flowthrough fraction. The expression level of this truncated protein was significantly 
reduced as compared to wild-type level, indicating a rapid degradation in the 
cytoplasm. Extracellular protein bound to the plasma membrane was not detectable 
by FACS analysis due to reduced amount of fusion protein present in the cytoplasm. 
The biotinylation of cell surface protein showed almost no fusion protein bound to the 
cell surface as it could be eluted only in minor amounts from streptavidin beads using 
SDS-containing sample buffer. 
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C1-56 – Deletion of 99 amino acids from the C-terminus 
 
 
 
Figure 3.115: C-terminal Truncations; 99 amino acids form the C-terminus deleted A FACS analysis of cell free supernatant 
bound to the surface of CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free 
supernatant to heparin beads. Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound 
(flowthrough, 10%) and bound material (eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative 
analysis of export employing flow cytometry.  Expression level (black bars) and secreted protein detected on the cell surface 
(red bars) is shown. FGF2-GFPwt was set to 100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-
impermeable biotin reagent. After cell lysis biotinylated and non-biotinylated proteins were separated by streptavidin beads. 
Total material (input, 5%) and the biotinylated fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All 
results shown represent an average of at least 3 different experiments. For further details see „Material and Methods“ and 
explanation of assays in chapter 3.3.2. To summarize the obtained data, this truncation shows a binding deficiency in vivo. From 
this point of degradation, the protein also fails to bind to heparin beads in vivo. The expression level is significantly reduced. 
 
Deleting 99 amino acids from the C-terminus led to a significant reduction of the 
ability to bind to HSPGs present on CHOMCAT/TAM2 cells. In the assay for binding of 
FGF2-GFP to bind to heparin in vitro, it was not possible to detect fusion protein in 
the eluate fraction, but truncated FGF2-GFP was found exclusively in the non-bound 
flowthrough fraction. The expression level of this truncated protein was significantly 
reduced as compared to wild-type level, indicating a rapid degradation in the 
cytoplasm. Extracellular protein bound to the plasma membrane was not detectable 
by FACS analysis due to reduced amount of fusion protein present in the cytoplasm. 
The biotinylation of cell surface protein showed almost no fusion protein bound to the 
cell surface as it could be eluted only in minor amounts from streptavidin beads using 
SDS-containing sample buffer. 
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C1-46 – Deletion of 109 amino acids from the C-terminus 
 
 
 
Figure 3.116: C-terminal Truncations; 109 amino acids form the C-terminus deleted A FACS analysis of cell free supernatant 
bound to the surface of CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free 
supernatant to heparin beads. Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound 
(flowthrough, 10%) and bound material (eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative 
analysis of export employing flow cytometry.  Expression level (black bars) and secreted protein detected on the cell surface 
(red bars) is shown. FGF2-GFPwt was set to 100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-
impermeable biotin reagent. After cell lysis biotinylated and non-biotinylated proteins were separated by streptavidin beads. 
Total material (input, 5%) and the biotinylated fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All 
results shown represent an average of at least 3 different experiments. For further details see „Material and Methods“ and 
explanation of assays in chapter 3.3.2. To summarize the obtained data, this truncation shows a binding deficiency in vivo. From 
this point of degradation, the protein also fails to bind to heparin beads in vivo. The expression level is significantly reduced. 
 
Deleting 109 amino acids from the C-terminus led to a significant reduction of the 
ability to bind to HSPGs present on CHOMCAT/TAM2 cells. In the assay for binding of 
FGF2-GFP to bind to heparin in vitro, it was not possible to detect fusion protein in 
the eluate fraction, but truncated FGF2-GFP was found exclusively in the non-bound 
flowthrough fraction. The expression level of this truncated protein was significantly 
reduced as compared to wild-type level, indicating a rapid degradation in the 
cytoplasm. Extracellular protein bound to the plasma membrane was not detectable 
by FACS analysis due to reduced amount of fusion protein present in the cytoplasm. 
The biotinylation of cell surface protein showed almost no fusion protein bound to the 
cell surface as it could be eluted only in minor amounts from streptavidin beads using 
SDS-containing sample buffer. 
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C1-36 – Deletion of 119 amino acids from the C-terminus 
 
 
 
Figure 3.117: C-terminal Truncations; 119 amino acids form the C-terminus deleted A FACS analysis of cell free supernatant 
bound to the surface of CHOMCAT/TAM2 cells. Cell surface signal of FGF2-GFPwt was set to 100%. B Binding of cell free 
supernatant to heparin beads. Cell free supernatant was incubated with heparin beads. Total (input, 10%), non-bound 
(flowthrough, 10%) and bound material (eluate, 10%) was analyzed by SDS-PAGE and Western blotting. C Quantitative 
analysis of export employing flow cytometry.  Expression level (black bars) and secreted protein detected on the cell surface 
(red bars) is shown. FGF2-GFPwt was set to 100%. D Biotinylation assay. Cell surface proteins were labelled with a membrane-
impermeable biotin reagent. After cell lysis biotinylated and non-biotinylated proteins were separated by streptavidin beads. 
Total material (input, 5%) and the biotinylated fraction (eluate, 50%) were analyzed by SDS-PAGE and Western blotting. All 
results shown represent an average of at least 3 different experiments. For further details see „Material and Methods“ and 
explanation of assays in chapter 3.3.2. To summarize the obtained data, this truncation shows a binding deficiency in vivo. From 
this point of degradation, the protein also fails to bind to heparin beads in vivo. The expression level is slightly enhanced 
compared to other truncations. Extracellular protein bound to the plasma membrane is not detectable via flow cytometry but in 
minor amounts with cell surface biotinylation. 
 
Deleting 119 amino acids from the C-terminus led to a significant reduction of the 
ability to bind to HSPGs present on CHOMCAT/TAM2 cells. In the assay for binding of 
FGF2-GFP to bind to heparin in vitro, it was not possible to detect fusion protein in 
the eluate fraction, but truncated FGF2-GFP was found exclusively in the non-bound 
flowthrough fraction. The expression level of this truncated protein was significantly 
reduced as compared to wild-type level, indicating a rapid degradation in the 
cytoplasm. Extracellular protein bound to the plasma membrane was not detectable 
by FACS analysis due to reduced amount of fusion protein present in the cytoplasm. 
The biotinylation of cell surface protein showed almost no fusion protein bound to the 
cell surface as it could be eluted only in minor amounts from streptavidin beads using 
SDS-containing sample buffer. 
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The results obtained by the functional characterization of FGF2 mutants with C-
terminal truncation are listed in the flowing table: 
 
Mutant Classification 
Cwt Wild-type 
C1-146 Instable Protein / impaired in vivo binding 
C1-136 Instable Protein / impaired in vivo binding 
C1-126 Instable Protein / impaired in vivo and in vitro binding 
C1-116 Instable Protein / impaired in vivo and in vitro binding 
C1-106 Instable Protein / impaired in vivo and in vitro binding 
C1-96 Instable Protein / impaired in vivo and in vitro binding 
C1-86 Instable Protein / Binding deficient 
C1-66 Instable Protein / Binding deficient 
C1-56 Instable Protein / Binding deficient 
C1-46 Instable Protein / Binding deficient 
C1-36 Instable Protein / Binding deficient 
 
Table 3.8: Overview of classifications made for C-terminal truncations 
 
As a summary, the C-terminus is crucial for both stability of the protein and ability to 
bind to heparin and HSPGs. The wild-type control, bearing a linker of two amino 
acids between FGF2 and GFP, showed phenotype characteristics and is used as a 
positive control. All truncations characterized, showed instability of the fusion protein 
present in the cytoplasm. Moreover all truncated proteins were not able to bind to 
HSPGs present on the cell surface. In contrast, the ability to bind to heparin in vitro 
was influenced by the number of deleted amino acids. Deleting up to 19 amino acids 
from the C-terminus had no effect on the in vitro binding to heparin, but truncation of 
29 amino acids led to a reduced binding affinity to heparin beads in vitro. Proportional 
to the stepwise deletion of 10 amino acids, the truncated versions of FGF2 lost their 
affinity to heparin in vitro. Expanding truncations to 69 amino acids resulted in a total 
loss of FGF2 affinity for heparin beads. The data collected during the analysis of C-
terminal truncations showed that the C-terminus is necessary to sustain protein 
stability. This data indicates that binding of FGF2 to heparan sulfate proteoglycans 
might be a prerequisite for FGF2 secretion. Therefore it has to be elucidated if the 
truncations are not secreted into the media of CHO cells expressing the truncated 
versions of FGF2-GFP.  
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3.4 Characterization of FGF2-GFP mutants differing from wild-
type as identified by the screening procedure 
 
After finishing screening of all mutants generated, some of them demonstrated a 
noticeable difference from wild-type characteristics. The C-terminal truncations did 
not bind to heparan sulfate proteoglycans present on the cell surface of CHO cells 
and were impaired to bind to heparin. Since secretion of Galectin-1 is dependent of 
binding to its counter receptor (Seelenmeyer et al., 2005), it has to be analyzed if the 
same is true for FGF2. Therefore it has to be elucidated, if the C-terminal truncations 
are not secreted from CHO cells. The mutant rM 156 showed a reduced secretion of 
the fusion protein as analyzed by flow cytometry and cell surface biotinylation. The 
data obtained for binding of rM 156 to heparin and to HSPGs are controversy, 
because the mutant was able to bind to heparin, but not to HSPGs present on the 
cell surface. For the dimerization mutant 53, bearing two mutated cysteines at 
position 78 and 96, the secretion assays demonstrated a controversary signal for 
export efficiency of the fusion protein. A reduced signal for secreted fusion protein 
was detected as analyzed by cell surface biotinylation. In contrast, wild-type levels for 
secreted fusion protein were observed by flow cytometry.  
Mutant rM 156 and the C-terminal truncations were analyzed in more detail as 
described in the following chapters. 
 
3.4.1 Analysis of C-terminal truncations with regard to unconventional 
secretion 
 
The assays used to quantify the amount of secreted FGF2-GFP detect only cell 
surface bound fusion protein. During the mutagenesis analysis it was shown that C-
terminally truncated versions of FGF2-GFP are not able to bind to the cell surface 
and are thus not detectable by flow cytometry or cell surface biotinylation, even if 
export took place. To analyze if these mutants, deficient in binding to the cell surface 
are also deficient in secretion, conditioned growth medium was applied to immune-
precipitation in order to detect extracellularly localized soluble fusion protein. 
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Figure 3.118: analysis of export employing medium immunoprecipitation. The fusion proteins indicated were expressed in CHO 
cells (lines 3-15) for 48 h at 37°C (6-well plates; 70% confluency). CHOMCAT/TAM2 cells without and with addition of recombinant 
GFP to the medium were used as a control (line 1 and 2). The medium was removed and subjected to immunoprecipitation 
using affinity-purified anti-GFP antibodies. 
 
C-terminal truncations were expressed in CHO cells by incubation in with doxicycline 
(1 g/ml) for 48 h at 37°C (6-well plates; 70% confluency). Additionally recombinant 
GFP was exogenously added to MCAT cells. The growth medium was removed and 
the cells were washed once with PBS. Medium and PBS wash buffer were combined 
and subjected to immunoprecipitation using affinity-purified anti-GFP antibodies. As 
shown in figure 
Exogenously added recombinant GFP was immunoprecipitated from the medium of 
MCAT cells (lane 2). GFP from expressing CHOGFP cells was not detectable in the 
medium. Additionally, C-terminal truncations were not immunoprecipitated from the 
growth medium. 
Since the fusion proteins were neither detected in the cell culture medium nor in the 
cell surface, it can be concluded that C-terminal truncations of FGF2 prevent its 
secretion.  
 
3.4.2 Characterization of mutant rM 156  
 
The mutant 156 generated by random mutagenesis showed a reduced secretion as 
detected by FACS analysis and biotinylation assay (see figure 3.38). Another 
characteristic of this mutant was its ability to bind in vitro to heparin beads, but its 
failure to bind in vivo to HSPGs of the cell surface. However, although the fusion 
protein was not able to bind to the cell surface, a significant signal was detected if it 
was applied in vitro to heparin beads. 
A set of experiments was conducted in order to confirm the results obtained by the 
screening procedure and to fully characterize this mutant with regard to protein 
degradation and potentially secreted FGF2 failed to bind to the cell surface. In order 
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to immuno-precipitate the potential population, which is not bound to the cell surface, 
but present in the medium, the cell surface biotinylation assay was modified. It was 
enhanced by using heparin beads on growth medium from secreting cells in order to 
detect the population which was not bound to the cell surface. A degradation 
experiment over time and at different temperatures was conducted, to exclude that 
the reduced signal for the unconventional secretion is mediated by protein 
degradation.  
Additionally, individual mutations of clone rM156 were subjected to a detailed 
analysis to detect if the potential defect of this mutant is caused by combination of 
the mutations or by a single amino acid. The point mutations used were the following: 
Mutant 36, bearing a mutation at position 87 changing glutamic acid to lysine (E to K), 
mutant 45, mutated at position 128 changing lysine to glutamic acid (K to E) and 
mutant 46, changing arginine to glutamine (R to Q) at position 129.  
 
 
3.4.2.1 Quantification of secretion employing FACS Analysis 
 
In order to reproduce the results from the screening, the amount of expressed and 
secreted fusion protein was quantified using flow cytometry under the same 
conditions as during screening process. 
 
 
Figure 3.119: FACS analysis. All Experiments performed as described during screening process and set as average of 13 
experiments. FGF2-GFPwt was set to 100%. Clone 156 and point mutation 36 (E87K), 45 (K128E) and 46 (R129Q) were 
depicted in relation to FGF2-GFPwt.Black bars represent GFP fluorescence, red bars indicate the cell surface staining as 
measured by antibody staining. 
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The experiment was performed under the same conditions as described for the 
screening. The result shown in figure 3.119 displays the average of 13 experiments. 
It was not possible to reproduce the signal for cell surface staining in mutant rM156 
as described for the screening in section 3.3.3.4. The single mutations did not display 
an altered signal for extracellular FGF2-GFP compared to the screening. 
 
 
3.4.2.2 Biotinylation of surface proteins to assess the amount of secreted FGF2 
 
In order to confirm the result obtained by cell surface biotinylation during screening, 
this assay was also repeated as described previously. As stated, this mutant displays 
an impaired binding to CHO cells. Therefore the signal for secreted FGF2-GFP has 
to be analyzed as a combined signal from cell surface associated FGF2 and soluble 
FGF2, which is not able to bind to CHO cells. In order to detect potential fusion 
protein, not associated with the cell surface, medium from secreting cells was 
targeted to heparin beads in order to fish the soluble population. The signal for both, 
biotinylated cell surface associated and heparin bound soluble FGF2-GFP 
represented the overall signal for secreted fusion protein. 
 
 
Figure 3.120: Quantification of FGF2-GFP fusion protein export of from CHO cells employing cell surface biotinylation and 
heparin binding from cell culture supernatants. The fusion proteins indicated were expressed in CHO cells for 16 h at 37°C (6-
well plates; 70% confluency). The medium was removed and subjected to binding to heparin beads. Cell surfaces were treated 
with a membrane-impermeable biotinylation reagent. Following detergent mediated cell lysis, biotinylated and non-biotinylated 
proteins were separated employing streptavidin beads. Aliquots from the input material (black bars, 2.5%), the biotinylated 
fraction (red bars, 50%) were analyzed by SDS-PAGE. Additionally the medium was subjected to heparin beads (1h, 4°C) in 
order to bind extracellular, non-bound FGF2-GFP to the beads. The protein was eluted from the beads using SDS-sample buffer 
and the eluate (yellow bars, 50%) was also analyzed by SDS-PAGE, followed by Western blotting using affinity-purified anti-
GFP antibodies. Primary antibodies were then detected with Alexa 680-coupled anti-rabbit secondary antibodies. Signals for 
FGF2-GFP fusion proteins were quantified using a LI-COR Odyssey imaging system. For further details, see Material and 
Methods. 
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The experiment was conducted as described previously for the screening. 
Additionally to the biotinylation of cell surface proteins, the medium was subjected to 
heparin beads (1h, 4°C) to bind secreted but non-bound material. The result depicted 
in figure 3.120 displays an average of four individual experiments. Strikingly and in 
contrast to the result obtained during the screening process, the signal for secreted 
fusion protein, bound to the cell surface was not reduced. Moreover, as a positive 
control, the mutants obtained by site-directed mutagenesis 36, 45 and 46 displayed a 
comparable level of biotinylated protein as detected during screening process. 
Additionally, it was not possible, to bind neither FGF2-GFPwt nor mutated proteins 
from the medium using heparin beads, indicating that secreted fusion protein was 
completely bound to heparan sulfate proteoglycans present on the cell surface. The 
in vivo binding assay made use of FGF2-GFP present in a cell free supernatant 
derived from CHO cells expressing the fusion proteins, whereas biotinylation assay 
detected secreted, endogenous FGF2-GFP associated with the plasma membrane. 
This might explain the difference in the result of both assays, because the 
translocation process might also directly mediate binding, thereby changing affinity of 
FGF2 to heparan sulfate proteoglycans. 
 
 
3.4.2.3 Degradation experiment  
 
The interpretation of the results obtained for mutant rM 156 would be further 
complicated if the signal is getting lost due to degradation of the fusion protein. 
Therefore an analysis was conducted to quantify the amount of degraded fusion 
proteins for FGF2-GFPwt and the mutated versions of FGF2-GFP as indicated in the 
following figure 3.121.  
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Figure 3.121: Stability of FGF2-GFP fusion proteins in conditioned media derived from CHO cells. The fusion proteins indicated 
were expressed in CHO cells for 16 h at 37°C (6-well plates; 70% confluency). From each cell line, a cell-free supernatant was 
prepared. Normalized amounts (GFP fluorescence) were incubated in conditioned medium derived from CHO cells for the times 
indicated followed by binding to heparin beads. The samples were analyzed by SDS-PAGE and Western blotting using 
antibodies directed against GFP. Black bar: input (no heparin binding, 10%); lane 2: no incubation (binding to heparin beads, 
10%); lane 3: incubation for 24 h at 4°C (binding to heparin beads, 10%); lane 4: incubation for 24 h at 37°C (binding to heparin 
beads, 10%). For further details, see Material and Methods 
 
 
The assay was performed using cell free supernatant, for the generation see Material 
and Methods, chapter 2.3.6. After normalizing the amount of protein (GFP 
fluorescence), the cell free supernatant was incubated in conditioned medium 
derived from CHO cells for 24 h at 4°C and 37°C. The solution was then subjected to 
heparin beads (1 h, 4°C) in order to precipitate FGF2-GFP from the medium. FGF2-
GFP bound to heparin was eluted from beads using SDS sample buffer, followed by 
SDS-PAGE and Western blotting. 
When comparing the signal for input (black bar) and non pre-incubated FGF2-GFP 
bound to heparin beads (red bar), there was no difference detectable, indicating 
quantitative binding to heparin beads and elution of FGF2-GFP from the beads.  
After an incubation of the fusion protein for 24 h at 4°C (Yellow bars), the signal for 
wild-type and mutated protein, was significantly reduced. 50% of the input material 
could be detected for wt protein and mutants 156, 36 and 45. This result showed that 
the fusion protein was degraded in 24 h at 4°C, but protein derived from mutants was 
degraded to the same amount compared to wild-type protein. The mutations did not 
have an influence on the stability of the fusion protein. But mutant 46 was an 
exception, showing a signal reduced to 20% when compared to wild-type for its 
fusion protein detectable after 24 h at 4°C. Therefore, the mutation R to Q at position 
129 affected the stability of the fusion protein. Incubating the proteins at 37°C for 24 
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h (light blue bars) did not result in a higher degradation when compared to incubation 
at 4°C for 24 h. 
This experiment displayed that FGF2-GFP was degraded independently from 
mutations and temperature. In all assays, FGF2-GFPwt is compared with a specific 
mutant. Since in the case for rM 156, mutants and FGF2-GFPwt were degraded to the 
same extent, a quantification of the secreted fraction, bound to the cell surface was 
possible. 
 
3.4.2.4 Binding efficiency to HSPGs of FGF2-GFPwt, rM 156 and clone 36 
 
The mutant rM 156 was tested during the screening process to be negative for 
binding to HSPGs present on the cell surface of CHO cells. In contrast, it was able to 
bind in vitro to heparin beads. To probe the binding efficiency of the mutants rM 156 
and point mutation 36, an experiment was conducted where cell free supernatant 
was normalized, subjected to CHOMCAT/TAM2 cells cells and incubated at 37°C or 4°C 
for 1 h or 16h. The detection of cell surface associated fusion protein occurred by 
flow cytometry. 
 
 
Figure 3.122: Analysis of FGF2 binding efficiency of various FGF2-GFP fusion proteins based on binding to CHO cells. The 
various fusion proteins indicated were expressed in CHO cells. Cell-free supernatants were prepared and normalized by GFP 
fluorescence. The supernatants indicated were then incubated with CHO cells for the time and temperature indicated to allow 
cell surface binding. Following treatment with affinity-purified anti-GFP antibodies and APC-conjugated secondary antibodies, 
cell surface binding was quantified by flow cytometry. 
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The assay was performed with cell free supernatant, for generation see Material and 
Methods. After normalizing the amount of protein (GFP fluorescence), the cell free 
supernatant was incubated for different time periods and at different temperatures 
with CHOMCAT/TAM2 cells to allow binding of the fusion proteins to heparan sulfate 
proteoglycans present on the cell surface. Cells were then processed with antibodies 
and prepared for FACS analysis, as described previously. FGF2-GFPwt displayed a 
signal of about 1150 arbitrary units, when incubated at 37°C for 1 h (black bars). 
Shifting the temperature to 4°C led to a reduced signal for FGF2-GFPwt bound to the 
cell surface as compared to incubation at 37°C, indicating that the binding of the 
fusion protein to the cell surface is temperature sensitive, since only 15% of the 
fusion protein bind to the cell surface at 4°C. Extending incubation time of cell free 
supernatant with CHOMCAT/TAM2 cells led to a reduced signal as well. The reduced 
amount of fusion protein bound to the cell surface after incubation of 16 h at 37°C 
may result from degradation of FGF2-GFP. The reduced signal for FGF2-GFP after 
an incubation of 16 h at 4°C was observed, again probably because of the fusion 
proteins sensitivity to temperature. Binding of the fusion protein to HSPGs is impaired 
at 4°C. This observation was also made for mutant 35, although the ability to bind to 
HSPGs at 4°C is slightly enhanced. In contrast to wild-type protein, cell surface 
staining could not be detected with flow cytometry for the mutant rM 156, indicating a 
total loss of binding ability to HSPGs. Another formal possibility would be a higher 
degree of degradation, but as shown in figure 3.121, a difference between 
degradation rates of FGF2-GFPwt and mutant rM 156 was not observed. 
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4 Discussion 
 
Most secretory proteins are exported by eukaryotic cells using an ER/Golgi-
dependent pathway which is well characterized on the molecular level. This classical 
secretory pathway starts with the recognition of an hydrophobic signal sequence 
present at the N-terminus of a secretory protein (Walter et al., 1984), followed by 
cotranslational insertion into the lumen of the endoplasmatic reticulum (ER) 
(Rapoport et al., 1996). In the ER the protein is modified and packaged into vesicles 
which are targeted to the Golgi apparatus. Following fusion of the vesicles with the 
membrane, the protein is released into the Golgi where it is further modified (Hille et 
al., 1984; Abeijon and Hirschberg, 1992). It is then transported from cis- to trans- 
direction along the various Golgi cisternae. Secretory vesicles bud off the trans-Golgi 
membrane and travel along the cytoskeleton to the plasma membrane (Goodson et 
al., 1997) with which the vesicles fuse (Rothman, 1990; Pelham, 1996), thereby 
releasing their cargo into the extracellular space (Pelham, 1996). 
 
A number of proteins which are not secreted by the ER/Golgi dependent secretory 
pathway were also found to be present in the extracellular space, leading to the 
postulation of an ER/Golgi independent export, which was termed unconventional 
secretion. These proteins lack a classical signal sequence (Muesch et al., 1990) and 
are not glycosylated despite bearing multiple consensus sequences (Hughes et al., 
1992). Additionally, those proteins cannot be found to be present in compartments of 
the classical export route. Furthermore, their externalization is not blocked by 
inhibitors of the classical secretory pathway such as brefeldin A and monensin 
(Rubartelli et al., 1990; Florkiewicz et al., 1995). The first proteins to be described as 
secreted in an unconventional manner were interleukin-1β, galectins and FGF2. 
Meanwhile, it was demonstrated that not only cytokines (Interleukins, MIF and 
thioredoxin), lectins (galectin-1 and galectin-3) and growth factors (fibroblast growth 
factors) are unconventionally secreted, but also viral proteins (HIV tat, FV bet and 
HSV VP22), Leishmania hydrophilic acylated surface protein B (HASPB) and 
homeodomain-containing transcription factors (reviewed in Nickel et al. 2003). 
 
The molecular machinery mediating unconventional secretion of these proteins has 
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yet to be reported. However, it has been demonstrated that the proteins do not share 
a common pathway, but are rather secreted individually involving different, but 
maybe similar molecular machineries.  
Proteins, exported by unconventional means are of high biomedical relevance. The 
pro-angiogenic growth factor FGF2 is released by tumour cells to establish growth 
and spreading through metastases by neovascularization of the tumour. By 
elucidating the molecular machinery, it would be possible to develop or find inhibitors 
which specifically block secretion of FGF2 without affecting viable non-tumour cells, 
thus providing a potent tool in the therapy of tumours.  
 
In the present thesis, a robust in vivo
 
system was established which made use of 
genetically modified CHO cell lines expressing various mutated versions of FGF2-
GFP in a doxicycline-dependent manner.  
 
 
4.1 Generation of CHO cells expressing FGF2-GFP in a 
doxicycline-dependent manner as a tool for the analysis of 
FGF2 secretion 
 
In order to analyze unconventional secretion of the 18 kDa isoform of FGF2, a model 
cell line based on CHO (Chinese hamster ovary) cells was generated. CHO cells are 
generally well suited for the characterization of FGF2, because they lack high affinity 
FGF receptors (FGFR) with tyrosine kinase activity (Rusnati et al., 2002), thus 
avoiding autocrine and paracrine induction of biological activities (proliferation, 
differentiation and others). However, they express low-affinity receptors like heparan 
sulfate proteoglycans (HSPG) and glycolipids (e.g. GM1) to which FGF2 binds over 
its heparin binding motifs. Different CHO clones were generated from precursor cells 
(CHOMCAT/TAM2) to express the reporter proteins FGF2-GFP and GFP, termed 
CHOFGF2-GFP and CHOGFP, respectively in a doxicycline-dependent manner as 
described in section 3.1. These cells were characterized regarding regulation of 
doxicycline-dependent expression using different cell biological and biochemical 
methods. 
The genetic information for FGF2-GFP was introduced into the genome of CHO cells 
by retroviral transduction. To verify the retroviral insertion of FGF2-GFP and GFP 
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cDNA into the genome of CHO cells, a PCR analysis was performed, using genomic 
DNA extracted from cultured CHO cells as a template. PCR constructs were 
analyzed by agarose gel electrophoresis and found to be detected with the correct 
size (figure 3.3), providing evidence for a stable integration of both reporter 
constructs. The cell lines were characterized using biochemical and cell biological 
assays in order to demonstrate the functional expression of the reporter proteins. A 
western blot analysis using affinity-purified anti-GFP antibodies was used to verify 
doxicycline-dependent expression of FGF2-GFP (45 kDa) and GFP (26 kDa) 
respectively, showing protein expression only in the presence of doxicycline. In 
absence of the antibiotic, the reporter proteins could not be detected. Thus, the 
expression of the reporter proteins is under the control of the transactivator, which 
was introduced into the CHO cells in the second step of the generation of these 
model cell lines (see material and methods). This result was confirmed by flow 
cytometry and fluorescence microscopy (figure 3.4). However, FGF2-GFP showed a 
prominent nuclear staining as shown by confocal microscopy. The observation of 
nuclear located FGF2 is discussed controversially in the literature. It was shown that 
the 18 kDa isoform resides in the cytoplasm, whereas the high molecular isoforms of 
FGF2 (22-35 kDa) possess a nuclear localization sequence (NLS) at their extended 
N-terminus, which targets the proteins to the nucleus (Renko et al., 1990).  
Like other polypeptides, such as insulin and interleukin-1, 18 kDa FGF2 can 
translocate into the nucleus after internalization (Bouche et al., 1987) where it is able 
to up-regulate the synthesis of ribosomal RNA (Baldin et al., 1990). The nuclear 
translocation was also shown to be independent of lysosomes and microtubules 
(Ishihara et al., 1993). Interestingly, nuclear translocation of FGF2 was dramatically 
inhibited by heparinase treatment or in heparin-deficient Chinese hamster ovary cells, 
suggesting that heparan sulfate proteoglycans of the cell surface are involved in the 
internalization of exogenous 18 kDa FGF2. Moreover, it was proposed that FGF2 
possesses an unconventional bipartite nuclear localization signal (NLS) at its C-
terminus, containing two small clusters of basic amino acid residues separated by a 
hydrophobic region containing eight amino acids, which directs the protein to the 
nucleus (Hsia et al., 2003). Another reason for the nuclear localization might be that 
fusion of GFP to FGF2 leads to the nuclear localization, because both proteins might 
possess one part of a bipartite NLS which is completed after fusion of both proteins, 
targeting FGF2-GFP to the nucleus. This presumption is supported by the 
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observation that FGF2-GFP was found to be present in the nucleus of corneal 
endothelial cells (Choi et al., 2000). Another possible explanation for the nuclear 
localization of FGF2-GFP would be that the fixation process for confocal microscopy 
leads to an artificial nuclear staining. This was shown for the unconventional 
secretory protein vp22. Its nuclear localization was shown to be an artificial effect of 
the fixation procedure used to analyze cells expressing vp22 employing confocal 
microscopy (Lundberg and Johansson, 2001). This hypothesis is supported by the 
observation that cells processed for live-imaging by confocal microscopy do not 
demonstrate a nuclear FGF2-GFP staining (recent data from our laboratory). 
 
The characterized cells express MCAT (mouse cationic amino acid transporter), 
which enables retroviral transduction with reporter proteins to analyze the 
mechanism of unconventionally secreted proteins. In our laboratory, these cells were 
used to analyze unconventional secretion of Leishmania HASPB, galectin-1 and 
FGF2. The model cell line expressing FGF2 in a doxicycline-dependent manner 
served as a tool for the development of an efficient model system, which allows for 
the molecular analysis of unconventional secretion of FGF2 in vivo. 
 
4.2 Establishing an in vivo system to analyze unconventional 
secretion of FGF2 
 
The model cell line CHOFGF2-GFP was used to develop an experimental system for the 
analysis of unconventional secretion of FGF2. This system makes use of heparan 
sulfate proteoglycans (HSPG) present on the cell surface (Burgess and Maciag, 1989; 
Thompson et al., 1994; Brucato et al., 2002) to which FGF2 is able to bind upon 
secretion. Extracellularly localized, cell surface associated FGF2-GFP can be 
detected with specific antibodies and the amount of FGF2-GFP bound to heparan 
sulfate proteoglycans can be quantified employing flow cytometry.  
 
4.2.1 FGF2-GFP is localized on the cell surface of CHO cells 
 
The binding of secreted FGF2-GFP to plasma membrane-associated heparan sulfate 
proteoglycans was verified by performing an anti-GFP or anti-FGF2 antibody 
processing of cells under native conditions, followed by detection of first antibodies 
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with fluorophore-coupled secondary antibodies (Phycoerythrin or allophycocyanin). 
The processed cells were then analyzed by flow cytometry to quantify the amount of 
secreted fusion protein. 
The experiments shown in section 3.2.1 demonstrate that a cell surface signal was 
only detectable if cells were cultured in presence of doxicycline. A cell surface signal 
could not be detected in the absence of doxicycline incubation, indicating the 
monospecificity of the antibodies used. Furthermore, these experiments provide 
evidence that the artificial fusion of GFP to FGF2 does not result in a difference of its 
binding properties to HSPGs. This result was confirmed by a biochemical assay, 
where secreted FGF2-GFP was set into relation to intracellular FGF2-GFP. 
Extracellular FGF2-GFP was released from the cell surface by heparin and subjected 
to heparin sepharose in order to precipitate secreted FGF2. Intracellular FGF2-GFP 
was obtained by cell lysis. Cell lysate and heparin sepharose was then incubated 
with SDS-containing buffer and applied to SDS-PAGE, FGF2-GFP was detected by 
anti-GFP antibodies. In case for GFP, the supernatant and cell lysate were directly 
applied to SDS-PAGE and Western blot using anti-GFP antibodies. These 
experiments demonstrate that the translocation over the plasma membrane is 
dependent on the FGF2 part of the fusion protein, since GFP alone could not be 
detected to be cell surface associated.  
 
4.2.2 Characterization of FGF2-GFP localization on the cell surface   
 
To evaluate that the signal detected on the cell surface derives from FGF2-GFP 
bound to HSPGs, two experiments were conducted. In the first experiment, trypsin 
was added prior to analysis by flow cytometry. Proteins on the surface were 
degraded by trypsin, leaving intracellular proteins intact. As shown in the experiment 
(figure 3.6), the FGF2-GFP derived signal for cell surface staining is reduced to 
autofluorescence level, indicating that antibody-detected FGF2-GFP is present on 
the cell surface and can be degraded by the protease trypsin. In a second 
experiment (figure 3.8), heparin was added to cells expressing FGF2-GFP, in order 
to specifically remove FGF2-GFP from the cell surface. Since heparin competes with 
HSPGs for the binding to FGF2, an excess of soluble heparin removes FGF2 from 
the cell surface. This experiment demonstrated that the signal for FGF2-GFP on the 
cell surface was almost quantitatively reduced to autofluorescence level. The results 
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obtained by FACS analysis were confirmed by performing confocal microscopy 
(figure 3.16). The experiments provide evidence that FGF2-GFP detected by flow 
cytometry or confocal microscopy is indeed a population of secreted protein bound to 
HSPGs of the cell surface. Furthermore it could be shown that FGF2 artificially fused 
to GFP is fully functional for unconventional secretion and binding to HSPGs present 
on the cell surface.  
 
4.2.3 Functional characterization of the translocation mechanism 
 
Before 1991, FGF2 was suggested to be released unspecifically from injured or dead 
cells which have lost membrane integrity and release FGF2 in an uncontrolled 
manner (McNeil et al., 1989). In 1991, Mignatti et al. proposed for the first time that 
FGF2 might not be released by injured cells but that it is rather secreted by a novel 
secretion mechanism, which was suggested to be independent from the classical 
secretory pathway (Mignatti and Rifkin, 1991). This proposal was confirmed later by 
different research groups, one of them also identifying the Na+/K+-ATPase as a 
potential component of the translocation machinery (Florkiewicz et al., 1998; Dahl et 
al., 2000). Unfortunately, no further investigations have been made to elucidate other 
components of the translocation machinery. However, evidence is accumulating that 
FGF2 is specifically released by a yet unknown mechanism. Multiple experiments 
were performed in order to functionally characterize the translocation mechanism of 
FGF2 secretion. 
 
 
4.2.3.1 Kinetics of the translocation process of FGF2 
 
To analyze the kinetics of FGF2-secretion from CHO cells, the cells were induced to 
express FGF2-GFP for increasing periods of time, leading to higher amounts of 
fusion protein expressed (section 3.2.3). The resulting cell surface staining was 
determined and a linear increase of extracellular FGF2-GFP was observed up to an 
incubation time of 48 h. Cells expressing the proteins for longer periods of time did 
not show a higher signal for secreted FGF2. The saturation of the signal after 48 h of 
doxicycline treatment might be due to limited binding capacities for FGF2-GFP on the 
plasma membrane or because the steady state level was reached, in which secretion 
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and endocytosis/degradation are in equilibrium. The observed time-dependency 
leads to the conclusion that the translocation of FGF2-GFP is a controlled 
mechanism. 
 
 
4.2.3.2 Binding capacity of FGF2 for binding to heparan sulfate proteoglycans 
present on the cell surface of FGF2-GFP 
 
The following experiment was performed to determine the capacity of FGF2 to bind 
to heparan sulfate proteoglycans present on the cell surface of CHO cells (. For this 
purpose, cells were incubated in absence of doxicycline and different amounts of 
recombinant FGF2 were added to the medium. Subsequently, cell surface-
associated FGF2 was detected by affinity-purified anti-FGF2 antibodies and 
quantified by flow cytometry (figure 3.10). The signal for cell surface staining 
increased linearly up to an addition of a maximal concentration of 500 ng 
recombinant FGF2 to the medium, indicating that the maximal binding capacity of 
heparan sulfate proteoglycans of the cell surface for FGF2 was not reached. The 
signal from exogenously added recombinant FGF2 was set in a direct relation to the 
signal for endogenous expressed and secreted FGF2-GFP bound to the cell surface. 
It was 10 times higher than the signal for biosynthetic, secreted FGF2. The 
concentration of endogenous FGF2 detected on the cell surface can be calculated to 
less than 1 ng when compared with exogenous added recombinant FGF2. This 
experiment demonstrates that the amount of expressed and unconventionally 
secreted protein alone is not able to saturate the heparan sulfate proteoglycan 
binding sites present on the cell surface. Therefore, the saturation observed after 48 
h in the kinetic studies did not represent low binding capacities but rather an 
equilibrium between endocytosis/degradation and secretion of FGF2. 
 
 
4.2.3.3 Unspecifically released FGF2-GFP does not contribute to the cell surface 
signal  
 
The contribution of unspecifically released FGF2-GFP from dead or damaged cells to 
the signal detected on the cell surface was investigated by the following experiment 
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(section 3.2.3). A membrane-free supernatant was obtained by homogenization of 
FGF2-GFP expressing cells employing sonication. This supernatant was then 
incubated with cells not expressing the fusion protein in order to allow binding of 
FGF2-GFP to the cell surface. The signal for cell surface staining of endogenous, 
secreted FGF2-GFP was shown to be twice as high as the amount equivalent to the 
material released from 10% completely lysed cells. The amount of dead cells was 
monitored by propidium iodide (PI), a low molecular dye, which enters cells with 
disrupted plasma membranes and accumulates in the nucleus by intercalating into 
DNA (Crissman et al., 1976). The typical amount of PI positive cells was found to be 
2-3%, indicating that the signal observed on the cell surface from FGF2-GFP 
secreting cells does not derive from FGF2-GFP unspecifically released by dead cells. 
The performed experiments provide evidence that the cell surface signal as detected 
by FACS analysis is derived from controlled secretion of FGF2-GFP.  
 
 
4.2.3.4 Inhibition of FGF2 secretion by ouabain 
 
The glycoside ouabain is a known inhibitor of unconventional secretion of FGF2 
(Trudel et al., 2000). It was shown to interact with the α-subunit of the Na+/K+-
ATPase which has been suggested to be a part of the translocation machinery of 
FGF2 export (Florkiewicz et al., 1998; Dahl et al., 2000). Therefore, an in vivo 
experiment based on flow cytometry was performed and ouabain was added in low 
concentrations (1-5 µM) to the medium of FGF2-GFP expressing CHO cells (figure 
3.14). The addition of ouabain resulted in up to 50% decrease of FGF2 export. 
Accordingly, a biochemical assay was performed (figure 3.15) and it was observed 
that addition of 25 µM ouabain also resulted in reduced amounts of secreted FGF2. 
These experiments indicate that the FACS-based signal detected for 
unconventionally secreted FGF2 results from a regulated translocation in which the 
Na+/K+-ATPase might be involved. 
 
4.2.4 Intercellular spreading of FGF2-GFP 
 
The biological activity of FGF2 is mediated by both autocrine and paracrine 
mechanisms (Bechtner et al., 1992; Okada-Ban et al., 2000). Therefore FGF2 has to 
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be able to spread from the producing cell to the target cell on which FGF2 is bound to 
receptors in order to execute its biological activity. By employing confocal microscopy, 
it was demonstrated that FGF2-GFP populations are able to spread from one cell to 
another cell in close proximity (Engling et al., 2002). CHOMCAT/TAM2 cells were used to 
simulate cells which are not able to express and secrete FGF2-GFP (figure 3.20). 
These cells were cultivated together with CHOFGF2-GFP cells and incubated with 
doxicycline to induce FGF2-GFP expression. By comparing the intracellular GFP-
derived signal, FGF2-GFP expressing cells (CHOFGF2-GFP) were distinguishable from 
cells not expressing FGF2-GFP (CHOMCAT/TAM2). Both populations were analyzed for 
FGF2-GFP cell surface localization. CHOMCAT/TAM2 cells, although not expressing 
FGF2-GFP were shown to be positive for cell surface localized fusion protein and 
therefore it must be derived from FGF2-GFP expressing CHOFGF2-GFP cells. The 
spreading of FGF2-GFP from expressing to non-expressing cells implicates that at 
least a part of the secreted material is probably released into the medium and is able 
to bind to any cell resulting in a homogenous cell surface staining of both cell lines. 
This result was confirmed by flow cytometry using the same experimental setup 
(figure 3.19). FGF2-GFP derived cell surface staining was found to be homogenous 
for both cell lines when cultivated together on one culture plate. A small, but 
significant difference of FGF2-GFP derived cell surface staining was observed by 
flow cytometry when cell populations were cultivated separately on two culture plates 
and combined for FACS processing and analysis. Cell surface derived signals for 
both populations were found to be separated, when the populations were cultivated 
and processed separately. This result indicates that cells have to be in contact either 
during cultivatation or procession in order to enable FGF2-GFP spreading. 
 
4.2.5 Refinement of FACS processing in order to prevent unspecific 
release of FGF2-GFP 
 
By performing flow cytometry, FGF2-GFP bound to the cell surface is detected with 
antibodies directed against GFP. It is not possible to differentiate secreted FGF2-
GFP from fusion protein which is released from cells in an uncontrolled fashion. 
Addition of doxicycline to cell cultures leads to an overexpression of FGF2-GFP and 
if those cells are injured or dead and lose plasma membrane integrity, they would 
release major amounts of fusion protein into the medium which subsequently binds to 
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the cell surface, resulting in an unspecific signal for secreted FGF2-GFP. As 
discussed in section 4.2.3.3, the amount of unspecifically released FGF2-GFP does 
not contribute significantly to the signal for secreted FGF2-GFP bound to the cell 
surface. However, the processing for FACS analysis was improved in a way that cell 
damage and uncontrolled release of fusion protein is further reduced. Formerly, cells 
were detached from the culture plates and antibody processing was performed in 
suspension. In contrast, by improving the procedure, cells were not detached prior to 
antibody processing and centrifuged during washing steps, but remained attached to 
the culture plate while treated with both primary and secondary antibodies. To verify 
if this improvement results in a signal reduced by the amount of unspecifically 
released FGF2-GFP, a control experiment was conducted, where FGF2-GFP 
expressing and CD4/GFP expressing cell lines were compared with regard to the 
FACS procedure (figure 3.21). The GFP fluorescence of both cell lines remained 
constant independently of the procedure. In contrast, cell surface staining was 
observed to be different. FGF2-GFP expressing cells showed a significantly reduced 
cell surface signal of about 40% when antibody processing was conducted on the 
culture plate as compared to the signal observed for cells processed in suspension. 
The cell surface signal detected for the plasma membrane protein CD4 remained 
constant for both procedures. Therefore about 60% of the signal for FGF2-GFP on 
the cell surface of cells processed in solution might originate either from 
unspecifically released fusion protein or steric hindrance due to the attachment of 
cells to the culture plate which might also prevent complete detection of the fusion 
protein bound to heparan sulfate proteoglycans. This can be excluded for the 
transmembrane protein CD4, which is equally well detected by flow cytometry, 
independent of the procedure used. However, steric hindrance can not be excluded 
to be the reason for the reduced signal detected for FGF2-GFP when cells were 
processed while being attached to the culture plate, since FGF2-GFP is bound to 
large heparan sulfate proteoglycan structures and therefore might not be well 
accessible for anti-GFP antibodies. It has to be assumed that a combination of both 
possibilities lead to the reduction of the signal for secreted FGF2-GFP. This 
procedure was then used to further analyze the secretion of FGF2. 
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4.3 Biosynthetic FGF2-GFP is localized to non-lipid raft 
microdomains following translocation 
 
The experimental system described was used in order to study the fate of 
biosynthetic (i.e. endogenous) FGF2-GFP following translocation to the extracellular 
compartment. FGF2-GFP was shown to accumulate in large macromolecular clusters 
that appear as bright spots on the cell surface (Engling et al., 2002). FGF2-GFP 
association with these structures is mediated by HSPGs as heparin treatment causes 
a loss of FGF2-GFP staining on the cell surface. In order to investigate as to whether 
FGF2 export and deposition in HSPG-containing microdomains are tightly linked 
processes, we analyzed the mode of delivery of FGF2-GFP to HSPGs following its 
externalization. FGF2-GFP was shown to spread between different populations of 
cultured cells. Moreover, FGF2-GFP prepared as a cell-free supernatant from 
homogenized CHOFGF2-GFP cells can associate with non-expressing cells, thereby 
forming morphologically similar microdomains on their surfaces. In conclusion, FGF2 
externalization and deposition in cell surface microdomains do not occur through an 
integrated process that would restrict cell surface deposition to FGF2-secreting cells. 
Rather it appears likely that is released as a soluble intermediate which eventually 
accumulates in HSPG-containing protein clusters. These data are consistent with our 
finding that the FGF2 binding capacity mediated by HSPGs does not influence the 
balance of intracellular FGF2 versus extracellular HSPG-bound FGF2. Rather, the 
cell surface signal detected provides a precise measure of FGF2 externalization 
which is not limited by the availability of HSPGs. Therefore, the FGF2 export 
machinery is rate-limiting under the conditions applied. The presence of FGF2-GFP 
in discrete microdomains on the cell surface implied that these structures might 
represent protein complexes involved in FGF2 signal transduction. In this context, 
Davy et al. reported that FGF2 signalling originates from caveolae-like lipid rafts on 
the cell surface (Davy et al., 2000). A functional FGF2 signal transduction complex 
consists of FGF2, HSPGs, the co-receptor GM1 and high-affinity FGF receptors 
(Rusnati et al., 2002). CHO wild-type cells do synthesize HSPGs and GM1, however, 
they do not express high-affinity FGF receptors (Rusnati et al., 2002). Therefore, it 
was interesting to study the biophysical properties of the FGF2-GFP-positive 
microdomains observed on the cell surface of CHO cells. Based on detergent 
solubility combined with flotation experiments in sucrose gradients (figure 3.18), we 
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can exclude that the FGF2-positive clusters observed are related to lipid rafts. 
Therefore, initial binding of FGF2 to HSPGs does not result in the correct targeting to 
caveolae-like lipid rafts where FGF2 signalling is initiated. Rather, FGF receptors are 
required to direct the core complex of FGF2 signalling to lipid rafts. Accordingly, upon 
doxicycline-induced FGF2-GFP expression and externalization, CHOFGF2-GFP cells do 
not appear to be significantly stimulated with respect to cell proliferation. Therefore, 
the large FGF2-GFP- and HSPG-containing cell surface clusters appear to represent 
signalling complex precursors that, in the presence of high affinity FGF receptors, are 
converted into functional signalling complexes. This transition appears to be 
accompanied by a targeting of the FGF2 signalling complex to caveolae-like lipid 
rafts (Engling et al., 2002). 
 
4.4 Screening of FGF2 mutants to elucidate targeting motifs for 
unconventional secretion 
 
In order to elucidate a potential motif which targets FGF2 to its transport machinery 
for unconventional secretion, a mutational analysis was conducted, altering multiple 
and distinct single amino acids as well as truncating the N- and C-termini of FGF2. 
It was demonstrated for galectin-1 that its secretion depends on their β-galactoside 
binding motifs (Seelenmeyer et al., 2005). FGF2 secretion was reconstituted by an in 
vitro experiment that uses inside-out vesicle derived from the plasma membrane of 
CHO cells. In contrast, FGF2 does not demonstrate membrane translocation when 
inside-out vesicles were generated from CHO cells treated with sodium chlorite 
(Schäfer et al., 2004). Sodium chlorite competes with sulfate ions for binding to the 
ATP-sulfyrulase, thereby inhibiting the generation of heparan sulfates (Baeuerle and 
Huttner, 1986; Klaassen and Boles, 1997; Safaiyan et al., 1999). Because of the 
observations made, a focus of the mutational analysis was to generate FGF2 
mutants that are deficient in heparin binding and to verify if these mutants are 
secretion deficient. In order to be able to asses the impact of FGF2 mutations, model 
cell lines based on CHO cells, transduced with a mutated version of FGF2 cDNA and 
thus expressing the fusion proteins in a doxicycline-dependent manner were 
generated. To assess secretion efficiency of the FGF2 mutants generated, two read-
out systems were used to monitor the secretion of FGF2.  
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1) FACS-based secretion assay. 
This assay was described in great detail in the first part of this thesis. It not 
only allows quantification of FGF2 which binds upon secretion to cell surface 
associated heparan sulfate proteoglycans, but additionally monitors protein 
expression by quantification of intracellular GFP fluorescence. This enables to 
normalize FGF2-GFP secretion for protein expression.  
 
2) Biochemical secretion assay employing cell surface biotinylation. 
This assay enables assessment of the amount of extracellular FGF2-GFP 
bound to the cell surface of CHO cells. A membrane-impermeable biotinylation 
reagent was used to label proteins associated with the extracellular side of the 
plasma membrane. Cells were subsequently lysed and biotin-labelled proteins 
were purified by using immobilized streptavidin. The secreted biotinylated and 
the intracellular non-biotinylated populations were analyzed by SDS-PAGE 
and Western blotting, enabling the quantification of the secreted population in 
comparison to the overall amount of protein expressed by CHO cells.  
 
Two read-out systems for binding efficiency were used to verify if FGF2-mutants are 
able to bind to heparin and heparan sulfate proteoglycans in order to employ 
secretion assays, since both assays detect secreted FGF2-GFP that is bound to 
heparan sulfate proteoglycans of the plasma membrane. Most importantly, these 
binding assays were performed in order to identify mutants deficient in heparin 
binding to verify if FGF2 secretion depends on the interaction of FGF2 with its low 
affinity receptors present on the outer leaflet of the plasma membrane. 
 
3) In vitro binding of FGF2 to heparin. 
This in vitro assay was developed to assess the heparin binding capability of 
FGF2 mutants. Therefore, soluble FGF2-GFP was obtained by disrupting 
fusion protein expressing cells (see preparation of cell free supernatant in 
material and methods, section 2.3.6) which was subsequently incubated with 
heparin beads. The amount of heparin-bound fusion protein was then 
compared to the overall amount of FGF2-GFP.  
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Binding to low molecular heparin in vitro does not reflect the conditions present in the 
extracellular space in vivo, because FGF2 binds to proteoglycans from which multiple 
different heparan sulfate side chains originate (23 different disaccharides are known 
to be present in heparin or heparan sulfates), which were proposed to bind FGF2 
with different affinities (Guimond and Turnbull, 1999).  
 
4) In vivo binding of FGF2-GFP to heparan sulfate proteoglycans. 
This in vivo assay was developed to monitor the binding efficiency of mutated 
versions of FGF2 to heparan sulfate proteoglycans present on the cell surface 
of CHO cells. Soluble FGF2-GFP, prepared as described in section 2.3.6, was 
added to the culture medium of CHO cells to allow binding of the fusion protein 
to the cell surface. Subsequently, heparan sulfate associated FGF2-GFP was 
quantified by flow cytometry.  
 
These assays were used to characterize more than one hundred FGF2 mutants 
obtained by random mutagenesis, site-directed mutagenesis and N- as well as C-
terminal truncations.  
 
4.4.1 Characterization of FGF2 mutants obtained by random mutagenesis  
 
In order to elucidate a transport motif directing FGF2 to its export machinery, a 
random mutagenesis of FGF2-GFP was performed to be able to hit a broad range of 
amino acids. The cloning strategy, as depicted in figure 3.22, was based on an 
intrinsic BamH I restriction site in the open reading frame (ORF) of FGF2. Therefore 
a low fidelity PCR was performed only with the 406 N-terminal nucleotides and not 
with the complete FGF2-GFP open reading frame, resulting in different FGF2 
mutants that demonstrated randomly distributed multiple amino acid changes and an 
unaltered GFP. The number of individual mutations generated in one open reading 
frame of FGF2 varied from two to seven (see table 3.1). Finally, 18 different CHO cell 
pools were generated which express different FGF2 mutants in a doxicycline-
dependent manner. These cell pools were subsequently characterized with regard to 
unconventional secretion and heparin binding capability using the four read-out 
systems introduced in section 3.3.2. The analysis of these pools showed that 55% of 
mutants with multiple amino acid changes did not differ in secretion efficiency, protein 
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stability and heparin binding properties as compared to wild-type protein. About 40% 
demonstrated significantly reduced secretion of the mutated versions of FGF2. These 
FGF2 mutants also displayed impaired binding efficiency to heparin as well as to 
heparan sulfate proteoglycans and decreased protein stability. The ratio of expressed 
FGF2-GFP to secreted fusion protein is similar for both mutant and wild-type cells, 
indicating that the mutant cells are still able to secrete FGF2. However, it is 
questionable if instable FGF2-GFP is efficiently targeted to the export machinery, 
thus resulting in a reduced signal for secretion efficiency. The reason for the protein 
instability of these mutants may be due to changes of amino acids which are 
essential for the correct folding of FGF2. Misfolded proteins are quickly degraded in 
the cytosol by the ubiquitin-proteasome system (Hendil and Hartmann-Petersen, 
2004), providing a quality control for the cell. The reason for impaired binding 
capacity of these mutants is that correct folding of the protein is a prerequisite for 
FGF2 to bind to heparin (Seddon et al., 1991). Another possible explanation would 
be that a heparin-binding region was hit by mutations, but that mutation of one amino 
acid of this region is not sufficient for causing complete heparin binding deficiency of 
FGF2. Additionally, heparin binding of FGF2 has been proposed not to be mediated 
by one distinct heparin-binding motif but that binding occurs by several regions 
localized at the N- and C-terminus of FGF2  (Baird et al., 1988; Li et al., 1994). By 
screening the clones obtained by random mutagenesis, only one mutant (rM 156) 
demonstrated a stable fusion protein and secreted the mutated version of FGF2 less 
efficiently as compared to wild-type cells, but showed a controversial result for 
heparin and HSPG-binding efficiency, since this mutant was able to bind to heparin in 
vitro, but failed to bind in vivo to heparan sulfate proteoglycans. This mutant was 
analyzed in more detail and will be discussed in section 4.4.5. 
 
4.4.2 Characterization of FGF2 mutants obtained by site-directed 
mutagenesis  
 
The point mutations were chosen based on the following criteria and appropriate 
amino acid changes were introduced into the open reading frame of FGF2 by site-
directed mutagenesis: 
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1) Three-dimensional structure 
The crystal structure of FGF2 was screened for hydrophobic amino acids 
exposed to the protein surface as these are potential sites for interactions with 
other proteins.   
2) Random mutagenesis 
Point mutations were introduced based on the results obtained by analyzing 
the random mutagenesis (section 4.4.1), choosing mutants showing altered 
secretion efficiency and binding capability when compared to wild-type FGF2. 
Multiple amino acid changes in one protein were individually introduced into 
FGF2 by site-directed mutagenesis in order to determine the effect of a single 
amino acid exchange with regard to the effect on FGF2 secretion and binding 
efficiency.  
3) Dimerization 
It has been shown for FGF1, that the protein is released in an unconventional 
manner in response to temperature stress as a latent homodimer (Tarantini et 
al., 1995). Additionally it was shown that dimerization is a prerequisite for 
FGF2 mediated signalling (Kwan et al., 2001). Therefore two cysteines, 
mediating dimerization of FGF2 (C78 and C96) were mutated individually and 
in combination. 
4) N-terminus 
N-terminal signal sequences targeting a protein to its translocation machinery 
are well described in the literature and might be involved in the unconventional 
secretion of FGF2 as well. Secretory proteins contain an N-terminal signal 
peptide (Walter et al., 1984), peroxisomal proteins have a peroxisomal 
targeting sequence at their N-terminus and C-terminus (Johnson and Olsen, 
2001) and proteins are targeted for the import into mitochondria by N-terminal 
cleavable signal sequences (Neupert, 1997). The N-terminal amino acids of 
FGF2 are disordered and of unknown structure and a potential export signal 
based on the three-dimensional structure was not discovered.  
 
In general, mutations were introduced by changing the original amino acid to alanine. 
Alanine is a small, uncharged hydrophobic amino acid and removes polar 
interactions at the respective position, thereby preventing association with potential 
interaction partners of the translocation machinery. N-terminal threonines were 
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substituted by alanine in order to remove the consensus site for phosphorylation. To 
rescue a potential secretion defect based on phosphorylation, threonine was also 
exchanged to aspartic acid or glutamic acid which are known to mimic 
phosphorylation (Maciejewski et al., 1995; Lu and Ou, 2002). 
 
Following cloning of point mutations, the various constructs were stably integrated 
into the genome of CHOMCAT/TAM2 cells using a retroviral gene transfer system (please 
refer to section 3.1). Cells transduced with the different reporter constructs were 
sorted via FACS to generate cell pools expressing the mutated fusion proteins in a 
doxicycline-dependent manner. These pools were characterized with regard to 
unconventional secretion and binding efficiency to heparin and HSPGs employing the 
four read-out systems described in section 4.3. The analysis of the cells revealed that 
about 84% (43 out of 51) of the characterized mutants did not differ in both secretion 
and heparin binding efficiency as compared to wild-type cells. Additionally, 14% of 
the generated mutants were found to be instable and impaired in binding to heparin 
in vitro and HSPGs in vivo. Only the mutant, which was mutated at two cysteine 
residues to prevent dimerization of FGF2, was observed to have reduced secretion 
efficiency when compared to wild-type fusion protein. Interestingly, the results 
obtained for this mutant by cell surface biotinylation and FACS analysis were not 
consistent. The biochemical assay showed significantly reduced secretion efficiency 
whereas the FACS-based assay did not display a difference as compared to wild-
type levels. The reason for this discrepancy has to be investigated, but it appears 
possible that FGF2 possesses a different accessibility to heparan sulfate side-chains 
of proteoglycans. One could envisable that FGF2 binds to heparan sulfates side-
chains more in proximity to the plasma membrane as well as due to the large 
structure of HSPGs to side-chains in distance to the plasma membrane and exposed 
to the medium. A possible explanation would be that antibodies used for FACS 
analysis only detect FGF2 bound to heparan sulfates side-chains exposed to the 
medium, whereas FGF2 bound to heparan sulfates in proximity to the plasma 
membrane is not detected, because antibodies might not have access to those side-
chains due to steric hindrance. In contrast, biotin as a small low molecular compound 
might be able to penetrate into heparan sulfate proteoglycans and therefore detect 
the population of FGF2 bound to heparan sulfates present in close proximity to the 
plasma membrane. As discussed in section 4.3, FGF2 is secreted from the cell and 
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probably exists as a soluble intermediate which binds to heparin sulfate side-chains 
of proteoglycans. FGF2 might first occupy easy accessible heparin sulfate side-
chains that are exposed to the medium. After saturation of these side-chains, FGF2 
binds to heparan sulfate side-chains closer to the plasma membrane. If the 
dimerization mutant secretes FGF2-GFP less efficiently as compared to wild-type 
cells, the fusion protein might be mainly localized to exposed heparan sulfate side-
chains and the signal for cell surface associated FGF2 analyzed by flow cytometry 
would therefore remain unchanged due to its accessibility to the antibody. However, 
since less protein is secreted and is associated with inner heparan sulfate side-
chains, the signal for FGF2 exported by the dimerization mutant and detected by 
biotinylation would be reduced in comparison to the wild-type. A possible explanation 
for the reduced secretion efficiency of a dimerization mutant might be that the 
dimerization status of FGF2 is somehow monitored by the putative translocation 
machinery and since secretion efficiency is reduced, dimerization appears to be a 
prerequisite for FGF2 secretion. This was observed for FGF1 since it was reported 
that dimerization plays an important role for the secretion of the growth factor 
(Jackson et al., 1992). In contrast to FGF2 dimerization, the FGF1 homodimer was 
shown to be formed in the presence of Cu2+ ions by disulfide bonds (Engleka and 
Maciag, 1992). Consequently, the dimer form is reverted to the monomer form in the 
presence of reducing agents such as dithiothreitol. Mutations of the cysteine residues 
involved in dimerization (Cys 30) inhibited the FGF1 secretion in response to heat 
shock (Jackson et al., 1995; Tarantini et al., 1995).  Additionally, FGF1 dimerization 
is required for and induced by the formation of a multiprotein complex consisting of 
FGF1, the p40 domain of synaptogamin 1 (Syt-1) and S100A13 (Landriscina et al., 
2001a). This complex is thought to be a prerequisite for FGF1 export (Landriscina et 
al., 2001b). Despite the differences between FGF1 and FGF2 regarding their mode 
of dimerization, it appears possible that the necessity of dimer formation before 
secretion might be a common property of FGF export. 
 
4.4.3 Characterization of N-terminally truncated versions of FGF2  
 
N-terminal truncations of FGF2 were performed for reasons which were already 
explained in section 4.3.2. They were generated by performing a PCR on FGF2-GFP 
wild-type cDNA using specific primers, thereby truncating N-terminal nucleotides. 
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CHOMCAT/TAM2 cells were retrovirally transduced with truncated versions of the 
reporter construct, followed by sorting of cell pools expressing the mutated fusion 
proteins in a doxicycline-dependent manner (for generation of cell lines refer to 
section 3.1). These pools were characterized with regard to unconventional secretion 
and binding efficiency to heparin and HSPGs employing the four read-out systems 
described in section 3.3.2. The analysis of these truncations revealed that deleting 
the first 20 amino acids form the N-terminus of FGF2 does not result in a different 
secretion efficiency and binding capacity to heparin when compared to wild-type 
FGF2. However, truncating more than 20 amino acids at the N-terminus resulted in 
decreased protein stability and heparin binding capability. These mutants appear to 
ineffectively secrete the truncated versions of FGF2-GFP, as demonstrated by the 
signal for FGF2-GFP detected on the cell surface by employing FACS analysis and 
biotinylation (section 3.3.5.1). However it is questionable if instable proteins, probably 
partially misfolded, are targeted efficiently to the transport machinery. From these 
results it has to be concluded, that the first 20 amino acids, which are part of a region 
of unknown structure are not involved in the transport process of FGF2. As already 
known from the literature, amino acids located from position 20 to 30 contribute to 
heparin binding (Baird et al., 1988; Heath et al., 1991). However, deletion of these 
amino acids does not lead to a block of heparin binding, because an additional 
heparin binding site remains which lies in the C-terminal part of FGF2 (Li et al., 1994).  
 
4.4.4 Characterization of C-terminally truncated versions of FGF2  
 
We were able in our laboratory to identify galectin counter receptors (i.e. -
galactoside-containing cell surface glycolipids and/or glycoproteins) as essential 
components of the overall process of galectin-1 secretion (Seelenmeyer et al., 2005). 
26 single-site mutations were identified that cause both binding deficiency to counter 
receptors and export deficiency (Seelenmeyer et al., 2005). These data provide a 
potential explanation for the apparent non-existence of a linear targeting motif in 
galectin-1 that directs sorting to the nonclassical export pathway. Moreover, these 
data suggest a direct role of counter receptors as export adaptors and the -
galactoside binding motif of galectin-1 as the primary targeting element. Recent 
experiments performed in our laboratory suggest a similar involvement of heparan 
sulfate proteoglycans in the secretion of FGF2. It was shown in vitro that inside-out 
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vesicles derived from the plasma membrane of CHO cells translocate FGF2 and 
galectin-1 into the lumen of the vesicles in presence of cytosol. However, if vesicles 
derived from CHO cells treated with sodium chlorate to inhibit sulfatation of heparan 
sulfates (Baeuerle and Huttner, 1986; Safaiyan et al., 1999), FGF2 was not shown to 
translocate into inside-out vesicles (Schäfer et al., 2004). Accordingly, in vivo 
experiments were conducted to examine the secretion efficiency of CHO cells treated 
with high-salt containing buffer. It was demonstrated that FGF2-GFP was secreted 
less efficiently from these cells as analyzed by FACS analysis and IP (unpublished 
data). Moreover, a mutant CHO cell line (CHOpgsA-745), defective in the synthesis 
of glycosaminoglycans due to lack of activity of xylosyl transferase (Esko et al., 1985) 
was retrovirally transduced with FGF2-GFP resulting in FGF2-GFP expression in a 
doxicycline-dependent manner. Because of lacking HSPGs on the cell surface, 
FGF2-GFP is not able to bind to the cell surface, but would remain in the medium if 
secretion occurs. It was not possible to detect neither FGF2-GFP bound to the cell 
surface nor FGF2-GFP present in the medium of the cells, suggesting a FGF2-GFP 
secretion deficiency (unpublished data). Most strikingly, when CHOpgsA-745 
expressing FGF2-GFP were cultivated with CHOMCAT/TAM2 cells on the same culture 
plate but spatially separated by different cover slips, FGF2-GFP could not be 
detected on the cell surface of CHOMCAT/TAM2 cells. However, when both cell lines 
were in close contact due to cultivation on the same cover slip, FGF2-GFP appeared 
on the cell surface of CHOMCAT/TAM2 cells (unpublished data). These results strongly 
suggest that heparan sulfate proteoglycans are required for the secretion of FGF2-
GFP. A major aim of this thesis was therefore to generate non-heparin binding 
mutants of FGF2 in order to clarify the role of heparan sulfate proteoglycans in the 
secretion mechanism of FGF2. In contrast to galectin-1 and as discussed in the 
previous sections, FGF2 single-site mutations were not able to cause binding 
deficiency. Additionally, N-terminal truncations, thereby deleting a predicted binding 
motif did not result in binding or secretion deficiency. However, Heparin binding of 
FGF2 is proposed to be mainly mediated by two C-terminal residues. It was 
demonstrated that mutation of two lysines to glutamine (K128Q and K138Q) leads to 
a significantly reduced affinity of FGF2 to heparin (Li et al., 1994). Therefore, 
truncations were generated to delete the C-terminal heparin binding motif of FGF2 by 
performing a PCR using specific primers to delete C-terminal amino acids (for cloning 
strategy see section 3.3.1.4). The various constructs were stably integrated into the 
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genome of CHOMCAT/TAM2 cells using a retroviral gene transfer system and followed 
by FACS sortings in absence and presence of doxicycline to generate cell pools 
expressing the truncated fusion proteins in a doxicycline-dependent manner (refer to 
section 3.1). These cell pools were finally characterized with regard to 
unconventional secretion, as well as binding efficiency to heparin and HSPGs 
employing the four read-out systems described in section 3.3.2. The analysis of 
these truncations demonstrated that the C-terminus of FGF2 plays a major role in 
heparin binding efficiency. In contrast to point mutations and N-terminal truncations, 
removing the C-terminal binding motifs leads to a loss of binding to heparin and 
heparan sulfate proteoglycans. All truncations demonstrated a significantly reduced 
signal for intracellular fusion protein as observed by FACS analysis. Interestingly, no 
truncation was found to be able to bind to heparan sulfate proteoglycans. These 
results suggest that a correctly folded, intact and complete protein is necessary to 
ensure protein stability and to be bound to HSPG. However, affinity of FGF2 to 
heparin and heparan sulfate proteoglycans are shown to be different throughout 
different truncations, because deletion of 19 amino acids from the C-terminus of 
FGF2 does not influence affinity of FGF2 to heparin, although this truncation is not 
able to bind to HSPGs, indicating a different affinity of FGF2 to heparin as to heparan 
sulfate proteoglycans. By truncating 29 amino acids, the heparin binding efficiency is 
reduced to about 50% as compared to wild-type protein, probably because of 
impairing the heparin binding motifs (predicted by Li et al., 1994). Further truncation 
of FGF2 led to a complete heparin binding deficiency. The standardised read-out 
systems were used to analyze the secretion efficiency of the truncated FGF2-GFP 
versions. Since the truncations were shown to be negative for binding to HSPGs in 
vivo, a signal for secreted FGF2-GFP versions was not expected and finally also not 
shown by performing the standard assays (FACS analysis and cell surface 
biotinylation). However, the truncated versions of the fusion protein, if secreted from 
cells, should be present in the medium of the cells. Therefore, an additional 
experiment was performed to precipitate secreted fusion protein potentially present in 
the medium (section 3.4.1). Anti-GFP antibodies were used in order to precipitate 
FGF2-GFP wild-type protein, as well as the different truncated versions of the fusion 
protein, but it was not possible to immunoprecipitate any fusion protein from the 
conditioned medium. This experiment shows that wild-type FGF2 is completely 
bound to the cell surface and thus not detectable in the medium but since the 
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truncations were also not precipitated from the medium as analyzed by IP, it appears 
possible that C-terminal truncated versions of FGF2 are not secreted from cells. 
However, it has been reported, that binding to heparan sulfate proteoglycans 
stabilizes FGF2 from degradation (Ornitz and Itoh, 2001), therefore it remains to be 
verified whether these observation are caused by secretion deficiency or by rapid 
degradation of the C-terminal truncated versions of FGF2. During this thesis, 
heparin-binding deficient truncations of FGF2 were successfully generated and if 
they prove to be also secretion deficient, evidence would be provided for a 
requirement of heparan sulfate proteoglycans in the secretion process of FGF2. 
 
4.4.5 Detailed analysis of mutant 156 with regard to secretion efficiency, 
protein stability, heparin and heparan sulfate binding efficiency 
 
The mutant rM 156, consisting of three individual amino acid changes (E87K, K128E 
and R129Q), was analyzed during the screening process of mutants generated by 
random mutagenesis and showed thereby striking differences to wild-type cells 
regarding unconventional secretion and binding efficiency to heparan sulfate 
proteoglycans. The secretion efficiency of rM 156 was significantly reduced 
compared to wild-type protein as demonstrated by the standard assays described in 
section 3.3.2. Additionally, this mutant was shown to be deficient for heparan sulfate 
proteoglycan binding in vivo, but strikingly, was able to bind to heparin in vitro. To 
elucidate if one amino acid change or a combination of the three mutations in rM 156 
mediate secretion- and HSPG-binding deficiency, individual point mutations, identical 
to those of mutant rM 156, were generated by site-directed mutagenesis. They were 
already analyzed during the screening process of point mutations. In this screening, 
the mutants 36 (E87K), 45 (K128E) and 46 (R129Q) did not demonstrate a difference 
in secretion efficiency and heparin binding characteristics as compared to wild-type 
protein, indicating that a combination of all amino acid changes is necessary to loose 
affinity of FGF2 to heparan sulfate proteoglycans and to reduce secretion efficiency. 
These mutants were further characterized with regard to degradation and binding 
affinity to heparan sulfate proteoglycans. 
To exclude that the reduced signal of secreted FGF2 bound to the cell surface 
observed in the secretion assays for rM 156 is caused by less available fusion 
protein due to a higher degree of protein degradation, the fate of the fusion protein in 
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the medium was monitored by the following experiment (figure 3.121). The different 
fusion proteins obtained from mutant rM 156, 36, 45 and 46 were incubated in 
conditioned medium derived from CHO cells for 24 h at 4°C. The mutated versions of 
FGF2-GFP were analysed by SDS-PAGE and Western blotting and the signal 
detected was about 50% as compared to the positive control for both wild-type and 
mutated proteins, showing that FGF2-GFP, independently of mutations, was 
degraded to the same extent at 4°C as well as after performing a temperature shift to 
37°C. This result provides evidence that introduction of these specific mutations into 
FGF2 does not influence the degree of protein degradation, suggesting that the 
signal observed for rM 156 is not reduced due to a decreased amount of available 
fusion protein in the medium caused by degradation. A second experiment was 
conducted to test the ability of the different fusion proteins to bind to heparan sulfate 
proteoglycans. It remains possible that the signal for cell surface associated, 
secreted FGF2 is reduced because of the missing ability of the FGF2 mutant to bind 
to heparan sulfate proteoglycans. Therefore, the binding of FGF2 and mutants to 
HSPGs was verified using cell free supernatant derived from wild-type, rM 156 and 
point mutation 36 cells (see figure 3.122). The various proteins were incubated with 
CHOMCAT/TAM2 cells for different periods of time and at different temperatures to 
mediate binding to cell surface-associated HSPGs. Cells were then prepared and 
analyzed by flow cytometry. This experiment suggests that binding of wild-type fusion 
protein to the cell surface is temperature-sensitive, since only 15% of the fusion 
protein still binds to the cell surface at 4°C after 1 h as compared to incubation at 
37°C for 1 h. Prolonging the incubation time or shifting the temperature to 37°C did 
not result in a different signal as observed before for 1 h at 4°C. It is most likely that 
the reduced signal detected at 4°C is caused by temperature sensitive binding of 
FGF2 to HSPGs and that the signal observed for protein incubated for 16 h at 37°C 
is reduced by proteolytical degradation of the fusion protein. This result was 
confirmed by the analysis of point mutation 36, because the results for this mutant 
are similar to those made for wild-type FGF2-GFP, although the ability to bind to 
HSPGs at 4°C is slightly enhanced. Strikingly, in contrast to wild-type protein, cell 
surface staining could not be detected with flow cytometry for the mutant rM 156, 
indicating a total defect in binding of the mutated fusion protein to HSPGs, 
irrespective of temperature and incubation time. Because of the degradation 
experiment described previously in this section, it has to be excluded that a higher 
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degree of degradation for mutant rM 156 compared to wild-type protein is responsible 
for the reduced signal in this assay.     
To verify the results obtained by the screening of mutants obtained by random 
mutagenesis and point mutations, the standardised screening assays were repeated 
using the mutant cell lines described in this section. Unfortunately the result obtained 
in previous experiments could no longer be observed. Performing flow cytometry and 
cell surface biotinylation of the mutant rM 156 revealed that the amount of FGF2-
GFP bound to the cell surface is comparable for the mutant and wild-type cells. 
Strikingly, mutant rM 156 was still negative for HSPG-binding in in vivo binding 
assays. This observation raises an important question: Why is biosynthetic mutated 
FGF2-GFP secreted from the mutant rM 156 detected in association with cell surface 
localized heparan sulfate proteoglycans by flow cytometry and cell surface 
biotinylation, although it was shown to be deficient in HSPG binding? So far, this 
question remains unanswered. An artefact from the experiments obtained can be 
excluded, because, as shown in section 4.2, the robust in vivo secretion assay using 
flow cytometry demonstrated a specific detection of FGF2-GFP bound to HSPGs of 
CHO cells. A hypothesis to explain this discrepancy would be that FGF2-GFP is 
somehow modified during the transport which causes an enhanced affinity of FGF2 
to heparan sulfate proteoglycans. It then appears likely that a modification would 
occur in the heparin binding motif, because the amino acid changed at position 128 
and 129 in mutant rM 156 belong to a predicted heparin-binding motif (Li et al., 1994).  
 
4.4.6 Future perspectives 
 
 
The FGF2 secretion assay based on flow cytometry described in the first part of this 
study is a powerful tool for the analysis of the molecular machinery mediating FGF2 
export. For example, the systematic testing of candidate proteins (e.g. identified by 
interaction studies or genetic screening in mammalian cells) can be carried out by 
transiently inhibiting their biosynthesis based on RNA interference (Elbashir et al., 
2001). In this context, a considerable advantage of the FGF2-GFP-based system is 
that total protein expression (GFP-derived fluorescence) and secreted FGF2-GFP 
(PE-derived cell surface staining) can be measured independently. Therefore, a 
phenotype determined by APC-derived cell surface staining can be corrected by 
normalization based on the degree of total FGF2-GFP expression. Due to the lack of 
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FGF receptors in CHO cells, another unique feature of the experimental system 
described is the uncoupling of FGF2 externalization from FGF2 signalling. Therefore, 
FGF2 export can be studied without the risk of secondary effects provoked by the 
action of the secreted product. 
Another obvious application is a systematic high throughput screening for inhibitors 
(e.g. derived from natural compound libraries) of FGF2 secretion and the subsequent 
functional identification of their cellular targets. Given the biological function of FGF2 
as a direct stimulator of tumour angiogenesis (Bikfalvi et al., 1997), inhibitors of FGF2 
secretion might have strong biomedical implications as potential lead compounds for 
the development of anti-angiogenic drugs. 
In the second part of this study, the secretion assay was used to carry out a genetic 
screen based on the mutagenesis of FGF2 in order to elucidate a potential motif 
which targets FGF2 to its transport machinery. Unfortunately, after mutagenesis of 
FGF2 and characterization of a vast variety of different mutants with regard to 
unconventional secretion, it was not possible to define a linear amino acid motif that 
influences FGF2 secretion. However, by performing C-terminal truncations of FGF2, 
it was possible to impair the heparin binding ability of FGF2. Several observations as 
already described in detail in section 4.4.4 have been made recently which support 
the hypothesis that FGF2-GFP secretion might depend on the interaction of heparin 
binding motifs of FGF2 with heparan sulfate proteoglycans present on the cell 
surface. Sodium chlorate treatment of cells led to a dramatic decrease of FGF2 
secretion efficiency (unpublished data). Strikingly, CHOpgsA-745 cells lacking 
glycosylaminoglycans were shown to be secretion deficient (unpublished data) and 
FGF2 export was reconstituted when CHOpgsA-745 cells were in close contact to 
CHOMCAT/TAM2 cells which are suggested to provided the HSPGs required for the 
unconventional secretion of FGF2-GFP (unpublished data). It remains elusive how 
the translocation over the plasma membrane of FGF2-GFP is facilitated. A highly 
speculative model would be that FGF2 is transported through a putative plasma 
membrane resident pore and heparan sulfate proteoglycans are involved in the 
translocation as cargo adaptors, exerting a pulling force that is required for the 
directional transport of FGF2. This model would be consistent to the observation that 
membrane translocation occurs in a folded state (Backhaus et al., 2004) since only 
properly folded FGF2 binds to heparin (Seddon et al., 1991). Finally, this model 
provides a functional basis for quality control in the overall process of FGF2 secretion. 
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As the heparin binding motif of FGF2 is shown to be the primary target element for 
secretion, quality control is in place since only properly folded FGF2 will be 
recognized by the export machinery. The next step would be the analysis of the 
heparin binding deficient C-terminal truncations with regard to secretion efficiency 
and degradation in order to verify if heparan sulfate proteoglycans are involved in 
FGF2 secretion. However, the mutants described in this thesis provide a basis for 
future studies to analyze the mechanism of FGF2 secretion. 
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5 Abbreviations 
 
ABC ATP binding cassette 
APC allophycocyanin 
APS ammonium peroxo disulphate 
ATP adenosin triphosphate 
BFA brefeldin A 
bp basepairs 
CDB cell dissociation buffer 
CHO Chinese hamster ovary (cells) 
CRD carbohydrate recognition domain 
C-terminal carboxy terminal 
DMSO dimethyl sulphoxide 
DNA desoxyribonucleic acid 
E.coli Escherichia coli 
e.g. exempli gratia 
ECL enhanced chemoluminescence 
EDTA ethylenediaminetetraacetic acid 
En2 engrailed 2 
ER endoplasmatic reticulum 
et al. et altera 
FACS fluorescence activated cell sorting 
FCS fetal calf serum 
FGF2 fibroblast growth factor 2 
FGFR fibroblast growth factor receptor 
FV Foamy virus 
g gravitation 
Gal-1 galectin-1 
GFP green fluorescence protein 
GTP guanosine triphosphate 
h hour 
HASPB hydrophilic acylated surface protein B 
HCl hydrochlorid acid 
HIV human immunodeficiency virus 
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HMGB high mobility group protein 
HRP horse raddish peroxidase 
HS heparan sulfate 
HSPG heparan sulfate proteoglycans 
i.e. id est 
IgG Immunoglobulin G 
IL interleukin 
kDa kilo Dalton 
LTR long terminal repeat 
MCAT Mouse cationic amino acid transporter 
MIF migration inhibtory factor 
NLS nuclear localization signal 
nm Nanometer (wavelength) 
ORF open reading frame 
ORF open reading frame 
PAGE polyacrylamide gel electrophoresis 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PE phycoerythrin 
PTS peroxisomal targeting sequence 
PVDF polyvinyliden fluoride 
RNA ribonucleic acid 
SDS sodium dodecyl sulfate 
SRP signal recognition particle 
Tat HIV transactivator protein 
TEMED N,N;N´,N´-tetramethylethylenediamine 
Tris Tris[hydroxymethyl]aminoethane 
TRX thioredoxin 
Tween 20 polyoxethylene sorbitane monolaureate 
U units (enzyme activity) 
v/v volume/volume relationship 
VEGF vascular endothelian growth factor 
w/v weight/volume relationship 
α-MEM α-modification of Minimal Essential Medium 
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